

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                     | DOSAGE FORM                 | STRENGTH                        | RLD/NDA                   | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|-----------------------------|---------------------------------|---------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Abacavir Sulfate                              | Tablets                     | 300 mg                          | Ziagen 20977              | 1/28/2009          | 1                         | Eligible       | 2/11/2020                     | 6/18/2012                        | 6/19/2012                                 | 5/14/2018                                 |
| Abacavir                                      | Oral Solution               | 20 mg/mL                        | Ziagen 20978              | 12/27/2012         | 1                         | Eligible       | 2/11/2020                     | 9/26/2016                        | 9/15/2017                                 | 5/14/2018                                 |
| Abacavir Sulfate, Dolutegravir and Lamivudine | Tablets                     | 600 mg/50 mg/ 300 mg            | Triumeq 205551            | 8/14/2017          | 5                         |                |                               |                                  |   | 12/8/2029                                 |
| Abacavir Sulfate, Dolutegravir and Lamivudine | Tablets for Oral Suspension | 60 mg/5 mg/30 mg                | Triumeq PD 215413         | 3/31/2023          | 1                         |                |                               |                                  |   | 12/8/2029                                 |
| Abacavir Sulfate and Lamivudine               | Tablets                     | 600 mg/300 mg                   | Epzicom 21652             | 9/27/2007          | 1                         | Eligible       | 2/11/2020                     | 9/29/2016                        | 9/29/2016                                 | 5/14/2018                                 |
| Abacavir Sulfate, Lamivudine and Zidovudine   | Tablets                     | 300 mg/150 mg/ 300 mg           | Trizivir 21205            | 3/22/2011          | 1                         | Eligible       | 2/11/2020                     | 12/5/2013                        | 12/17/2013                                | 5/14/2018                                 |
| Abaloparatide                                 | Subcutaneous Injection      | 3.12 mg/1.56 mL                 | Tymlos 208743             | 6/21/2022          | 1                         |                |                               |                                  |   | 1/10/2040                                 |
| Abiraterone Acetate                           | Tablets                     | 125 mg                          | Yonsa 210308              | 7/23/2018          | 1                         | Deferred       | 7/25/2022                     | 6/24/2022                        |   | 3/17/2034                                 |
| Abiraterone Acetate                           | Tablets                     | 250 mg                          | Zytiga 202379             | 4/28/2015          | 13                        | Eligible       | 6/18/2019                     | 10/31/2018                       | 11/21/2018                                | 8/24/2027                                 |
| Abiraterone Acetate                           | Tablets                     | 500 mg                          | Zytiga 202379             | 8/23/2017          | 1                         | Extinguished   | 1/12/2021                     |                                  |   | 8/24/2027                                 |
| Acalabrutinib                                 | Capsules                    | 100 mg                          | Calquence 210259          | 11/1/2021          | 5                         |                |                               |                                  |   | 7/1/2036                                  |
| Acarbose                                      | Tablets                     | 25 mg, 50 mg and 100 mg         | Precose 20482             | 3/22/2005          | 1                         | Extinguished   | 2/11/2020                     | 5/7/2008                         |   | 9/6/2009                                  |
| Acetylcysteine                                | Injection                   | 200 mg/mL, 30 mL vials          | Acetadote 21539           | 4/4/2012           | 3                         | Eligible       | 2/11/2020                     | 11/7/2012                        | 11/30/2012                                | 5/21/2026                                 |
| Acetaminophen                                 | Injection                   | 1000 mg/100 mL (10 mg/mL)       | Ofirmev 22450             | 4/7/2011           | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 6/6/2021                                  |
| Acetaminophen                                 | Extended-release Tablets    | 650 mg                          | Tylenol 19872             | Pre-MMA            |                           |                |                               |                                  |   |   |
| Acetaminophen and Tramadol Hydrochloride      | Tablets                     | 325 mg/ 37.5 mg                 | Ultracet 21123            | Pre-MMA            |                           |                |                               |                                  |   |   |
| Acetaminophen/ Aspirin/ Caffeine              | Tablets                     | 250 mg/ 250 mg/ 65 mg           | Excedrin (migraine) 20802 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Acyclovir Sodium                              | Injection                   | 50 mg/mL, 10 mL and 20 mL vials | Zovirax 18603             | Pre-MMA            |                           |                |                               |                                  |   |   |
| Adapalene                                     | Topical Gel                 | 0.30%                           | Differin 21753            | 9/15/2009          | 1                         | Eligible       | 2/11/2020                     | 6/14/2012                        | 4/28/2014                                 | 2/23/2025                                 |
| Adapalene and Benzoyl Peroxide                | Gel                         | 0.1%/2.5%                       | Epiduo 22320              | 12/30/2011         | 1                         | Eligible       | 2/11/2020                     | 9/30/2015                        | 7/27/2017                                 | 7/18/2027                                 |
| Adapalene and Benzoyl Peroxide                | Gel                         | 0.3%/2.5%                       | Epiduo Forte 207917       | 5/4/2016           | 1                         | Eligible       | 6/18/2019                     | 10/17/2018                       | 12/1/2021                                 | 3/12/2023                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                      | DOSAGE FORM              | STRENGTH   | RLD/NDA                  | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS          | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|--|--------------------------|--------------------|---------------------------|-------------------------|-------------------------------|----------------------------------|---|---|
| Adefovir Dipivoxil                             | Tablets                  | 10 mg  | Hepsera 21449            | 6/8/2010           | 1                         | Eligible                | 2/11/2020                     | 8/29/2013                        | 9/3/2013                                  | 7/23/2018                                 |
| Afatinib Dimaleate                             | Tablets                  | 20 mg, 30 mg and 40 mg   | Gilotrif 201292          | 7/12/2017          | 7                         |                         |                               |                                  |   | 12/19/2029                                |
| Adenosine                                      | Injection                | 3 mg/mL, 20 mL and 30 mL vials                                   | Adenoscan 20059          | 4/18/2005          | 1                         | Eligible                | 2/11/2020                     | 8/29/2013                        | 9/23/2013                                 | 3/24/2015                                 |
| Albuterol Sulfate                              | Oral Syrup               | 2 mg(base)/ 5 mL   | Ventolin 19621           | Pre-MMA            |                           |                         |                               |                                  |   |   |
| Albuterol Sulfate                              | Extended-release Tablets | 4 mg and 8 mg  | Volmax 19604             | Pre-MMA            |                           |                         |                               |                                  |   |   |
| Albuterol Sulfate                              | Inhalation Solution      | 0.021%   | Accuneb 20949            | 10/19/2005         | 1                         | Eligible                | 2/11/2020                     | 9/25/2007                        |   | 12/28/2021                                |
| Albuterol Sulfate                              | Inhalation Solution      | 0.042%   | Accuneb 20949            | 4/6/2004           | 1                         | Eligible                | 2/11/2020                     | 6/28/2004                        |   | 12/28/2021                                |
| Albuterol Sulfate and Ipratropium Bromide      | Inhalation Solution      | 0.083%/ 0.017%   | Duoneb 20950             | Pre-MMA            |                           |                         |                               |                                  |   |   |
| Albuterol Sulfate and Ipratropium Bromide      | Inhalation Aerosol       | 100 mcg/20 mcg per actuation                                     | Combivent Respimat 21747 | 3/30/2023          | 1                         |                         |                               |                                  |   | 10/16/2030                                |
| Albuterol Sulfate                              | Inhalation Aerosol       | 0.09 mg base per actuation                                       | Pro-Air HFA 21457        | 5/18/2012          | 1                         | Non-Forfeiture Deferred | 8/24/2020<br>3/10/2020        | 2/24/2020                        | 2/26/2020                                 | 9/12/2023                                 |
| Albuterol Sulfate                              | Inhalation Aerosol       | 0.09 mg base per actuation                                       | Proventil HFA 20503      | 5/20/2015          | 1                         | Extinguished            | 2/11/2020                     |                                  |   | 12/28/2016                                |
| Alcaftadine                                    | Ophthalmic Solution      | 0.25%  | Lastacaft 22134          | 7/30/2014          | 1                         | Extinguished            | 8/27/2019                     |                                  |   | 10/5/2029                                 |
| Alectinib                                      | Capsules                 | 150 mg   | Alecensa 208434          | 12/11/2019         | 1                         |                         |                               |                                  |   | 3/4/2032                                  |
| Alendronate Sodium                             | Oral Solution            | 70 mg/75 mL  | Fosamax 21575            | 9/7/2007           | 1                         | Extinguished            | 2/11/2020                     |                                  |   | 7/17/2018                                 |
| Alendronate Sodium                             | Tablets                  | 5 mg, 10 mg, 35 mg, 40 mg and 70 mg                              | Fosamax 20560            | Pre-MMA            |                           |                         |                               |                                  |   |   |
| Alendronate Sodium and Cholecalciferol         | Tablets                  | 70 mg/2800 IU and 70 mg/5600 IU                                  | Fosamax Plus D 21762     | 11/20/2007         | 1                         | Extinguished            | 2/11/2020                     |                                  |   | 7/17/2018                                 |
| Alfuzosin Hydrochloride                        | Extended-release Tablets | 10 mg  | Uroxatral 21287          | 6/12/2007          | 9                         | Eligible                | 2/11/2020                     | 7/18/2011                        | 7/18/2011                                 | 8/22/2017                                 |
| Aliskiren Hemifumarate                         | Tablets                  | 150 mg and 300 mg  | Tekturna 21985           | 1/27/2014          | 1                         | Deferred                | 8/13/2019                     | 3/22/2019                        | 3/25/2019                                 | 2/19/2026                                 |
| Aliskiren Hemifumarate and Hydrochlorothiazide | Tablets                  | 150 mg/12.5 mg<br>150 mg/25 mg<br>300 mg/12.5 mg<br>300 mg/25 mg | Tekturna HCT 22107       | 3/7/2014           | 1                         | Extinguished            | 2/11/2020                     |                                  |   | 7/13/2028                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                    | DOSAGE FORM                   | STRENGTH                                    | RLD/NDA         | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS        | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|-------------------------------|---|-----------------|--------------------|---------------------------|-----------------------|-------------------------------|----------------------------------|---|---|
| Almotriptan Malate                           | Tablets                       | 6.25 mg and 12.5 mg                         | Axert 21001     | 12/8/2005          | 1                         | Extinguished          | 2/11/2020                     | 7/7/2015                         |   | 5/7/2015                                  |
| Alogliptin                                   | Tablets                       | 6.25 mg, 12.5 mg and 25 mg                  | Nesina 22271    | 1/25/2017          | 5                         |                       |                               |                                  |   | 6/16/2029                                 |
| Alogliptin and Metformin Hydrochloride       | Tablets                       | 12.5 mg/500 mg and 12.5 mg/1000 mg          | Kazano 203414   | 1/25/2017          | 3                         |                       |                               |                                  |   | 5/24/2029                                 |
| Alosetron Hydrochloride                      | Tablets                       | 0.5 mg and 1 mg                             | Lotronex 21107  | 12/2/2010          | 1                         | Deferred              | 2/11/2020                     | 5/4/2015                         | 5/21/2015                                 | 10/5/2018                                 |
| Alprazolam                                   | Orally Disintegrating Tablets | 0.25 mg, 0.5 mg, 1 mg and 2 mg              | Niravam 21726   | 12/27/2005         | 1                         | Extinguished Eligible | 7/2/2019<br>7/2/2019          | 1/9/2009                         | 1/14/2009                                 | 4/9/2018                                  |
| Alprazolam                                   | Tablets                       | 0.25 mg, 0.5 mg, 1 mg and 2 mg              | Xanax 18276     | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Alvimopan                                    | Capsules                      | 12 mg                                       | Entereg 21775   | 6/16/2017          | 1                         | Deferred              | 1/2/2020                      | 12/19/2019                       | 12/19/2019                                | 7/31/2030                                 |
| Amantadine                                   | Extended-release Capsules     | 137 mg                                      | Gocovri 208944  | 1/16/2018          | 1                         |                       |                               |                                  |   | 12/2/2030                                 |
| Amantadine                                   | Extended-release Capsules     | 68.5 mg                                     | Gocovri 208944  | 4/30/2020          | 1                         |                       |                               |                                  |   | 12/4/2034                                 |
| Ambrisentan                                  | Tablets                       | 5 mg and 10 mg                              | Letairis 22081  | 2/9/2015           | 1                         | Extinguished          | 8/27/2019                     | 3/28/2019                        |   | 7/9/2018                                  |
| Amifampridine Phosphate                      | Tablets                       | 10 mg                                       | Firdapse 208078 | 11/28/2022         | 3                         |                       |                               |                                  |   | 2/25/2037                                 |
| Amifostine                                   | For Injection                 | 500 mg/vial                                 | Ethylol 20221   | 4/16/2004          | 1                         | Eligible              | 2/11/2020                     | 3/14/2008                        | 3/27/2008                                 | 7/31/2012                                 |
| Amlodipine Benzoate                          | Oral Suspension               | 1 mg/mL                                     | Katerzia 211340 | 12/29/2020         | 1                         | Eligible              | 6/26/2023                     | 6/13/2023                        |   | 4/11/2039                                 |
| Amlodipine Besylate                          | Tablets                       | 2.5 mg, 5 mg and 10 mg                      | Norvasc 19787   | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Amlodipine Besylate and Atorvastatin Calcium | Tablets                       | 2.5 mg/10 mg<br>2.5 mg/20 mg<br>10 mg/40 mg | Caduet 21540    | 9/17/2009          | 1                         | Extinguished          | 2/11/2020                     | 11/29/2013                       | 2/1/2011                                  | 8/11/2018                                 |
| Amlodipine Besylate and Atorvastatin Calcium | Tablets                       | 2.5 mg/40 mg                                | Caduet 21540    | 9/17/2009          | 1                         | Extinguished          | 2/11/2020                     | 11/29/2013                       | 2/1/2011                                  | 8/11/2018                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME  | DOSAGE FORM              | STRENGTH   | RLD/NDA               | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|--|-----------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Amlodipine Besylate and Atorvastatin Calcium     | Tablets                  | 5 mg/10 mg<br>5 mg/20 mg<br>5 mg/40 mg<br>10 mg/10 mg<br>10 mg/20 mg<br>10 mg/80 mg        | Caduet<br>21540       | 12/29/2006         | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 8/11/2018                                 |
| Amlodipine Besylate and Atorvastatin Calcium     | Tablets                  | 5 mg/80 mg   | Caduet<br>21540       | 4/7/2009           | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 8/11/2018                                 |
| Amlodipine Besylate and Benazepril Hydrochloride | Capsules                 | 2.5 mg/10 mg<br>5 mg/10 mg<br>5 mg/20 mg<br>10 mg/20 mg                                    | Lotrel<br>20364       | 6/9/2004           | 1                         | Eligible       | 2/11/2020                     | 3/18/2007                        |   | 12/19/2017                                |
| Amlodipine Besylate and Benazepril Hydrochloride | Capsules                 | 5 mg/40 mg and<br>10 mg/40 mg  | Lotrel<br>20364       | 11/17/2006         | 1                         | Eligible       | 2/11/2020                     | 7/29/2010                        | 1/3/2011                                  | 12/19/2017                                |
| Amlodipine Besylate and Celecoxib                | Tablets                  | 2.5 mg/200 mg,<br>5 mg/200 mg,<br>10 mg/200 mg   | Consensi<br>210045    | 6/29/2020          | 1                         |                |                               |                                  |   | 6/14/2038                                 |
| Amlodipine Besylate and Olmesartan Medoxomil     | Tablets                  | 5 mg/20 mg and<br>10 mg/40 mg  | Azor<br>22100         | 2/11/2008          | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 4/25/2016                                 |
| Amlodipine Besylate and Olmesartan Medoxomil     | Tablets                  | 10 mg/20 mg and<br>5 mg/40 mg  | Azor<br>22100         | 3/31/2008          | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 4/25/2016                                 |
| Amlodipine Besylate and Valsartan                | Tablets                  | 5 mg/160 mg  | Exforge<br>21990      | 10/22/2007         | 1                         | Eligible       | 2/11/2020                     | 3/28/2013                        | 9/30/2014                                 | 7/8/2019                                  |
| Amlodipine Besylate and Valsartan                | Tablets                  | 5 mg/320 mg  | Exforge<br>21990      | 11/26/2007         | 1                         | Eligible       | 2/11/2020                     | 3/28/2013                        | 9/30/2014                                 | 7/8/2019                                  |
| Amlodipine Besylate and Valsartan                | Tablets                  | 10 mg/160 mg   | Exforge<br>21990      | 10/1/2007          | 1                         | Eligible       | 2/11/2020                     | 3/28/2013                        | 9/30/2014                                 | 7/8/2019                                  |
| Amlodipine Besylate and Valsartan                | Tablets                  | 10 mg/320 mg   | Exforge<br>21990      | 11/9/2007          | 1                         | Eligible       | 2/11/2020                     | 3/28/2013                        | 9/30/2014                                 | 7/8/2019                                  |
| Amlodipine, Hydrochlorothiazide and Valsartan    | Tablets                  | 5 mg/12.5 mg/160 mg,<br>5 mg/25 mg/160 mg,<br>10 mg/25 mg/160 mg and<br>10 mg/25 mg/320 mg | Exforge HCT<br>22314  | 9/14/2009          | 1                         | Eligible       | 2/11/2020                     | 9/25/2012                        | 12/1/2014                                 | 7/18/2017                                 |
| Amlodipine, Hydrochlorothiazide and Valsartan    | Tablets                  | 10 mg/12.5 mg/<br>160 mg   | Exforge HCT<br>22314  | 10/22/2009         | 1                         | Eligible       | 2/11/2020                     | 9/25/2012                        | 12/1/2014                                 | 7/18/2017                                 |
| Amoxicillin and Clavulanate Potassium            | Extended-release Tablets | 1000 mg/62.5 mg  | Augmentin XR<br>50785 | 1/21/2009          | 1                         | Eligible       | 2/11/2020                     | 4/21/2010                        |   | 4/4/2020                                  |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME   | DOSAGE FORM                                    | STRENGTH  | RLD/NDA                  | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|--|---|--------------------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Amphetamine   | Extended-release Orally Disintegrating Tablets | 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg | Adzenys XR-ODT<br>204326 | 5/10/2016          | 1                         | Deferred                 | 6/26/2023                     | 6/22/2023                        |   | 1/28/2032                                 |
| Amphetamine Aspartate;Amphetamine Sulfate;Dextroamphetamine Saccharate; Dextroamphetamine Sulfate | Extended-release Capsules                      | 37.5 mg and 50 mg                                 | Mydayis<br>22063         | 8/3/2017           | 1                         | Extinguished<br>Deferred | 9/4/2023<br>2/8/2022          | 1/31/2022                        |   | 8/24/2029                                 |
| Amphetamine Aspartate;Amphetamine Sulfate;Dextroamphetamine Saccharate; Dextroamphetamine Sulfate | Extended-release Capsules                      | 12.5 mg and 25 mg                                 | Mydayis<br>22063         | 8/7/2017           | 1                         | Extinguished<br>Deferred | 9/4/2023<br>2/8/2022          | 1/31/2022                        |   | 8/24/2029                                 |
| Angiotensin II Acetate  | Injection                                      | 2.5 mg/mL   | Giapreza<br>209360       | 12/21/2021         | 1                         |                          |                               |                                  |   | 12/18/2034                                |
| Apalutamide   | Tablets  | 60 mg   | Erleada<br>210951        | 2/14/2022          | 5                         |                          |                               |                                  |   | 4/30/2038                                 |
| Apixaban  | Tablets  | 2.5 mg and 5 mg                                   | Eliquis<br>202155        | 12/28/2016         | 25                        | Eligible                 | 1/14/2020                     | 12/23/2019                       |   | 2/24/2031                                 |
| Apremilast  | Tablets  | 10 mg, 20 mg and 30 mg                            | Otezla<br>205437         | 3/22/2018          | 10                        | Eligible                 | 2/22/2021                     | 2/17/2021                        |   | 5/29/2034                                 |
| Aprepitant  | Capsule  | 40 mg, 80 mg and 125 mg                           | Emend<br>21549           | 11/3/2008          | 1                         | Deferred                 | 2/11/2020                     | 9/24/2012                        | 12/27/2016                                | 4/17/2015                                 |
| Aprepitant  | for Oral Suspension                            | 125 mg/Kit  | Emend<br>207865          | 11/23/2016         | 1                         | Extinguished             | 2/11/2020                     |                                  |   | 9/26/2027                                 |
| Aprepitant  | Intravenous Emulsion                           | 130 mg/18 mL                                      | Cinvanti<br>209296       | 4/29/2022          | 1                         |                          |                               |                                  |   | 9/18/2035                                 |
| Arformoterol Tartrate   | Inhalation Solution                            | Eq. 0.015 mg base/<br>2 mL                        | Brovana<br>21912         | 10/1/2009          | 1                         | Extinguished             | 7/2/2019                      |                                  |   | 11/9/2021                                 |
| Argatroban  | Injection                                      | 100 mg/mL,<br>2.5 mL vials                        | Argatroban<br>20883      | 9/24/2007          | 1                         | Extinguished             | 2/11/2020                     |                                  |   | 6/30/2014                                 |
| Argatroban in Sodium Chloride   | Injection                                      | 1 mg/mL,<br>50 mL vials                           | Argatroban<br>22434      | 12/16/2011         | 1                         | Extinguished             | 2/11/2020                     |                                  |   | 9/26/2027                                 |
| Aripiprazole  | Oral Solution                                  | 1 mg/mL   | Abilify<br>21713         | 12/20/2007         | 1                         | Extinguished             | 2/11/2020                     |                                  |   | 4/24/2022                                 |
| Aripiprazole  | Tablets  | 2 mg, 5 mg, 10 mg,<br>15 mg, 20 mg and 30 mg      | Abilify<br>21436         | 11/15/2006         | 8                         | Extinguished             | 2/11/2020                     |                                  |   | 10/20/2014                                |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                              | DOSAGE FORM                            | STRENGTH                      | RLD/NDA                     | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--|-------------------------------|-----------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Aripiprazole                           | Orally Disintegrating Tablets          | 10 mg, 15 mg, 20 mg and 30 mg | Abilify 21729               | 11/15/2006         | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 10/20/2014                                |
| Aripiprazole                           | Extended-release Injectable Suspension | 300 mg/vial and 400 mg/vial   | Abilify Maintena Kit 202971 | 12/20/2021         | 1                         |                |                               |                                  |   | 9/24/2033                                 |
| Armodafinil                            | Tablets                                | 50 mg, 150 mg and 250 mg      | Nuvigil 21875               | 7/24/2009          | 1                         | Eligible       | 2/11/2020                     | 6/1/2012                         | 6/1/2016                                  | 12/18/2024                                |
| Armodafinil                            | Tablets                                | 100 mg                        | Nuvigil 21875               | 9/8/2009           | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 12/18/2023                                |
| Armodafinil                            | Tablets                                | 200 mg                        | Nuvigil 21875               | 9/3/2009           | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 12/18/2023                                |
| Arsenic Trioxide                       | Injection                              | 1 mg/mL                       | Trisenox 21248              | 8/11/2015          | 1                         | Deferred       | 2/11/2020                     | 8/31/2018                        |   | 11/10/2018                                |
| Asenapine Maleate                      | Sublingual Tablets                     | 5 mg and 10 mg                | Saphris 22117               | 8/13/2013          | 4                         | Eligible       | 1/12/2021                     | 12/10/2020                       | 12/10/2020                                | 4/6/2026                                  |
| Asenapine Maleate                      | Sublingual Tablets                     | 2.5 mg                        | Saphris 22117               | 7/27/2017          | 1                         | Deferred       | 1/12/2021                     | 12/10/2020                       | 12/10/2020                                | 4/6/2026                                  |
| Aspirin and Omeprazole                 | Delayed-release Tablets                | 81 mg/40 mg and 325 mg/40 mg  | Yosprala 205103             | 10/14/2016         | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 2/28/2023                                 |
| Aspirin and Dipyridamole               | Extended-release Capsules              | 25 mg and 200 mg              | Aggrenox 20884              | 2/1/2007           | 1                         | Deferred       | 2/11/2020                     | 8/14/2009                        | 7/1/2015                                  | 1/18/2017                                 |
| Atazanavir Sulfate                     | Capsules                               | 100 mg and 150 mg             | Reyataz 21567               | 3/19/2010          | 1                         | Eligible       | 2/11/2020                     | 4/22/2014                        | 12/27/2017                                | 12/21/2018                                |
| Atazanavir Sulfate                     | Capsules                               | 200 mg                        | Reyataz 21567               | 2/16/2010          | 1                         | Eligible       | 2/11/2020                     | 4/22/2014                        | 12/27/2017                                | 12/21/2018                                |
| Atazanavir Sulfate                     | Capsules                               | 300 mg                        | Reyataz 21567               | 7/20/2009          | 1                         | Eligible       | 2/11/2020                     | 4/22/2014                        | 12/27/2017                                | 12/21/2018                                |
| Atazanavir Sulfate and Cobicistat      | Tablets                                | 300 mg/150 mg                 | Evotaz 206353               | 9/13/2017          | 1                         |                |                               |                                  |   | 9/3/2029                                  |
| Atenolol                               | Tablets                                | 25 mg, 50 mg and 100 mg       | Tenormin 18240              | Pre-MMA            |                           |                |                               |                                  |   |   |
| Atenolol/ Chlorthalidone               | Tablets                                | 50 mg/25 mg and 100 mg/25 mg  | Tenoretic 18760             | Pre-MMA            |                           |                |                               |                                  |   |   |
| Atovaquone                             | Oral Suspension                        | 750 mg/5 mL                   | Mepron 20500                | 10/20/2009         | 1                         | Extinguished   | 2/11/2020                     |                                  |   |   |
| Atovaquone and Proguanil Hydrochloride | Tablets                                | 62.5 mg/25 mg                 | Malarone 21078              | 9/14/2010          | 1                         | Extinguished   | 2/11/2020                     | 5/27/2014                        |   | 11/25/2013                                |
| Atovaquone and Proguanil Hydrochloride | Tablets                                | 250 mg/100 mg                 | Malarone 21078              | 4/3/2009           | 1                         | Eligible       | 2/11/2020                     | 1/12/2011                        | 9/15/2011                                 | 11/25/2013                                |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME   | DOSAGE FORM         | STRENGTH  | RLD/NDA                                 | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---------------------|---|---|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Atomoxetine Hydrochloride                           | Capsules            | 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg | Strattera 21411                         | 5/29/2007          | 10                        | Extinguished   | 2/11/2020                     | 5/30/2017                        |   | 11/26/2016                                |
| Atorvastatin Calcium                                | Tablets             | 10 mg, 20 mg, 40 mg and 80 mg                       | Lipitor 20702                           | Pre-MMA            |                           |                |                               |                                  |   |   |
| Avanafil  | Tablets             | 50 mg, 100 mg and 200 mg                            | Stendra 202276                          | 4/27/2016          | 1                         |                |                               |                                  |   | 4/27/2025                                 |
| Axitinib  | Tablets             | 1 mg and 5 mg                                       | Inlyta 202324                           | 2/23/2018          | 1                         |                |                               |                                  |   | 12/14/2030                                |
| Azacitidine   | Tablets             | 200 mg and 300 mg                                   | Onureg 214120                           | 9/30/2021          | 1                         |                |                               |                                  |   | 6/3/2030                                  |
| Azelaic Acid  | Gel                 | 15%   | Finacea 21470                           | 7/27/2012          | 1                         | Extinguished   | 2/11/2020                     | 11/19/2018                       |   | 11/18/2018                                |
| Azelaic Acid  | Topical Foam        | 15%   | Finacea 207071                          | 9/14/2017          | 1                         | Eligible       | 9/6/2022                      | 10/7/2020                        |   | 2/28/2029                                 |
| Azelastine Hydrochloride                            | Nasal Spray         | 0.125 mg base/spray                                 | Astelin 20114                           | 11/14/2005         | 1                         | Eligible       | 2/11/2020                     | 4/30/2009                        | 6/23/2010                                 | 5/1/2011                                  |
| Azelastine Hydrochloride                            | Nasal Spray         | 205.5 mcg/spray                                     | Astepro 22203                           | 12/15/2011         |                           |                |                               |                                  |   |   |
| Azelastine Hydrochloride                            | Nasal Spray         | 205.5 mcg/spray                                     | Astepro Allergy (OTC) 213872            | 7/12/2021          | 1                         |                |                               |                                  |   | 6/4/2028                                  |
| Azelastine Hydrochloride                            | Nasal Spray         | 205.5 mcg/spray                                     | Children's Astepro Allergy (OTC) 213872 | 7/12/2021          | 1                         |                |                               |                                  |   | 6/4/2028                                  |
| Azelastine Hydrochloride                            | Ophthalmic Solution | 0.05%   | Optivar 21127                           | 12/13/2006         | 1                         | Eligible       | 2/11/2020                     | 8/3/2009                         | 12/1/2009                                 | 5/1/2011                                  |
| Azelastine Hydrochloride and Fluticasone Propionate | Nasal Spray         | 137 mcg/50 mcg per spray                            | Dymista 202236                          | 6/13/2014          | 1                         | Eligible       | 6/18/2019                     | 4/28/2017                        | 3/2/2020                                  | 8/24/2026                                 |
| Azilsartan Kamedoxomil                              | Tablets             | 40 mg and 80 mg                                     | Edarbi 200796                           | 4/10/2020          | 1                         | Eligible       | 9/6/2022                      | 7/20/2022                        |   | 3/26/2028                                 |
| Azilsartan Kamedoxomil and Chlorthalidone           | Tablets             | 40 mg/12.5 mg and 40 mg/25 mg                       | Edarbyclor 202331                       | 4/19/2022          | 1                         |                |                               |                                  |   | 7/1/2031                                  |
| Azithromycin  | for Injection       | 500 mg/vial   | Zithromax 20733                         | 1/26/2009          | 2                         | Eligible       | 2/11/2020                     | 3/24/2009                        | 5/11/2009                                 | 7/31/2018                                 |
| Azithromycin  | Ophthalmic Solution | 1%  | Azasite 50810                           | 3/3/2011           | 1                         | Extinguished   | 2/11/2020                     |                                  |   | 3/31/2019                                 |
| Baclofen  | Oral Solution       | 5 mg/5 mL   | Ozobax 208193                           | 7/26/2021          | 1                         |                |                               |                                  |   | 8/30/2039                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME  | DOSAGE FORM         | STRENGTH                                       | RLD/NDA         | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|---------------------|--|-----------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Baclofen   | Oral Suspension     | 25 mg/5 mL                                     | Fleqsuvy 215602 | 5/20/2022          | 1                         | Eligible                 | 6/12/2023                     | 6/8/2023                         | 6/19/2023                                 | 9/29/2037                                 |
| Baloxavir Marboxil   | Tablets             | 40 mg and 80 mg                                | Xofluza 210854  | 10/24/2022         | 1                         |                          |                               |                                  |   | 9/25/2038                                 |
| Balsalazide Disodium   | Capsules            | 750 mg   | Colazal 20610   | 5/26/2022          | 1                         |                          |                               |                                  |   | 8/24/2026                                 |
| Balsalazide Disodium   | Tablets             | 1.1 g  | Giazo 22205     | 11/5/2013          | 1                         | Eligible                 | 2/11/2020                     | 9/8/2015                         |   | 6/23/2031                                 |
| Baricitinib  | Tablets             | 1 mg and 2 mg                                  | Olumiant 207924 | 5/31/2022          | 2                         |                          |                               |                                  |   | 6/8/2030                                  |
| Beclomethasone Dipropionate  | Inhalation Aerosol  | 40 mcg/actuation and 80 mcg/actuation          | Qvar 20911      | 1/10/2020          | 1                         |                          |                               |                                  |   | 5/18/2031                                 |
| Belinostat   | Injection           | 500 mg/vial                                    | Beleodaq 206256 | 7/3/2018           | 1                         |                          |                               |                                  |   | 10/27/2027                                |
| Bendamustine Hydrochloride   | Injection           | 25 mg/vial and 100 mg/vial                     | Treanda 22249   | 6/4/2013           | 10                        | Eligible                 | 1/10/2023                     | 12/7/2022                        | 12/7/2022                                 | 10/26/2030                                |
| Bendamustine Hydrochloride   | Injection           | 90 mg/mL, 0.5 mL and 2 mL in single-dose vials | Treanda 22249   | 6/19/2014          | 1                         |                          |                               |                                  |   | 9/23/2029                                 |
| Bendamustine Hydrochloride   | Injection           | 100 mg/4 mL (25 mg/mL) multiple-dose vials     | Bendeka 208194  | 5/4/2017           | 1                         |                          |                               |                                  |   | 3/15/2033                                 |
| Bendamustine Hydrochloride   | Injection           | 100 mg/4 mL (25 mg/mL) multiple-dose vials     | Belrapzo 205580 | 7/17/2018          | 1                         |                          |                               |                                  |   | 1/28/2031                                 |
| Benzyl Alcohol   | Lotion              | 5%   | Ulesfia 22129   | 4/11/2016          | 1                         | Extinguished             | 6/15/2020                     |                                  |   | 5/19/2024                                 |
| Bepotastine Besilate   | Ophthalmic Solution | 1.5%   | Bepreve 22288   | 9/9/2013           | 3                         | Extinguished<br>Deferred | 2/11/2020<br>2/11/2020        | 3/5/219                          |   | 9/19/2019                                 |
| Betamethasone Valerate   | Foam                | 0.12%  | Luxiq 20934     | 8/10/2007          | 1                         | Deferred                 | 2/11/2020                     | 11/26/2012                       |   | 5/24/2017                                 |
| Betamethasone Dipropionate   | Topical Spray       | 0.05%  | Sernivo 208079  | 2/15/2018          | 1                         | Eligible                 | 7/13/2020                     | 6/17/2020                        |   | 8/31/2030                                 |
| Betaxolol  | Ophthalmic Solution | 0.5%(base)                                     | Betoptic 19270  | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Bexarotene   | Capsules            | 75 mg  | Targretin 20155 | 6/6/2011           | 1                         | Eligible                 | 2/11/2020                     | 8/12/2014                        | 7/9/2015                                  | 10/5/2016                                 |
| Bictegravir Sodium, Emtricitabine and Tenofovir Alafenamide Fumarate | Tablets             | 50 mg/200 mg/ 25 mg                            | Biktaryv 210251 | 2/7/2022           | 3                         |                          |                               |                                  |   | 11/8/2036                                 |



**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME   | DOSAGE FORM           | STRENGTH   | RLD/NDA                | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|-----------------------|--|------------------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Bimatoprost   | Ophthalmic Solution   | 0.01%  | Lumigan<br>22184       | 4/5/2011           | 1                         |                          |                               |                                  |   | 6/13/2027                                 |
| Bimatoprost   | Ophthalmic Solution   | 0.03%  | Lumigan<br>21275       | 12/22/2008         | 1                         | Extinguished             | 2/11/2020                     |                                  |   |   |
| Bimatoprost   | Topical Solution      | 0.03%  | Latisse<br>22369       | 5/3/2010           | 1                         | Extinguished<br>Deferred | 6/18/2019<br>6/18/2019        | 12/1/2014                        |   | 5/25/2024                                 |
| Binimetinib   | Tablets               | 15 mg  | Mektovi<br>210498      | 6/27/2022          | 3                         |                          |                               |                                  |   | 10/18/2033                                |
| Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Hydrochloride | Capsules              | 140 mg/125 mg/<br>125 mg                         | Pylera<br>50786        | 8/12/2014          | 1                         | Extinguished             | 2/11/2020                     |                                  |   | 12/14/2018                                |
| Bivalirudin   | For Injection         | 250 mg/vial                                      | Angiomax<br>20873      | 9/1/2009           | 1                         | Extinguished             | 2/11/2020                     |                                  |   | 7/27/2028                                 |
| Bosentan  | for Oral Suspension   | 32 mg  | Tracleer<br>209279     | 2/8/2019           | 1                         |                          |                               |                                  |   | 12/28/2027                                |
| Bosutinib   | Tablets               | 100 mg and 500 mg                                | Bosulif<br>203341      | 9/6/2016           | 2                         |                          |                               |                                  |   | 11/23/2026                                |
| Bosutinib   | Tablets               | 400 mg   | Bosulif<br>203341      | 10/25/2018         | 1                         |                          |                               |                                  |   | 11/23/2026                                |
| Bortezomib  | For Injection         | 3.5 mg/vial                                      | Velcade<br>21602       | 11/20/2008         | 1                         | Extinguished             | 1/27/2020                     |                                  |   | 1/25/2022                                 |
| Brexipiprazole  | Tablets               | 0.25 mg, 0.5 mg,<br>1 mg, 2 mg, 3 mg<br>and 4 mg | Rexulti<br>205422      | 7/10/2019          | 18                        | Deferred                 | 9/6/2022                      | 8/11/2022                        |   | 10/12/2032                                |
| Brimonidine   | Topical Gel           | 0.33%  | Mirvaso<br>204708      | 12/15/2014         | 1                         | Extinguished             | 10/8/2019                     |                                  |   | 6/13/2031                                 |
| Brimonidine Tartrate  | Ophthalmic Solution   | 0.1%   | Alphagan P<br>21770    | 12/20/2006         | 1                         | Extinguished             | 12/13/2022                    |                                  |   | 7/28/2021                                 |
| Brimonidine Tartrate  | Ophthalmic Solution   | 0.15%  | Alphagan P<br>21262    | 11/03/2006         | 1                         | Extinguished             | 2/11/2020                     |                                  |   | 1/28/2022                                 |
| Brimonidine Tartrate  | Ophthalmic Solution   | 0.2%   | Alphagan<br>20613      | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Brimondinie Tartrate  | Ophthalmic Solution   | 0.025%   | Lumify (OTC)<br>208144 | 7/12/2021          | 1                         |                          |                               |                                  |   | 7/14/2030                                 |
| Brimonidine Tartrate and Timolol Maleate                                    | Ophthalmic Solution   | 0.2%/0.5%  | Combigan<br>21398      | 11/21/2008         | 1                         | Extinguished             | 5/5/2022                      |                                  |   | 4/19/2022                                 |
| Brinzolamide and Brimonidine Tartrate                                       | Ophthalmic Suspension | 1%/0.2%  | Simbrinza<br>204251    | 8/1/2022           | 1                         |                          |                               |                                  |   | 10/30/2030                                |
| Brivaracetam  | Injection             | 50 mg/5 mL                                       | Briviact<br>205837     | 5/12/2020          | 2                         |                          |                               |                                  |   | 2/21/2026                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                    | DOSAGE FORM              | STRENGTH  | RLD/NDA                        | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS                 | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|---|--------------------------------|--------------------|---------------------------|--------------------------------|-------------------------------|----------------------------------|---|---|
| Brivaracetam                                 | Oral Solution            | 10 mg/mL  | Briviact<br>205838             | 5/12/2020          | 1                         |                                |                               |                                  |   | 2/21/2026                                 |
| Brivaracetam                                 | Tablets                  | 10 mg, 25 mg,<br>50 mg, 75 mg and<br>100 mg                               | Briviact<br>205836             | 5/12/2020          | 7                         | Eligible                       | 7/25/2022                     | 6/9/2022                         |   | 2/21/2026                                 |
| Bromfenac Sodium                             | Ophthalmic Solution      | 0.07%   | Prolensa<br>203168             | 7/26/2013          | 1                         | Non-Forfeiture                 | 11/19/2019                    |                                  |   | 9/11/2025                                 |
| Bromfenac Sodium                             | Ophthalmic Solution      | 0.075%  | Bromsite<br>206911             | 10/25/2017         | 1                         |                                |                               |                                  |   | 8/7/2029                                  |
| Budesonide                                   | Enteric Coated Capsules  | 3 mg  | Entocort EC<br>21324           | 2/1/2008           | 1                         | Extinguished                   | 2/11/2020                     | 4/2/2014                         |   | 1/1/2015                                  |
| Budesonide                                   | Nasal Spray              | 0.032 mg<br>(32 mcg)/spray  | Rhinocort<br>20746             | 5/14/2007          | 1                         | Deferred                       | 2/11/2020                     | 5/12/2014                        | 5/13/2014                                 | 10/29/2017                                |
| Budesonide                                   | Inhalation Suspension    | 0.25 mg/2 mL and<br>0.5 mg/2 mL   | Pulmicort<br>Respules<br>20929 | 9/15/2005          | 1                         | Extinguished                   | 4/7/2020                      | 11/18/2008                       |   | 2/27/2006                                 |
| Budesonide                                   | Inhalation Suspension    | 1 mg/2 mL   | Pulmicort<br>Respules<br>20929 | 5/28/2010          | 1                         | Eligible                       | 2/11/2020                     | 9/27/2013                        | 7/27/2015                                 | 12/23/2018                                |
| Budesonide                                   | Extended-release Tablets | 9 mg  | Uceris<br>203634               | 3/11/2013          | 1                         | Deferred                       | 6/18/2019                     | 7/3/2018                         | 7/5/2018                                  | 6/9/2020                                  |
| Budesonide and Formoterol Fumarate Dihydrate | Metered Inhalation       | 80 mcg/4.5 mcg per<br>inhalation and<br>160 mcg/4.5 mcg per<br>inhalation | Symbicort<br>21929             | 6/26/2018          | 1                         | Deferred                       | 3/18/2022                     | 3/15/2022                        | 7/31/2023                                 | 10/16/2028                                |
| Bupivacaine Liposome                         | Injectable Suspension    | 133 mg/10 mL  | Exparel<br>22496               | 12/28/2021         | 1                         |                                |                               |                                  |   | 1/22/20241                                |
| Bupivacaine Liposome                         | Injectable Suspension    | 266 mg/20 mL  | Exparel<br>22496               | 8/20/2021          | 1                         |                                |                               |                                  |   | 1/22/2041                                 |
| Buprenorphine and Naloxone                   | Buccal Film              | 2.1 mg/0.3 mg and<br>4.2 mg/0.7 mg  | Bunavail<br>205637             | 11/23/2016         | 1                         |                                |                               |                                  |   | 8/20/2032                                 |
| Buprenorphine and Naloxone                   | Buccal Film              | 6.3 mg/1 mg   | Bunavail<br>205637             | 12/21/2015         | 1                         |                                |                               |                                  |   | 8/20/2032                                 |
| Buprenorphine Hydrochloride                  | Buccal Film              | 75 mcg and<br>150 mcg   | Belbuca<br>207932              | 10/24/2016         | 1                         | Extinguished<br>Non-Forfeiture | 6/29/2021<br>2/9/2021         |                                  |   | 7/23/2027                                 |
| Buprenorphine Hydrochloride                  | Buccal Film              | 300 mcg, 450 mcg,<br>600 mcg and<br>750 mcg                               | Belbuca<br>207932              | 10/4/2016          | 1                         | Extinguished<br>Non-Forfeiture | 6/29/2021<br>2/9/2021         |                                  |   | 7/23/2027                                 |
| Buprenorphine Hydrochloride                  | Buccal Film              | 900 mcg   | Belbuca<br>207932              | 9/12/2016          | 1                         | Extinguished<br>Non-Forfeiture | 6/29/2021<br>2/9/2021         |                                  |   | 7/23/2027                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME  | DOSAGE FORM              | STRENGTH                           | RLD/NDA             | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|------------------------------------|---------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Buprenorphine Hydrochloride and Naloxone Hydrochloride           | Sublingual Film          | 2 mg/0.5 mg* and 8 mg/2 mg         | Suboxone 22410      | 10/15/2012         | 1                         | Extinguished   | 2/25/2020                     |                                  |   | 2/13/2023                                 |
| Buprenorphine Hydrochloride and Naloxone Hydrochloride*          | Sublingual Film          | 4 mg/1 mg                          | Suboxone 22410      | 5/14/2013          | 1                         | Extinguished   | 2/25/2020                     |                                  |   | 2/13/2023                                 |
| Buprenorphine Hydrochloride and Naloxone Hydrochloride           | Sublingual Film          | 12 mg/3 mg                         | Suboxone 22410      | 5/14/2013          | 1                         | Extinguished   | 2/25/2020                     |                                  |   | 2/13/2023                                 |
| Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate | Sublingual Tablets       | 1.4 mg/0.36 mg and 5.7 mg/1.4 mg   | Zubsolv 204242      | 10/22/2013         | 1                         |                |                               |                                  |   | 5/22/2030                                 |
| Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate | Sublingual Tablets       | 8.6 mg/2.1 mg and 11.4 mg/2.9 mg   | Zubsolv 204242      | 7/24/2015          | 1                         |                |                               |                                  |   | 9/18/2032                                 |
| Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate | Sublingual Tablets       | 2.9 mg/7.1 mg                      | Zubsolv 204242      | 12/21/2015         | 1                         |                |                               |                                  |   | 9/18/2032                                 |
| Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate | Sublingual Tablets       | 0.7 mg/0.18 mg                     | Zubsolv 204242      | 5/4/2017           | 1                         |                |                               |                                  |   | 9/18/2032                                 |
| Buprenorphine  | Transdermal System       | 5 mcg/hr<br>10 mcg/hr<br>20 mcg/hr | Butrans 21306       | 6/6/2013           | 1                         | Extinguished   | 6/18/2019                     | 11/20/2018                       |   | 9/29/2017                                 |
| Buprenorphine  | Transdermal System       | 15 mcg/hr                          | Butrans 21306       | 12/16/2013         | 1                         | Extinguished   | 6/18/2019                     | 11/20/2018                       |   | 9/29/2017                                 |
| Bupropion Hydrobromide   | Extended-release Tablets | 174 mg                             | Aplenzin 22108      | 9/28/2009          | 1                         | Extinguished   | 2/25/2020                     |                                  |   | 6/27/2026                                 |
| Bupropion Hydrobromide   | Extended-release Tablets | 348 mg                             | Aplenzin 22108      | 9/24/2009          | 1                         | Extinguished   | 2/25/2020                     |                                  |   | 6/27/2026                                 |
| Bupropion Hydrobromide   | Extended-release Tablets | 522 mg                             | Aplenzin 22108      | 12/24/2009         | 1                         | Extinguished   | 2/25/2020                     |                                  |   | 6/27/2026                                 |
| Bupropion Hydrochloride  | Extended-release Tablets | 100 mg, 150 mg and 200 mg          | Wellbutrin SR 20358 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Bupropion Hydrochloride  | Extended-release Tablets | 150 mg                             | Zyban 20711         | Pre-MMA            |                           |                |                               |                                  |   |   |
| Bupropion Hydrochloride  | Extended-release Tablets | 150 mg and 300 mg                  | Wellbutrin XL 21515 | 9/21/2004          | 1                         | Eligible       | 2/25/2020                     | 12/14/2006                       | 5/30/2008 - 150 mg<br>12/4/2006 - 300 mg  | 10/30/2018                                |
| Bupropion Hydrochloride  | Extended-release Tablets | 450 mg                             | Forfivo XL 22497    | 2/28/2013          | 1                         | Extinguished   | 2/25/2020                     |                                  | 10/1/2018                                 | 6/25/2027                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME  | DOSAGE FORM      | STRENGTH                              | RLD/NDA               | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS    | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|------------------|---------------------------------------|-----------------------|--------------------|---------------------------|-------------------|-------------------------------|----------------------------------|---|---|
| Bupropion Hydrochloride  | Tablets          | 75 mg and 100 mg                      | Wellbutrin 18644      | Pre-MMA            |                           |                   |                               |                                  |   |   |
| Buspirone Hydrochloride  | Tablets          | 5 mg, 7.5 mg, 10 mg, 15 mg and 30 mg  | Buspar 18731          | Pre-MMA            |                           |                   |                               |                                  |   |   |
| Busulfan   | Injection        | 6 mg/mL                               | Busulfex 20954        | 12/26/2012         | 1                         | Extinguished      | 2/25/2020                     | 9/21/2018                        |   | 9/30/2013                                 |
| Butoconazole Nitrate   | Vaginal Cream    | 2%                                    | Gynazole-1 19881      | 12/23/2009         | 1                         | Eligible          | 2/25/2020                     | 5/18/2012                        | 11/15/2012                                | 11/17/2017                                |
| Butorphanol Tartrate   | Nasal Spray      | 10 mg/mL                              | Stadol NS 19890       | Pre-MMA            |                           |                   |                               |                                  |   |   |
| Cabazitaxel  | Injection        | 60 mg/1.5 mL                          | Jevtana Kit 201023    | 6/17/2014          | 8                         | Eligible Deferred | 2/20/2023<br>7/25/2022        | 6/23/2022                        |   | 12/10/2025                                |
| Cabozantinib   | Tablets          | 20 mg, 40 mg and 60 mg                | Cabometyx 208692      | 8/16/2019          | 1                         |                   |                               |                                  |   | 7/9/2033                                  |
| Calcipotriene  | Topical Cream    | 0.005%                                | Dovonex 20554         | 12/2/2009          | 1                         | Eligible          | 2/25/2020                     | 5/30/2012                        | 7/27/2012                                 | 6/9/2015                                  |
| Calcipotriene  | Topical Solution | 0.005%                                | Dovonex 20611         | 5/19/2006          | 1                         | Eligible          | 2/25/2020                     | 5/6/2008                         | 5/6/2008                                  | 6/9/2015                                  |
| Calcipotriene and Betamethasone Dipropionate                             | Ointment         | 0.005%/0.064%                         | Taclonex 21852        | 3/31/2010          | 1                         | Eligible          | 2/25/2020                     | 1/14/2013                        | 3/31/2014                                 | 1/27/2020                                 |
| Calcipotriene and Betamethasone Dipropionate                             | Topical Foam     | 0.005%/0.064%                         | Enstilar 207589       | 6/22/2020          | 1                         | Eligible          | 4/18/2023                     | 3/21/2023                        |   | 6/10/2031                                 |
| Calcitonin-Salmon  | Nasal Spray      | 200 IU/spray                          | Miacalcin 20313       | Pre-MMA            |                           |                   |                               |                                  |   |   |
| Calcitonin-Salmon (Recombinant)  | Nasal Spray      | 200 IU/spray                          | Fortical 21406        | 3/29/2006          | 1                         | Extinguished      | 4/7/2020                      |                                  |   | 2/2/2021                                  |
| Calcitriol   | Injection        | 1 mcg/mL and 2 mcg/mL, 1 mL vials     | Calcijex 18874        | Pre-MMA            |                           |                   |                               |                                  |   |   |
| Calcium Acetate  | Capsules         | EQ 169 mg calcium                     | PhosLo 21160          | 5/31/2005          | 1                         | Eligible          | 2/25/2020                     | 2/26/2008                        |   | 4/3/2021                                  |
| Calcium Acetate  | Oral Solution    | 667 mg/5 mL                           | Phoslyra 22581        | 12/5/2013          | 2                         |                   |                               |                                  |   | 2/23/2030                                 |
| Calcium Carbonate/ Famotadine/ Magnesium Hydroxide                       | Chewable Tablets | 800 mg/10 mg/ 165 mg (OTC)            | Pepcid Complete 20958 | 11/1/2004          | 1                         | Deferred          | 3/10/2020                     | 2/6/2008                         |   | 3/30/2016                                 |
| Calcium Oxybate, Magnesium Oxybate, Potassium Oxybate and Sodium Oxybate | Oral Solution    | 0.234 g/0.096 g/ 0.13 g/0.04 g per mL | Xywav 212690          | 4/12/2021          | 1                         |                   |                               |                                  |   | 3/15/2033                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                     | DOSAGE FORM                  | STRENGTH   | RLD/NDA                | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|------------------------------|--|------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Canagliflozin                                 | Tablets                      | 100 mg and 300 mg  | Invokana<br>204042     | 3/29/2017          | 10                        |                |                               |                                  |   | 2/26/2029                                 |
| Canagliflozin and Metformin Hydrochloride     | Tablets                      | 50 mg/500 mg<br>50 mg/1000 mg<br>150 mg/500 mg<br>150 mg/1000 mg | Invokamet<br>204353    | 3/29/2017          | 6                         |                |                               |                                  |   | 2/26/2029                                 |
| Canagliflozin and Metformin Hydrochloride     | Extended-release<br>Tablets  | 50 mg/500 mg<br>50 mg/1000 mg<br>150 mg/500 mg<br>150 mg/1000 mg | Invokamet-XR<br>205879 | 11/21/2018         | 1                         |                |                               |                                  |   | 2/26/2029                                 |
| Candesartan Cilexetil                         | Tablets                      | 4 mg, 8 mg, 16 mg<br>and 32 mg                                   | Atacand<br>20838       | 12/22/2006         | 1                         | Eligible       | 3/10/2020                     | 5/3/2013                         | 5/21/2013                                 | 1/9/2014                                  |
| Candesartan Cilexetil and Hydrochlorothiazide | Tablets                      | 16 mg/12.5 mg and<br>32 mg/12.5 mg                               | Atacand HCT<br>21093   | 6/25/2008          | 1                         | Extinguished   | 3/10/2020                     | 12/4/2012                        |   | 2/24/2015                                 |
| Candesartan Cilexetil and Hydrochlorothiazide | Tablets                      | 32 mg/25 mg  | Atacand HCT<br>21093   | 3/6/2009           | 1                         | Eligible       | 3/10/2020                     | 12/4/2012                        | 12/4/2012                                 | 2/24/2015                                 |
| Cangrelor                                     | For Injection                | 50 mg/vial   | Kengreal<br>204958     | 6/24/2019          | 2                         |                |                               |                                  |   | 7/10/2035                                 |
| Cannabidiol                                   | Oral Solution                | 100 mg/mL  | Epidiolex<br>210365    | 9/28/2022          | 10                        |                |                               |                                  |   | 3/1/2041                                  |
| Capecitabine                                  | Tablets                      | 150 mg and 500 mg  | Xeloda<br>20896        | 11/10/2008         | 1                         | Extinguished   | 3/10/2020                     | 8/8/2014                         |   | 12/14/2013                                |
| Captopril                                     | Tablets                      | 12.5 mg, 25 mg,<br>50 mg, and 100 mg                             | Capoten<br>18343       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Carbamazepine                                 | Extended-release<br>Capsules | 100 mg and 200 mg  | Carbatrol<br>20712     | 2/2/2006           | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 6/15/2016                                 |
| Carbamazepine                                 | Extended-release<br>Capsules | 200 mg and 300 mg  | Equetro<br>21710       | 8/21/2007          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 5/19/2024                                 |
| Carbamazepine                                 | Extended-release<br>Capsules | 100 mg   | Equetro<br>21710       | 5/23/2014          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 5/19/2024                                 |
| Carbamazepine                                 | Extended-release<br>Capsules | 300 mg   | Carbatrol<br>20712     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Carbamazepine                                 | Extended-release<br>Tablets  | 100 mg   | Tegretol-XR<br>20234   | 12/30/2005         | 1                         | Deferred       | 3/10/2020                     | 3/31/2009                        |   | 2/8/2011                                  |
| Carbamazepine                                 | Extended-release<br>Tablets  | 200 mg and 400 mg  | Tegretol-XR<br>20234   | Pre-MMA            |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                          | DOSAGE FORM                  | STRENGTH  | RLD/NDA                                   | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|------------------------------------|------------------------------|---|---|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Carbidopa, Levodopa and Entacapone | Tablets                      | 12.5 mg, 50 mg and 200 mg                                   | Stalevo 50<br>21485                       | 8/5/2008           | 1                         | Extinguished<br>Deferred | 3/10/2020<br>3/10/2020        | 11/20/2012                       |   | 6/29/2020                                 |
| Carbidopa, Levodopa and Entacapone | Tablets                      | 18.75 mg/75 mg/<br>200 mg and<br>31.25 mg/125 mg/<br>200 mg | Stalevo 75 and<br>Stalevo 125<br>21485    | 5/19/2009          | 1                         | Deferred                 | 3/10/2020                     | 11/20/2012                       |   | 6/29/2020                                 |
| Carbidopa, Levodopa and Entacapone | Tablets                      | 25/100/200 mg and<br>37.5/150/200 mg                        | Stalevo 100 and<br>Stalevo 150<br>21485   | 6/29/2007          | 1                         | Extinguished             | 4/7/2020                      | 5/10/2012                        |   | 6/29/2020                                 |
| Carbidopa, Levodopa and Entacapone | Tablets                      | 50 mg/200 mg/<br>200 mg                                     | Stalevo 200<br>21485                      | 8/28/2008          | 1                         | Deferred                 | 3/10/2020                     |                                  |   |   |
| Carbidopa/ Levodopa                | Extended-release<br>Tablets  | 25 mg/100 mg and<br>50 mg/200 mg                            | Sinemet CR<br>19856                       | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Carbidopa and Levodopa             | Extended-release<br>Capsules | 61.25 mg/245 mg   | Rytary<br>203312                          | 6/10/2015          | 1                         | Non-Forfeiture           | 8/10/2020                     |                                  |   | 12/26/2028                                |
| Carbidopa and Levodopa             | Extended-release<br>Capsules | 23.75 mg/95 mg,<br>36.25 mg/145 mg,<br>48.75 mg/195 mg      | Rytary<br>203312                          | 6/24/2015          | 1                         | Non-Forfeiture           | 8/10/2020                     |                                  |   | 12/26/2028                                |
| Carboplatin                        | For Injection                | 50 mg/vial,<br>150 mg/vial and<br>450 mg/vial               | Paraplatin<br>19880                       | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Carboplatin                        | Injection                    | 50 mg/vial,<br>150 mg/vial and<br>450 mg/vial               | Paraplatin<br>20452                       | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Carfilzomib                        | For Injection                | 10 mg/vial  | Kyprolis<br>202714                        | 11/28/2018         | 1                         | Deferred                 | 7/13/2021                     | 6/11/2021                        |   | 2/27/2033                                 |
| Carfilzomib                        | For Injection                | 60 mg/vial  | Kyprolis<br>202714                        | 7/20/2016          | 9                         | Eligible                 | 7/13/2021                     | 9/9/2019                         |   | 12/7/2027                                 |
| Carfilzomib                        | For Injection                | 30 mg/vial  | Kyprolis<br>202714                        | 10/5/2017          | 1                         | Eligible                 | 7/25/2022                     | 3/20/2020                        |   | 2/27/2033                                 |
| Cariprazine                        | Capsules                     | 1.5 mg, 3 mg,<br>4.5 mg and 6 mg                            | Vraylar<br>204370                         | 9/17/2019          | 3                         | Eligible                 | 10/4/2022                     | 9/9/2022                         |   | 7/16/2029                                 |
| Carisoprodol/ Aspirin              | Tablets                      | 200 mg/ 325 mg  | Soma<br>Compound<br>12365                 | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Carisoprodol/ Aspirin/ Codeine     | Tablets                      | 200 mg/325 mg/<br>16 mg                                     | Soma<br>Compound with<br>Codeine<br>12366 | Pre-MMA            |                           |                          |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME  | DOSAGE FORM               | STRENGTH                             | RLD/NDA         | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|---------------------------|--------------------------------------|-----------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Carvedilol   | Tablets                   | 3.125 mg, 6.25 mg, 12.5 mg and 25 mg | Coreg 20297     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Carvedilol Phosphate                                   | Extended-release Capsules | 10 mg and 20 mg                      | Coreg CR 22012  | 3/18/2008          | 1                         | Deferred       | 4/7/2020                      | 10/25/2017                       | 11/8/2017                                 | 12/27/2023                                |
| Carvedilol Phosphate                                   | Extended-release Capsules | 40 mg                                | Coreg CR 22012  | 12/21/2007         | 1                         | Deferred       | 4/7/2020                      | 10/25/2017                       | 11/8/2017                                 | 12/27/2023                                |
| Carvedilol Phosphate                                   | Extended-release Capsules | 80 mg                                | Coreg CR 22012  | 11/19/2007         | 1                         | Deferred       | 4/7/2020                      | 10/25/2017                       | 11/8/2017                                 | 12/27/2023                                |
| Caspofungin Acetate                                    | for Injection             | 50 mg/vial and 70 mg/vial            | Cancidas 21227  | 6/26/2009          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 3/28/2017                                 |
| Cefixime   | for Oral Suspension       | 500 mg/5 mL                          | Suprax 202091   | 7/22/2016          | 1                         | Deferred       | 4/7/2020                      | 2/6/2017                         |   | 12/14/2028                                |
| Ceftaroline Fosamil                                    | for Injection             | 400 mg/vial and 600 mg/vial          | Teflaro 200327  | 10/29/2014         | 2                         | Deferred       | 10/19/2021                    | 9/21/2021                        |   | 2/10/2031                                 |
| Celecoxib  | Capsules                  | 50 mg                                | Celebrex 20998  | 3/21/2008          | 1                         | Extinguished   | 3/10/2020                     | 5/30/2014                        |   | 4/14/2018                                 |
| Celecoxib  | Capsules                  | 100 mg, 200 mg and 400 mg            | Celebrex 20998  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Cetirizine Hydrochloride                               | Syrup                     | 5 mg/5 mL                            | Zyrtec 20346    | 3/19/2007          | 1                         | Extinguished   | 4/7/2020                      | 5/11/2012                        |   | 6/25/2007                                 |
| Cetirizine Hydrochloride                               | Chewable Tablets          | 5 mg and 10 mg                       | Zyrtec 21621    | 3/25/2005          |                           |                |                               |                                  |   |   |
| Cetirizine Hydrochloride and Pseudoephedrine           | Extended-release Tablets  | 5 mg/120 mg                          | Zyrtec-D 21150  | 6/2/2004           | 1                         | Extinguished   | 4/7/2020                      | 2/25/2008                        |   | 7/13/2019                                 |
| Cevimeline Hydrochloride                               | Capsules                  | 30 mg                                | Evoxac 20989    | 2/27/2009          | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 7/7/2013                                  |
| Chlorhexidine Gluconate                                | Scrub brush/sponge        | 4%                                   | Hibiclens 18423 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Chlorpheniramine Polistirex and Hydrocodone Polistirex | Extended-release Capsules | 8 mg/10 mg and 4 mg/5 mg             | Tussionex 19111 | 9/10/2004          | 1                         | Extinguished   | 4/7/2020                      | 10/4/2007                        |   | 8/9/2005                                  |
| Ciclesonide  | Nasal Spray               | 50 mcg                               | Omnaris 22004   | 2/13/2012          | 1                         | Extinguished   | 2/22/2021                     |                                  |   | 10/21/2020                                |
| Ciclopirox   | Gel                       | 0.77%                                | Loprox 20519    | 5/10/2006          | 1                         | Extinguished   | 4/7/2020                      | 1/7/2009                         | 12/3/2007                                 | 9/5/2018                                  |
| Cinacalcet Hydrochloride                               | Tablets                   | 30 mg, 60 mg and 90 mg               | Sensipar 21688  | 3/10/2008          | 1                         | Extinguished   | 8/27/2019                     |                                  |   | 12/14/2016                                |
| Ciprofloxacin  | Oral Suspension           | 250 mg/5 mL and 500 mg/ 5 mL         | Cipro 20780     | 10/16/2009         | 1                         | Deferred       | 4/7/2020                      | 3/5/2014                         |   | 12/9/2014                                 |
| Ciprofloxacin Hydrochloride                            | Tablets                   | 100 mg, 250 mg, 500 mg and 750 mg    | Cipro 19537     | Pre-MMA            |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                  | DOSAGE FORM              | STRENGTH                                       | RLD/NDA           | DATE OF SUBMISSION             | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|--|-------------------|--------------------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Ciprofloxacin and Dexamethasone            | Otic Suspension          | 0.3%/0.1%                                      | Ciprodex 21537    | 7/31/2012                      | 1                         | Extinguished   | 11/17/2020                    |                                  |   | 8/10/2020                                 |
| Cisatracurium Besylate (multi-dose)        | Injection                | 2 mg/mL, 10 mL vial                            | Nimbex 20551      | 8/12/2009                      | 1                         | Eligible       | 4/7/2020                      | 2/3/2012                         |   | 9/26/2012                                 |
| Cisatracurium Besylate (preserve free)     | Injection                | 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial    | Nimbex 20551      | 8/4/2009                       | 1                         | Eligible       | 4/7/2020                      | 2/3/2012                         |   | 9/26/2012                                 |
| Cisplatin                                  | Injection                | 1 mg/mL, 10 mL, 50 mL, 100 mL and 200 mL vials | Platinol-AQ 18057 | Pre-MMA                        |                           |                |                               |                                  |   |   |
| Cisplatin                                  | For Injection            | 10 mg/vial and 50 mg/vial                      | Platinol 18057    | Pre-MMA                        |                           |                |                               |                                  |   |   |
| Cladribine                                 | Tablets                  | 10 mg  | Mavenclad 22561   | 4/7/2022                       | 1                         |                |                               |                                  |   | 10/16/2026                                |
| Clarithromycin                             | Extended-release Tablets | 500 mg   | Biaxin XL 50775   | PIV received prior to 2/5/2009 |                           |                |                               |                                  |   |   |
| Clevidipine                                | Injectable Emulsion      | 25 mg/50 mL and 50 mg/100 mL                   | Cleviprex 22156   | 7/2/2019                       | 1                         |                |                               |                                  |   | 10/10/2031                                |
| Clindamycin Phosphate                      | Foam                     | 1%   | Evoclin 50801     | PIV received prior to 2/5/2009 | 1                         | Eligible       | 3/10/2020                     | 3/31/2010                        | 3/31/2010                                 | 8/9/2026                                  |
| Clindamycin Phosphate                      | Vaginal Cream            | 2%   | Clindesse 50793   | 2/5/2015                       | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 4/27/2023                                 |
| Clindamycin Phosphate and Tretinoin        | Gel                      | 1.2%/0.025%                                    | Ziana 50802       | 12/17/2010                     | 1                         | Deferred       | 6/18/2019                     | 6/12/2015                        | 7/5/2016                                  | 8/3/2020                                  |
| Clindamycin Phosphate and Benzoyl Peroxide | Gel                      | 1% / 5%  | Duac 50741        | 12/11/2008                     | 1                         | Deferred       | 6/18/2019                     | 6/26/2012                        | 6/26/2012                                 | 11/14/2012                                |
| Clindamycin Phosphate and Benzoyl Peroxide | Gel                      | 1.2%/2.5%                                      | Acanya 50819      | 12/20/2012                     | 1                         | Eligible       | 6/18/2019                     | 6/19/2015                        | 2/19/2019                                 | 8/5/2029                                  |
| Clindamycin Phosphate and Benzoyl Peroxide | Gel                      | 1.2%/3.75%                                     | Onexton 50819     | 9/30/2015                      | 1                         | Eligible       | 6/18/2019                     | 6/5/2018                         |   | 8/5/2029                                  |
| Clobetasol Propionate                      | Emulsion Foam            | 0.05%  | Olux-E 22013      | 2/25/2010                      | 1                         | Eligible       | 4/7/2020                      | 8/14/2012                        | 2/1/2013                                  | 9/8/2019                                  |
| Clobetasol Propionate                      | Topical Foam             | 0.05%  | Olux 21142        | 6/27/2005                      | 1                         | Eligible       | 4/7/2020                      | 3/10/2008                        |   | 10/3/2017                                 |
| Clobetasol Propionate                      | Lotion                   | 0.05%  | Clobex 21535      | 3/27/2006                      | 1                         | Eligible       | 4/7/2020                      | 12/4/2008                        | 1/2/2012                                  | 9/22/2017                                 |
| Clobetasol Propionate                      | Spray                    | 0.05%  | Clobex 21835      | 9/29/2008                      | 1                         | Eligible       | 4/7/2020                      | 6/16/2011                        | 1/1/2015                                  | 3/24/2018                                 |



**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                 | DOSAGE FORM                   | STRENGTH                               | RLD/NDA            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------|-------------------------------|--|--------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Clobetasol Propionate     | Topical Shampoo               | 0.05%                                  | Clobex 21644       | 1/9/2008           | 1                         | Non-Forfeiture | 4/7/2020                      | 6/7/2011                         | 1/2/2012                                  | 6/17/2019                                 |
| Clobetasol Propionate     | Cream                         | 0.025%                                 | Impoyz 209483      | 12/6/2019          | 1                         |                |                               |                                  |   | 3/11/2035                                 |
| Clofarabine               | Injection                     | 1 mg/mL, 20 mL vial                    | Clolar 21673       | 2/23/2012          | 1                         | Eligible       | 4/7/2020                      | 5/9/2017                         | 5/9/2017                                  | 1/14/2018                                 |
| Clonidine Hydrochloride   | Extended-release Tablets      | 0.1 mg and 0.2 mg                      | Jenloga 22331      | 3/4/2011           | 1                         | Extinguished   | 4/7/2020                      | 4/2/2014                         |   | 10/13/2013                                |
| Clonidine Hydrochloride   | Extended-release Tablets      | 0.1 mg and 0.2 mg                      | Kapvay 22331       | 3/4/2011           | 1                         | Eligible       | 4/7/2020                      | 9/30/2013                        | 10/7/213                                  | 10/13/2013                                |
| Clonidine Hydrochloride   | Transdermal System            | 0.1 mg/day<br>0.2 mg/day<br>0.3 mg/day | Catapres-TTS 18891 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Clopidogrel Bisulfate     | Tablets                       | 75 mg                                  | Plavix 20839       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Clopidogrel Bisulfate     | Tablets                       | 300 mg                                 | Plavix 20839       | 3/4/2009           | 1                         | Eligible       | 4/7/2020                      | 5/17/2012                        | 5/17/2012                                 | 6/10/2019                                 |
| Clozapine                 | Orally Disintegrating Tablets | 12.5 mg                                | Fazaclo 21590      | 6/5/2008           | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 4/9/2018                                  |
| Clozapine                 | Orally Disintegrating Tablets | 25 mg and 100 mg                       | Fazaclo 21590      | 4/28/2008          | 1                         | Extinguished   | 4/7/2020                      | 11/25/2015                       | 8/30/2012                                 | 4/9/2018                                  |
| Clozapine                 | Orally Disintegrating Tablets | 150 mg                                 | Fazaclo 21590      | 4/8/2011           | 1                         | Deferred       | 4/7/2020                      | 11/25/2015                       | 5/4/2015                                  | 4/9/2018                                  |
| Clozapine                 | Orally Disintegrating Tablets | 200 mg                                 | Fazaclo 21590      | 4/18/2011          | 1                         | Deferred       | 4/7/2020                      | 11/25/2015                       | 5/4/2015                                  | 4/9/2018                                  |
| Cobicistat                | Tablets                       | 150 mg                                 | Tybost 203094      | 11/14/2016         | 1                         |                |                               |                                  |   | 9/3/2029                                  |
| Colchicine                | Capsules                      | 0.6 mg                                 | Mitigare 204820    | 6/10/2016          | 1                         | Eligible       | 8/27/2019                     | 11/29/2018                       |   | 8/22/2033                                 |
| Colchicine                | Tablets                       | 0.3 mg                                 | Colcrys 22352      | 7/19/2019          | 1                         | Eligible       | 4/7/2020                      | 11/14/2019                       |   | 2/17/2029                                 |
| Colchicine                | Tablets                       | 0.6 mg                                 | Colcrys 22352      | 12/23/2011         | 1                         | Extinguished   | 4/7/2020                      |                                  | 7/2/2018                                  | 2/17/2029                                 |
| Colchicine                | Oral Solution                 | 0.6 mg/5 mL                            | Gloperba 210942    | 4/2/2020           | 1                         | Non-Forfeiture | 1/10/2023                     |                                  |   | 12/20/2037                                |
| Colesevelam Hydrochloride | Powder for Oral Suspension    | 1.875 g/Package and 3.75 g/Package     | Welchol 22362      | 4/9/2010           | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 12/2/2014                                 |
| Colesevelam Hydrochloride | Tablets                       | 625 mg                                 | Welchol 21176      | 7/1/2009           | 1                         | Extinguished   | 4/7/2020                      | 5/16/2018                        |   | 12/10/2014                                |
| Colestipol Hydrochloride  | Tablets                       | 1 g                                    | Colestid 02222     | 8/23/2005          | 1                         |                |                               | 10/24/2006                       |   |   |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                         | DOSAGE FORM              | STRENGTH  | RLD/NDA          | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS              | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-----------------------------------|--------------------------|---|------------------|--------------------|---------------------------|-----------------------------|-------------------------------|----------------------------------|---|---|
| Conjugated Estrogen (Synthetic A) | Tablets                  | 0.3 mg, 0.45 mg and 0.9 mg  | Cenestin 20992   | 3/19/2009          | 1                         | Extinguished                | 4/7/2020                      |                                  |   | 7/26/2015                                 |
| Conjugated Estrogen (Synthetic A) | Tablets                  | 1.25 mg   | Cenestin 20992   | 11/3/2008          | 1                         | Extinguished                | 4/7/2020                      |                                  |   | 7/26/2015                                 |
| Conjugated Estrogen (Synthetic A) | Tablets                  | 0.625 mg  | Cenestin 20992   | 3/2/2009           | 1                         | Extinguished                | 4/7/2020                      |                                  |   | 7/26/2015                                 |
| Conjugated Estrogens              | Tablets                  | 0.3 mg and 0.625 mg   | Premarin 04782   | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Cyanocobalamin                    | Nasal Spray              | 500 mcg/spray   | Nascobal 21642   | 4/28/2017          | 1                         | Extinguished                | 4/6/2021                      |                                  |   | 8/1/2024                                  |
| Crisaborole                       | Topical Ointment         | 2%  | Eucrisa 207695   | 6/14/2021          | 5                         |                             |                               |                                  |   | 1/20/2030                                 |
| Cyclobenzaprine Hydrochloride     | Tablets                  | 10 mg   | Flexeril 17821   | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Cyclobenzaprine Hydrochloride     | Extended-release Capsule | 15 mg and 30 mg   | Amrix 21777      | 8/11/2008          | 1                         | Extinguished Non-Forfeiture | 4/7/2020<br>4/7/2020          |                                  | 5/13/2011                                 | 2/26/2025                                 |
| Cyclophosphamide                  | For Injection            | 100 mg/vial<br>200 mg/vial<br>500 mg/vial<br>1 g/vial<br>2 g/vial | Cytosan 12142    | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Cyclophosphamide                  | Injection                | 500 mg/2.5 mL and 1 g/5 mL  | Cyclophos 212501 | 3/7/2022           | 1                         |                             |                               |                                  |   | 2/15/2036                                 |
| Cyclophosphamide                  | Injection                | 2 g/10 mL   | Cyclophos 212501 | 1/17/2023          | 1                         |                             |                               |                                  |   | 2/15/2036                                 |
| Cyclosporine                      | Ophthalmic Emulsion      | 0.05%   | Restasis 50790   | 1/13/2014          | 1                         | Extinguished                | 2/8/2022                      |                                  |   | 5/17/2014                                 |
| Cysteamine Bitartrate             | Delayed-release Capsules | 25 mg and 75 mg   | Procysbi 203389  | 5/11/2020          | 1                         |                             |                               |                                  |   | 8/16/2036                                 |
| Cysteamine Bitartrate             | Delayed-release Granules | 75 mg/Package and 300 mg/Package                                  | Procysbi 213491  | 12/16/2021         | 1                         |                             |                               |                                  |   | 8/16/2036                                 |
| Cysteine Hydrochloride            | Injection                | 500 mg/10 mL  | Elcys 210660     | 12/10/2019         | 1                         | Eligible                    | 5/5/2022                      | 4/8/2022                         |   | 1/15/2039                                 |
| Dabigatran Etxilate Mesylate      | Capsules                 | eq. to 75 mg base and 150 mg base                                 | Pradaxa 22512    | 10/20/2014         | 17                        | Eligible                    | 6/15/2020                     | 5/6/2020                         |   | 8/31/2027                                 |
| Dabigatran Etxilate Mesylate      | Capsules                 | eq. to 110 mg base  | Pradaxa 22512    | 12/15/2015         | 2                         |                             |                               |                                  |   | 1/20/2031                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME   | DOSAGE FORM              | STRENGTH   | RLD/NDA          | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|--------------------------|--|------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Dalbavancin Hydrochloride                                   | Powder For Injection     | 500 mg/vial  | Dalvance         | 5/23/2023          | 3                         |                |                               |                                  |   | 5/23/2028                                 |
| Dalfampridine   | Extended-release Tablets | 10 mg  | Ampyra 22250     | 1/22/2014          | 8                         | Eligible       | 11/19/2019                    | 1/23/2017                        | 9/10/2018                                 | 5/26/2027                                 |
| Dapagliflozin   | Tablets                  | 5 mg and 10 mg   | Farxiga 202293   | 1/8/2018           | 20                        | Deferred       | 3/22/2022                     | 2/22/2022                        |   | 5/26/2030                                 |
| Dapagliflozin and Saxagliptan                               | Tablets                  | 5 mg/5 mg  | Qtern 209091     | 7/29/2020          | 1                         |                |                               |                                  |   | 12/16/2029                                |
| Dapagliflozin and Saxagliptan                               | Tablets                  | 10 mg/5 mg   | Qtern 209091     | 1/8/2018           | 5                         |                |                               |                                  |   | 12/16/2029                                |
| Dapagliflozin and Metformin Hydrochloride                   | Extended-release Tablets | 2.5 mg/1000 mg   | Xigduo XR 205649 | 10/29/2018         | 1                         |                |                               |                                  |   | 12/16/2029                                |
| Dapagliflozin and Metformin Hydrochloride                   | Extended-release Tablets | 5 mg/500 mg<br>5 mg/1000 mg<br>10 mg/500 mg<br>10 mg/1000 mg | Xigduo XR 205649 | 1/8/2018           | 10                        |                |                               |                                  |   | 5/26/2030                                 |
| Dapsone   | Gel                      | 7.5%   | Aczone 207154    | 2/13/2017          | 1                         | Eligible       | 7/2/2019                      | 6/26/2019                        | 6/26/2019                                 | 11/18/2033                                |
| Daptomycin  | For Injection            | 500 mg/vial  | Cubicin 21572    | 11/19/2008         | 1                         | Extinguished   | 11/19/2019                    |                                  |   | 9/24/2019                                 |
| Darifenacin Hydrobromide                                    | Extended-release Tablets | 7.5 mg and 15 mg   | Enablex 21513    | 12/22/2008         | 3                         | Deferred       | 4/7/2020                      | 3/13/2015                        | 3/15/2016                                 | 8/21/2016                                 |
| Darolutamide  | Tablets                  | 300 mg   | Nubeqa 212099    | 7/31/2023          | 1                         |                |                               |                                  |   | 2/27/2038                                 |
| Darunavir Ethanolate  | Tablets                  | 75 mg, 150 mg and 300 mg                                     | Prezista 21976   | 6/23/2010          | 1                         |                |                               |                                  |   | 12/26/2026                                |
| Darunavir Ethanolate  | Tablets                  | 400 mg   | Prezista 21976   | 6/23/2010          | 3                         |                |                               |                                  |   | 12/26/2026                                |
| Darunavir Ethanolate  | Tablets                  | 600 mg   | Prezista 21976   | 6/23/2010          | 4                         | Deferred       | 7/2/2019                      | 11/21/2017                       | 6/1/2023                                  | 12/26/2026                                |
| Darunavir Ethanolate  | Tablets                  | 800 mg   | Prezista 21976   | 5/14/2013          | 1                         | Eligible       | 10/4/2022                     | 9/29/2022                        | 6/1/2023                                  | 12/26/2026                                |
| Darunavir and Cobicistat                                    | Tablets                  | 800 mg/150 mg  | Prezcobix 205395 | 7/24/2020          | 1                         |                |                               |                                  |   | 10/6/2032                                 |
| Darunavir, Cobicistat, Emtricitabine, Tenofovir Alafenamide | Tablets                  | 800 mg/150 mg/<br>200 mg/10 mg                               | Symtuza 210455   | 8/16/2021          | 1                         |                |                               |                                  |   | 7/19/2038                                 |
| Dasatinib   | Tablets                  | 80 mg and 140 mg   | Sprycel 21986    | 6/17/2011          | 1                         | Non-Forfeiture | 10/2/2021                     | 11/23/2021                       |   | 3/28/2026                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                 | DOSAGE FORM                   | STRENGTH                       | RLD/NDA                  | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS          | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|-------------------------------|--------------------------------|--------------------------|--------------------|---------------------------|-------------------------|-------------------------------|----------------------------------|---|---|
| Dasatinib                                 | Tablets                       | 20 mg, 50 mg, 70 mg and 100 mg | Sprycel 21986            | 6/28/2010          | 1                         | Non-Forfeiture Deferred | 10/19/2021 4/7/2020           | 6/10/2016                        |   | 3/28/2026                                 |
| Deferasirox                               | Tablets for Suspension        | 125 mg, 250 mg, and 500 mg     | Exjade 21882             | 10/28/2011         | 1                         | Eligible                | 7/2/2019                      | 1/26/2016                        | 3/22/2019                                 | 4/5/2019                                  |
| Deferasirox                               | Tablets                       | 90 mg and 360 mg               | Jadenu 206910            | 10/19/2015         | 1                         | Extinguished            | 7/16/2019                     |                                  |   | 4/5/2019                                  |
| Deferasirox                               | Tablets                       | 180 mg                         | Jadenu 206910            | 4/21/2016          | 1                         | Eligible                | 7/16/2019                     | 12/13/2019                       | 12/17/2019                                | 11/21/2034                                |
| Deferiprone                               | Tablets                       | 500 mg                         | Ferriprox 21825          | 1/29/2016          | 1                         | Eligible                | 8/13/2019                     | 2/8/2019                         | 9/28/2020                                 | 6/28/2021                                 |
| Degarelix Acetate                         | Powder for Injection          | 80 mg/vial and 120 mg/vial     | Firmagon 22201           | 12/20/2019         | 1                         |                         |                               |                                  |   | 4/27/2032                                 |
| Deoxycholic Acid                          | Injection                     | 10 mg/mL (2 mL)                | Kybella 206333           | 7/13/2018          | 1                         | Deferred                | 5/4/2021                      | 4/2/2021                         |   | 3/2/2030                                  |
| Desflurane                                | Inhalation                    | 99.9%                          | Suprane 20118            | 9/11/2008          | 1                         | Extinguished            | 4/7/2020                      |                                  |   | 4/8/2014                                  |
| Desloratadine                             | Tablets                       | 5 mg                           | Clarinet 21165           | 6/21/2006          | 11                        | Extinguished            | 4/7/2020                      | 10/25/2010                       |   | 7/7/2019                                  |
| Desloratadine                             | Orally Disintegrating Tablets | 2.5 mg and 5 mg                | Clarinet 21165           | 6/21/2006          | 3                         | Extinguished            | 4/7/2020                      | 7/12/2010                        |   | 7/7/2019                                  |
| Desloratadine                             | Oral Solution                 | 0.5 mg/mL                      | Clarinet Syrup 21300     | 5/8/2008           | 1                         | Extinguished            | 4/7/2020                      |                                  |   | 6/1/2018                                  |
| Desloratadine and Pseudoephedrine Sulfate | Extended-release Tablets      | 2.5 mg/120 mg                  | Clarinet-D 24 Hour 21313 | 6/1/2007           | 1                         | Extinguished            | 4/7/2020                      |                                  |   | 2/18/2021                                 |
| Desloratadine and Pseudoephedrine Sulfate | Extended-release Tablets      | 5 mg/240 mg                    | Clarinet-D 24 Hour 21313 | 6/21/2006          | 1                         | Extinguished            | 4/7/2020                      | 4/26/2011                        |   | 3/28/2022                                 |
| Desmopressin Acetate                      | Injection                     | 4 mcg/mL, 1 mL and 10 mL vials | DDAVP 18938              | Pre-MMA            |                           |                         |                               |                                  |   |   |
| Desmopressin Acetate                      | Nasal Spray                   | 0.01%                          | DDAVP 17922              | Pre-MMA            |                           |                         |                               |                                  |   |   |
| Desmopressin Acetate                      | Tablets                       | 0.1 mg and 0.2 mg              | DDAVP 19955              | Pre-MMA            |                           |                         |                               |                                  |   |   |
| Desogestrel; Ethinyl Estradiol Tablets    | Tablets                       | 0.15mg/ 0.02 mg and 0.01 mg    | Mircette 20713           | Pre-MMA            |                           |                         |                               |                                  |   |   |
| Desonide                                  | Gel                           | 0.05%                          | Desonate 21844           | 12/1/2010          | 1                         | Deferred                | 6/15/2020                     | 5/11/2020                        | 7/9/2020                                  | 8/3/2020                                  |
| Desoximetasone                            | Topical Spray                 | 0.25%                          | Topicort 204141          | 12/18/2013         | 1                         | Extinguished            | 4/7/2020                      | 1/20/2017                        |   | 4/23/2028                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME   | DOSAGE FORM               | STRENGTH                                   | RLD/NDA           | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS        | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---------------------------|--|-------------------|--------------------|---------------------------|-----------------------|-------------------------------|----------------------------------|---|---|
| Desvenlafaxine Succinate  | Extended-release Tablets  | 50 mg and 100 mg                           | Pristiq 21992     | 2/29/2012          | 12                        | Eligible              | 6/18/2019                     | 6/29/2015                        | 2/28/2017                                 | 2/11/2022                                 |
| Desvenlafaxine Succinate  | Extended-release Tablets  | 25 mg                                      | Pristiq 21992     | 5/8/2015           | 1                         | Eligible              | 4/7/2020                      | 7/29/2016                        | 7/29/2016                                 | 7/5/2027                                  |
| Deutetrabenazine  | Tablets                   | 6 mg, 9 mg and 12 mg                       | Austedo 208082    | 4/5/2021           | 2                         |                       |                               |                                  |   | 3/7/2036                                  |
| Dexlansoprazole   | Delayed-release Capsules  | 30 mg                                      | Dexilant 22287    | 11/30/2010         | 1                         | Extinguished          | 4/7/2020                      |                                  |   | 8/2/2026                                  |
| Dexlansoprazole   | Delayed-release Capsules  | 60 mg                                      | Dexilant 2287     | 8/25/2010          | 1                         | Extinguished Deferred | 9/20/2022<br>4/7/2020         | 4/19/2017                        | 11/22/2022                                | 8/2/2026                                  |
| Dexmedetomidine   | Injection                 | 100 mcg/mL                                 | Precedex 21038    | 4/8/2009           | 1                         | Eligible              | 4/7/2020                      | 6/14/2016                        | 9/22/2014                                 | 3/31/2019                                 |
| Dexmedetomidine   | Injection                 | 4 mcg/mL, 50 mL and 100 mL vials           | Precedex 21038    | 12/26/2013         | 1                         | Extinguished          | 8/13/2019                     | 1/30/2020                        |   | 1/4/2032                                  |
| Dexmedetomidine   | Injection                 | 4 mcg/mL, 20 mL vials                      | Precedex 21038    | 9/30/2015          | 1                         | Eligible              | 7/2/2019                      | 11/29/2018                       | 6/3/2019                                  | 1/4/2032                                  |
| Dexmethylphenidate Hydrochloride  | Tablets                   | 2.5 mg                                     | Focalin 21278     | 7/27/2004          | 1                         | Eligible              | 4/7/2020                      | 1/29/2007                        |   | 12/4/2015                                 |
| Dexmethylphenidate Hydrochloride  | Tablets                   | 5 mg and 10 mg                             | Focalin 21278     | 5/27/2004          | 1                         | Eligible              | 4/7/2020                      | 1/29/2007                        |   | 12/4/2015                                 |
| Dexmethylphenidate Hydrochloride  | Extended-release Capsules | 15 mg                                      | Focalin XR 21802  | 5/14/2007          | 1                         | Eligible              | 1/27/2020                     | 11/18/2013                       |   | 11/1/2019                                 |
| Dexmethylphenidate Hydrochloride  | Extended-release Capsules | 5 mg, 10 mg and 20 mg                      | Focalin XR 21802  | 3/30/2007          | 1                         | Eligible              | 1/27/2020                     | 11/19/2013                       | 11/10/2014                                | 11/1/2019                                 |
| Dexmethylphenidate Hydrochloride  | Extended-release Capsules | 30 mg                                      | Focalin XR 21802  | 12/15/2010         | 1                         | Eligible              | 1/27/2020                     | 8/28/2013                        | 11/18/2013                                | 11/1/2019                                 |
| Dexmethylphenidate Hydrochloride  | Extended-release Capsules | 40 mg                                      | Focalin XR 21802  | 12/20/2010         | 1                         | Eligible              | 1/27/2020                     | 11/19/2013                       | 11/22/2013                                | 11/1/2019                                 |
| Dexmethylphenidate  | Extended-release Capsules | 35 mg                                      | Focalin XR 21802  | 9/29/2011          | 1                         | Eligible              | 1/27/2020                     | 11/30/2016                       | 1/5/2017                                  | 11/1/2019                                 |
| Dexmethylphenidate  | Extended-release Capsules | 25 mg                                      | Focalin XR 21802  | 9/30/2011          | 1                         | Eligible              | 1/27/2020                     | 11/30/2016                       | 1/5/2017                                  | 11/1/2019                                 |
| Dexrazoxane   | For Injection             | 250 mg/vial                                | Zinecard 20212    | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Dextroamphetamine saccharate; Amphetamine aspartate; Dextroamphetamine Sulfate; Amphetamine Sulfate | Extended-release Capsules | 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg | Adderall XR 21303 | Pre-MMA            |                           |                       |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME   | DOSAGE FORM                 | STRENGTH   | RLD/NDA               | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|-----------------------------|--|-----------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Dextroamphetamine saccharate; Amphetamine aspartate; Dextroamphetamine Sulfate; Amphetamine Sulfate | Tablets                     | 5 mg, 10 mg, 20 mg, 30 mg  | Adderall 11522        | 11/18/2009         | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 7/6/2020                                  |
| Dextroamphetamine saccharate; Amphetamine aspartate; Dextroamphetamine Sulfate; Amphetamine Sulfate | Tablets                     | 7.5 mg, 12.5 mg and 15 mg  | Adderall 11522        | Pre-MMA            |                           |                |                               |                                  |   |   |
| Dextromethorphan Polistirex   | Extended-release Suspension | 30 mg/5 mL   | Delsym 18658          | 1/12/2009          | 1                         | Eligible       | 4/7/2020                      | 5/25/2012                        | 8/27/2012                                 | 4/16/2017                                 |
| Dextromethorphan Hydrobromide and Bupropion Hydrochloride   | Extended-release Tablet     | 45 mg/105 mg   | Auvelity 215430       | 12/22/2022         | 1                         |                |                               |                                  |   | 1/7/2040                                  |
| Dextromethorphan Hydrobromide and Quinidine Sulfate   | Capsules                    | 20 mg/10 mg  | Nuedexta 21879        | 3/7/2011           | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 8/13/2026                                 |
| Diazepam  | Tablets                     | 2 mg, 5 mg and 10 mg   | Valium 13263          | Pre-MMA            |                           |                |                               |                                  |   |   |
| Diazepam  | Rectal Gel                  | 2.5 mg/0.5 mL<br>5 mg/mL<br>10 mg/2 mL<br>15 mg/3 mL<br>20 mg/4 mL | Diastat 20648         | 3/23/2004          | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 10/31/2012                                |
| Diazepam  | Rectal Gel                  | 5 mg/mL, 4mL pre-filled syringe                                    | Diastat Acudial 20648 | 12/8/2008          | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 9/17/2013                                 |
| Diazepam  | Rectal Gel                  | 5 mg/mL, 2mL pre-filled syringe                                    | Diastat Acudial 20648 | 12/23/2008         | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 9/17/2013                                 |
| Diclofenac Potassium  | Oral Solution (Sachet)      | 50 mg  | Cambia 22165          | 1/24/2011          | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 6/16/2026                                 |
| Diclofenac Potassium  | Capsules                    | 25 mg  | Zipsor 22202          | 11/14/2012         | 1                         | Extinguished   | 2/11/2020                     | 2/23/2016                        |   | 2/24/2029                                 |
| Diclofenac Sodium   | Injection                   | 37.5 mg/mL, 1 mL single-dose vials                                 | Dyloject 22396        | 12/15/2015         | 1                         | Eligible       | 7/2/2019                      | 6/18/2019                        |   | 3/22/2027                                 |
| Diclofenac Sodium   | Topical Gel                 | 3%   | Solaraze 21005        | 12/16/2009         | 1                         | Deferred       | 4/7/2020                      | 10/28/2013                       | 11/21/2013                                | 8/11/2015                                 |
| Diclofenac Sodium   | Topical Solution            | 1.5%   | Pennsaid 20947        | 7/11/2012          | 1                         | Eligible       | 4/7/2020                      | 5/27/2014                        | 5/27/2014                                 | 7/10/2029                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                         | DOSAGE FORM               | STRENGTH  | RLD/NDA           | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-----------------------------------|---------------------------|---|-------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Diclofenac Sodium                 | Topical Solution          | 2.0%  | Pennsaid 204623   | 6/3/2014           | 1                         | Extinguished   | 5/5/2022                      |                                  |   | 8/9/2030                                  |
| Diclofenac                        | Capsules                  | 18 mg and 35 mg                                   | Zorvolex 204592   | 6/6/2014           | 1                         |                |                               |                                  |   | 4/23/2030                                 |
| Diclofenac Epolamine              | Topical Patch             | 1.3%  | Flector 21234     | 6/26/2015          | 1                         | Extinguished   | 7/2/2019                      |                                  |   | 4/13/2019                                 |
| Diclofenac Sodium and Misoprostol | Delayed-release Tablets   | 50 mg/0.2 mg                                      | Arthrotec 20607   | 6/29/2009          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 2/11/2014                                 |
| Diclofenac Sodium and Misoprostol | Delayed-release Tablets   | 75 mg/0.2 mg                                      | Arthrotec 20607   | 11/28/2008         | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 2/11/2014                                 |
| Didanosine                        | Delayed-release Capsules  | 200 mg, 250 mg and 400 mg                         | Videx EC 21183    | 6/1/2004           | 1                         | Eligible       | 4/7/2020                      | 12/3/2004                        |   | 3/1/2007                                  |
| Difluprednate                     | Ophthalmic Emulsion       | 0.05%   | Durezol 22212     | 5/1/2014           | 1                         | Extinguished   | 7/2/2019                      |                                  |   | 5/18/2019                                 |
| Diltiazem Hydrochloride           | Extended-release Capsules | 60 mg, 90 mg and 120 mg                           | Cardizem SR 19471 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Diltiazem Hydrochloride           | Extended-release Capsules | 120 mg, 180 mg and 240 mg                         | Dilacor XR 20092  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Diltiazem Hydrochloride           | Extended-release Capsules | 120 mg, 180 mg, 240 mg, 300 mg and 360 mg         | Cardizem CD 20062 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Diltiazem Hydrochloride           | Extended-release Capsules | 120 mg, 180 mg, 240 mg, 300 mg, 360 mg and 420 mg | Tiazac 20401      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Diltiazem Hydrochloride           | Extended-release Tablets  | 120 mg, 180 mg, 240 mg, 300 mg and 360 mg         | Cardizem LA 21392 | 8/30/2005          | 1                         | Deferred       | 11/19/2019                    | 3/15/2010                        | 3/15/2010                                 | 6/25/2013                                 |
| Diltiazem Hydrochloride           | Extended-release Tablets  | 420 mg  | Cardizem LA 21392 | 4/25/2005          | 1                         | Deferred       | 11/19/2019                    | 3/15/2010                        | 3/15/2010                                 | 6/25/2013                                 |
| Dimethyl Fumarate                 | Delayed-release Capsules  | 120 mg and 240 mg                                 | Tecfidera 204063  | 3/27/2017          | 29                        | Deferred       | 8/24/2020                     | 8/17/2020                        | 8/18/2020                                 | 2/7/2028                                  |
| Diroximel Fumarate                | Delayed-release Capsules  | 231 mg  | Vumerity 211855   | 12/23/2020         | 1                         |                |                               |                                  |   | 9/20/2033                                 |
| Divalproex Sodium                 | Delayed-release Tablets   | 125 mg, 250 mg and 500 mg                         | Depakote 18723    | Pre-MMA            |                           |                |                               |                                  |   |   |
| Divalproex Sodium*                | Extended-release Tablets  | 250 mg  | Depakote ER 21168 | 5/3/2004           |                           |                |                               |                                  |   |   |
| Divalproex Sodium                 | Extended-release Tablets  | 500 mg  | Depakote ER 21168 | 2/8/2005           |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME  | DOSAGE FORM                   | STRENGTH                        | RLD/NDA           | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS        | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|-------------------------------|---------------------------------|-------------------|--------------------|---------------------------|-----------------------|-------------------------------|----------------------------------|---|---|
| Docetaxel  | Injection                     | 40 mg/mL, 0.5 mL and 2 mL vials | Taxotere 20449    | 6/30/2009          | 1                         | Extinguished          | 4/7/2020                      |                                  |   | 11/22/2013                                |
| Dofetilide   | Capsules                      | 0.125 mg, 0.25 mg, and 0.5 mg   | Tikosyn 20931     | 5/1/2014           | 1                         | Eligible              | 8/13/2019                     | 6/6/2016                         | 6/7/2016                                  | 10/9/2018                                 |
| Dolutegravir Sodium                                      | Tablets                       | 10 mg, 25 mg and 50 mg          | Tivicay 204790    | 8/14/2017          | 4                         |                       |                               |                                  |   | 12/8/2029                                 |
| Dolutegravir Sodium                                      | Tablets for Suspension        | 5 mg                            | Tivicay PD 213983 | 7/21/2021          | 1                         |                       |                               |                                  |   | 12/8/2029                                 |
| Dolutegravir Sodium and Lamivudine                       | Tablets                       | 50 mg/300 mg                    | Dovato 211994     | 7/30/2019          | 1                         |                       |                               |                                  |   | 12/8/2029                                 |
| Dolutegravir Sodium and Rilpivirine                      | Tablets                       | 50 mg/25 mg                     | Juluca 210192     | 11/19/2019         | 1                         |                       |                               |                                  |   | 1/24/2031                                 |
| Donepezil Hydrochloride                                  | Tablets                       | 5 mg and 10 mg                  | Aricept 20690     | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Donepezil Hydrochloride                                  | Orally Disintegrating Tablets | 5 mg and 10 mg                  | Aricept ODT 21720 | 6/30/2010          | 1                         | Extinguished          | 4/7/2020                      | 11/26/2010                       |   | 6/23/2022                                 |
| Donepezil Hydrochloride                                  | Tablets                       | 23 mg                           | Aricept 22568     | 7/9/2013           |                           | Eligible              | 4/7/2020                      | 7/24/2013                        | 7/26/2013                                 | 10/4/2026                                 |
| Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate | Tablets                       | 100 mg/300 mg/300 mg            | Delstrigo 210807  | 8/30/2022          | 1                         |                       |                               |                                  |   | 11/29/2036                                |
| Doripenem  | Injection                     | 250 mg/vial and 500 mg/vial     | Doribax 22106     | 10/12/2011         | 1                         | Extinguished          | 4/7/2020                      |                                  |   | 6/5/2015                                  |
| Dorzolamide Hydrochloride                                | Ophthalmic Solution           | 2%                              | Trusopt 20408     | 10/11/2005         | 1                         | Extinguished          | 4/7/2020                      | 10/28/2008                       |   | 4/28/2008                                 |
| Dorzolamide Hydrochloride and Timolol Maleate            | Ophthalmic Solution           | 2%/0.5%                         | Cosopt 20869      | 10/11/2005         | 1                         | Extinguished          | 4/7/2020                      | 10/28/2008                       |   | 4/28/2008                                 |
| Doxazosin Mesylate                                       | Tablets                       | 1 mg, 2 mg, 4 mg and 8 mg       | Cardura 19668     | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Doxepin Hydrochloride                                    | Tablets                       | 3 mg and 6 mg                   | Silenor 22036     | 9/16/2010          | 2                         | Extinguished Eligible | 7/27/2020<br>6/18/2019        | 7/26/2013                        |   | 2/17/2020                                 |
| Doxercalciferol  | Capsules                      | 1 mcg                           | Hectorol 20862    | 2/12/2010          | 1                         | Extinguished          | 4/7/2020                      | 9/9/2016                         |   | 2/11/2014                                 |
| Doxercalciferol  | Capsules                      | 0.5 mcg and 2.5 mcg             | Hectorol 20862    | 3/25/2009          | 1                         | Eligible              | 4/7/2020                      | 1/14/2014<br>9/23/2011           |   | 7/18/2021                                 |
| Doxercalciferol  | Injection                     | 2 mcg/mL, 2 mL ampules          | Hectorol 21027    | 10/15/2007         | 1                         | Extinguished          | 11/19/2019                    |                                  |   |   |
| Doxercalciferol  | Injection                     | 2 mcg/mL, 1 mL in 2 mL vial     | Hectorol 21027    | 12/28/2011         | 1                         | Extinguished          | 11/19/2019                    |                                  |   |   |



**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME  | DOSAGE FORM              | STRENGTH                                  | RLD/NDA         | DATE OF SUBMISSION             | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS        | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|---|-----------------|--------------------------------|---------------------------|-----------------------|-------------------------------|----------------------------------|---|---|
| Doxycycline  | Delayed-release Capsules | 40 mg                                     | Oracea 50805    | 12/12/2008                     | 1                         | Extinguished          | 8/24/2022                     |                                  |   | 4/5/2022                                  |
| Doxycycline Hyclate  | Delayed-release Tablets  | 75 mg and 100 mg                          | Doryx 50795     | PIV received prior to 2/5/2009 | 1                         | Eligible              | 4/7/2020                      | 12/28/2010                       | 12/30/2010                                | 12/15/2022                                |
| Doxycycline Hyclate  | Delayed-release Tablets  | 150 mg                                    | Doryx 50795     | 12/19/2008                     | 1                         | Extinguished          | 4/7/2020                      |                                  |   | 12/15/2022                                |
| Doxycycline Hyclate  | Delayed-release Tablets  | 200 mg                                    | Doryx 50795     | 5/19/2014                      | 1                         | Eligible              | 4/7/2020                      | 5/19/2016                        | 5/19/2016                                 | 12/15/2022                                |
| Doxycycline Hyclate  | Delayed-release Tablets  | 80 mg                                     | Doryx 50795     | 7/1/2015                       | 1                         | Extinguished Eligible | 4/18/2023<br>4/7/2020         | 4/29/2016                        |   | 12/15/2022                                |
| Doxycycline Hyclate  | Delayed-release Tablets  | 50 mg                                     | Doryx 50795     | 11/5/2015                      | 1                         | Eligible              | 4/7/2020                      | 5/23/2016                        | 5/23/2016                                 | 2/3/2028                                  |
| Doxycycline Hyclate  | Delayed-release Tablets  | 60 mg and 120 mg                          | Doryx MPC 50795 | 9/28/2017                      | 1                         | Extinguished          | 8/7/2023                      |                                  |   | 12/23/2034                                |
| Doxylamine Succinate and Pyridoxine Hydrochloride                                    | Delayed-release Tablets  | 10 mg/10 mg                               | Diclegis 21876  | 8/1/2013                       | 1                         | Extinguished          | 7/2/2019                      | 8/19/2016                        | 6/21/2019                                 | 6/21/2021                                 |
| Doxylamine Succinate and Pyridoxine Hydrochloride                                    | Extended-release Tablets | 20 mg/20 mg                               | Bonjesta 209661 | 8/28/2018                      | 1                         | Deferred              | 5/5/2022                      | 3/1/2022                         |   | 2/18/2033                                 |
| Dronabinol   | Oral Solution            | 5 mg/mL                                   | Syndros 205525  | 4/17/2017                      | 1                         | Extinguished          | 1/12/2021                     |                                  |   | 8/6/2028                                  |
| Dronedarone Hydrochloride  | Tablets                  | 400 mg                                    | Multaq 22425    | 7/1/2013                       | 7                         |                       |                               |                                  |   | 4/16/2029                                 |
| Drospirenone and Estradiol   | Tablets                  | 0.5 mg/1 mg                               | Angeliq 21355   | 12/26/2007                     | 1                         | Extinguished          | 4/7/2020                      |                                  |   | 8/11/2017                                 |
| Drospirenone and Estradiol   | Tablets                  | 0.25 mg/0.5 mg                            | Angeliq 21355   | 1/8/2015                       | 1                         | Extinguished          | 4/7/2020                      |                                  |   | 10/22/2031                                |
| Drospirenone and Ethinyl Estradiol   | Tablets                  | 3 mg/0.02 mg                              | Yaz 21676       | 9/29/2006                      | 1                         | Extinguished Deferred | 11/17/2022<br>11/17/2022      | 3/30/2009                        | 6/1/2010                                  | 12/20/2021                                |
| Drospirenone and Ethinyl Estradiol   | Tablets                  | 3 mg/0.03 mg                              | Yasmin 21098    | 1/7/2005                       | 1                         | Extinguished          | 4/7/2020                      | 5/9/2008                         |   | 8/31/2020                                 |
| Drospirenone and Ethinyl Estradiol and Levomefolate Calcium and Levomefolate Calcium | Tablets                  | 3 mg/0.03 mg/<br>0.451 mg and<br>0.451 mg | Safyral 22574   | 9/28/2012                      | 1                         | Extinguished          | 4/7/2020                      | 10/11/2016                       |   | 3/3/2022                                  |
| Drospirenone and Ethinyl Estradiol and Levomefolate Calcium and Levomefolate Calcium | Tablets                  | 3 mg/0.02 mg/<br>0.451 mg and<br>0.451 mg | Beyaz 22532     | 11/13/2012                     | 1                         | Eligible              | 4/7/2020                      | 10/11/2016                       | 10/11/2016                                | 3/3/2022                                  |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME  | DOSAGE FORM              | STRENGTH                          | RLD/NDA                            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|-----------------------------------|------------------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Drospirenone   | Tablets                  | 4 mg                              | Slynd<br>211367                    | 1/7/2022           | 1                         |                |                               |                                  |   | 6/28/2031                                 |
| Duloxetine Hydrochloride   | Delayed-release Capsules | 20 mg, 30 mg and 60 mg            | Cymbalta<br>21427                  | 8/4/2008           | 16                        | Eligible       | 4/7/2020                      | 12/11/2013                       |   | 7/18/2014                                 |
| Duloxetine Hydrochloride   | Delayed-release Capsules | 40 mg                             | Cymbalta<br>21427                  | 5/10/2012          | 1                         | Eligible       | 4/7/2020                      | 12/11/2013                       | 7/15/2015                                 | 7/18/2014                                 |
| Dutasteride  | Capsules                 | 0.5 mg                            | Avodart<br>21319                   | 10/29/2007         | 1                         | Deferred       | 4/7/2020                      | 12/21/2010                       | 10/9/2015                                 | 11/20/2015                                |
| Dutasteride and Tamsulosin Hydrochloride                           | Capsules                 | 0.5 mg/0.4 mg                     | Jalyn<br>22460                     | 10/26/2010         | 1                         | Eligible       | 4/7/2020                      | 2/26/2014                        | 11/18/2015                                | 11/20/2015                                |
| Edaravone  | Oral Suspension          | 105 mg/5 mL                       | Radicava ORS<br>215446             | 4/20/2023          | 1                         |                |                               |                                  |   | 11/1/2039                                 |
| Edoxaban Tosylate  | Tablets                  | 15 mg, 30 mg and 60 mg            | Savaysa<br>206316                  | 1/28/2019          | 1                         |                |                               |                                  |   | 3/28/2028                                 |
| Efavirenz  | Tablets                  | 600 mg                            | Sustiva<br>21360                   | 4/9/2009           | 1                         | Eligible       | 4/7/2020                      | 2/17/2016                        | 1/30/2018                                 | 1/20/2018                                 |
| Efavirenz  | Capsules                 | 50 mg, 100 mg and 200 mg          | Sustiva<br>20972                   | 11/3/2016          | 1                         | Eligible       | 7/2/2019                      | 12/15/2017                       | 12/21/2017                                | 4/6/2019                                  |
| Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate         | Tablets                  | 600 mg/200 mg/300 mg              | Atripla<br>21937                   | 12/29/2008         | 1                         | Extinguished   | 4/7/2020                      | 11/9/2018                        |   | 3/9/2021                                  |
| Efinaconazole  | Topical Solution         | 10%                               | Jublia<br>203567                   | 6/6/2018           | 19                        | Eligible       | 2/9/2021                      | 12/16/2020                       |   | 10/2/2034                                 |
| Elagolix Sodium  | Tablets                  | 150 mg and 200 mg                 | Orilissa<br>210450                 | 7/25/2022          | 9                         |                |                               |                                  |   | 9/1/2036                                  |
| Elagolix Sodium, Estradiol, Norethindrone Acetate; Elagolix Sodium | Capsules                 | 300 mg/1 mg/<br>0.5 mg;<br>300 mg | Oriahnn<br>(Co-Packaged)<br>213388 | 11/3/2022          | 1                         |                |                               |                                  |   | 3/14/2034                                 |
| Eletriptan Hydrobromide  | Tablets                  | 20 mg and 40 mg                   | Relpax<br>21016                    | 3/29/2010          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 8/29/2017                                 |
| Eliglustat Tartrate  | Capsules                 | 84 mg                             | Cerdelga<br>205494                 | 8/20/2018          | 6                         | Deferred       | 10/5/2021                     | 9/8/2021                         |   | 6/26/2026                                 |
| Eltrombopag Olamine  | Tablets                  | 50 mg and 75 mg                   | Promacta<br>22291                  | 1/7/2014           | 1                         |                |                               |                                  |   | 2/1/2028                                  |
| Eltrombopag Olamine  | Tablets                  | 12.5 mg and 25 mg                 | Promacta<br>22291                  | 2/4/2014           | 1                         |                |                               |                                  |   | 2/1/2028                                  |
| Eltrombopag Olamine  | For Oral Suspension      | 12. mg/packet and 25 mg/packet    | Promacta Kit<br>207027             | 4/22/2022          | 1                         |                |                               |                                  |   | 7/13/2025                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME  | DOSAGE FORM                 | STRENGTH   | RLD/NDA               | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|-----------------------------|--|-----------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate | Tablets                     | 150 mg/150 mg/<br>200 mg/300 mg  | Stribild<br>203100    | 10/4/2018          | 1                         |                |                               |                                  |   | 4/24/2030                                 |
| Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide         | Tablets                     | 150 mg/150 mg/<br>200 mg/10 mg   | Genvoya<br>207561     | 4/12/2023          | 1                         |                |                               |                                  |   | 10/6/2032                                 |
| Eluxadoline  | Tablets                     | 75 mg and 100 mg   | Viberzi<br>206940     | 5/28/2019          | 6                         |                |                               |                                  |   | 3/14/2033                                 |
| Empagliflozin  | Tablets                     | 10 mg and 25 mg  | Jardiance<br>204629   | 8/1/2018           | 14                        | Eligible       | 9/6/2022                      | 8/3/2022                         |   | 6/11/2034                                 |
| Empagliflozin and Metformin Hydrochloride                              | Tablets                     | 5 mg/500 mg<br>5 mg/1000 mg<br>12.5 mg/500 mg<br>12.5 mg/1000 mg           | Synjardy<br>206111    | 8/1/2018           | 4                         | Eligible       | 9/6/2022                      | 7/7/2022                         |   | 4/3/2034                                  |
| Empagliflozin and Metformin Hydrochloride                              | Extended-release<br>Tablets | 5 mg/1000 mg<br>10 mg/1000 mg<br>12.5 mg/1000 mg<br>25 mg/1000 mg          | Synjardy XR<br>208658 | 8/1/2018           | 3                         |                |                               |                                  |   | 6/11/2034                                 |
| Empagliflozin and Linagliptin  | Tablets                     | 10 mg/5 mg and<br>25 mg/5 mg   | Glyxambi<br>206073    | 8/1/2018           | 9                         |                |                               |                                  |   | 6/11/2034                                 |
| Empagliflozin, Linagliptin and Metformin Hydrochloride                 | Extended-release<br>Tablets | 5 mg/2.5 mg/1 g,<br>10 mg/5 mg/1 g,<br>12.5 mg/5 mg/1 g,<br>25 mg/5 mg/1 g | Trijardy XR<br>212614 | 5/26/2020          | 1                         |                |                               |                                  |   | 4/3/2034                                  |
| Emtricitabine  | Capsules                    | 200 mg   | Emtriva<br>21500      | 7/16/2012          | 1                         | Eligible       | 11/17/2020                    | 7/2/2018                         | 8/31/2020                                 | 3/9/2021                                  |
| Emtricitabine and Tenofovir Alafenamide Fumarate                       | Tablets                     | 120 mg/15 mg   | Descovy<br>208215     | 10/31/2022         | 1                         |                |                               |                                  |   | 8/15/2032                                 |
| Emtricitabine and Tenofovir Alafenamide Fumarate                       | Tablets                     | 200 mg/25 mg   | Descovy<br>208215     | 11/5/2019          | 6                         |                |                               |                                  |   | 8/15/2032                                 |
| Emtricitabine and Tenofovir Disoproxil Fumarate                        | Tablets                     | 200 mg/300 mg  | Truvada<br>21752      | 9/26/2008          | 1                         | Extinguished   | 8/13/2019                     | 6/8/2017                         |   | 3/9/2021                                  |
| Emtricitabine and Tenofovir Disoproxil Fumarate                        | Tablets                     | 100 mg/150 mg<br>133 mg/200 mg<br>167 mg/250 mg                            | Truvada<br>21752      | 5/19/2017          | 1                         | Eligible       | 8/13/2019                     | 8/22/2018                        | 1/18/2021                                 | 3/9/2021                                  |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME   | DOSAGE FORM              | STRENGTH  | RLD/NDA                  | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS          | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|--------------------------|---|--------------------------|--------------------|---------------------------|-------------------------|-------------------------------|----------------------------------|---|---|
| Emtricitabine, Rilpivirine Hydrochloride and Tenofovir Disoproxil Fumarate  | Tablets                  | 200 mg/25 mg/300 mg   | Complera 202123          | 5/20/2015          | 1                         |                         |                               |                                  |   | 12/9/2025                                 |
| Emtricitabine, Rilpivirine Hydrochloride and Tenofovir Alafenamide Fumarate | Tablets                  | 200 mg/25 mg/25 mg  | Odefsey 208351           | 11/5/2019          | 3                         |                         |                               |                                  |   | 8/15/2032                                 |
| Enalapril Maleate   | Tablets                  | 2.5 mg, 5 mg, 10 mg and 20 mg   | Vasotec 18998            | Pre-MMA            |                           |                         |                               |                                  |   |   |
| Enalapril Maleate   | Powder for Oral Solution | 1 mg/mL   | Epaned Kit 204308        | 6/21/2016          | 1                         |                         |                               |                                  |   | 11/6/2032                                 |
| Enalapril Maleate   | Oral Solution            | 1 mg/mL   | Epaned 208686            | 8/31/2018          | 1                         | Eligible                | 9/7/2021                      | 8/10/2021                        | 8/17/2021                                 | 3/25/2036                                 |
| Encorafenib   | Capsules                 | 75 mg   | Braftovi 210496          | 6/27/2022          | 3                         |                         |                               |                                  |   | 11/21/2032                                |
| Enoxaparin Sodium   | Injection                | 100 mg/mL, 0.3 mL, 0.4 mL, 0.6 mL, 0.8 mL and 1 mL prefilled syringes | Lovenox 20164            | Pre-MMA            |                           |                         |                               |                                  |   |   |
| Enoxaparin Sodium   | Injection                | 150 mg/mL, 0.6 mL, 0.8 mL and 1 mL prefilled syringes                 | Lovenox 20164            | Pre-MMA            |                           |                         |                               |                                  |   |   |
| Enoxaparin Sodium   | Injection                | 100 mg/mL, 3 mL vials   | Lovenox 20164            | 12/7/2006          | 1                         | Non-Forfeiture          | 4/7/2020                      | 11/28/2011                       |   | 2/14/2012                                 |
| Entacapone  | Tablets                  | 200 mg  | Comtan 20796             | 4/11/2007          | 1                         | Extinguished            | 4/7/2020                      | 8/16/2012                        |   | 9/14/2018                                 |
| Entecavir   | Tablets                  | 0.5 mg and 1 mg   | Baraclude 21797          | 6/14/2010          | 1                         | Eligible                | 4/7/2020                      | 8/26/2014                        | 9/4/2014                                  | 8/21/2015                                 |
| Enzalutamide  | Capsules                 | 40 mg   | Xtandi 203415            | 8/31/2016          | 3                         | Non-Forfeiture Deferred | 9/18/2023<br>6/15/2021        | 5/14/2021                        |   | 8/13/2027                                 |
| Enzalutamide  | Tablets                  | 40 mg and 80 mg   | Xtandi 213674            | 3/31/2021          | 1                         |                         |                               |                                  |   | 8/13/2027                                 |
| Ephedrine Sulfate   | Injection                | 50 mg/10 mL   | Emerphed 213407          | 10/14/2021         | 1                         |                         |                               |                                  |   | 5/16/2040                                 |
| Ephedrine Sulfate   | Injection                | 25 mg/5 mL and 50 mg/10 mL  | Ephedrine Sulfate 213994 | 3/17/2023          | 1                         |                         |                               |                                  |   | 1/22/2040                                 |
| Epinastine Hydrochloride  | Ophthalmic Solution      | 0.05%   | Elestat 21565            | 10/14/2008         | 1                         | Eligible                | 4/7/2020                      | 3/14/2011                        | 5/2/2011                                  | 11/29/2020                                |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME               | DOSAGE FORM               | STRENGTH                         | RLD/NDA                      | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-------------------------|---------------------------|----------------------------------|------------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Epinephrine             | Injection (Auto-injector) | 0.15 mg/0.3 mL and 0.3 mg/0.3 mL | Epipen and Epipen Jr. 19430  | 7/20/2009          | 1                         | Deferred       | 8/27/2019                     | 8/16/2018                        | 8/19/2019                                 | 9/11/2025                                 |
| Epinephrine             | Injection                 | 1 mg/mL ampules                  | Adrenalin 204200             | 3/9/2016           | 1                         | Deferred       | 4/7/2020                      | 7/6/2018                         |   | 3/13/2035                                 |
| Epinephrine             | Injection                 | 30 mg/30 mL                      | Adrenalin 204640             | 8/20/2018          | 1                         | Eligible       | 9/6/2022                      | 4/24/2020                        | 5/19/2020                                 | 3/13/2035                                 |
| Epinephrine             | Injection                 | 1 mg/mL                          | Epinephrine Injection 205029 | 8/13/2020          | 1                         |                |                               |                                  |   | 8/15/2034                                 |
| Eplerenone              | Tablets                   | 25 mg and 50 mg                  | Inspira 21437                | 9/27/2006          | 2                         | Eligible       | 4/7/2020                      | 7/30/2008                        | 7/30/2008                                 | 4/10/2020                                 |
| Epoprostenol Sodium     | Injection                 | 0.5m/vial and 1.5 mg/vial        | Veletri 22260                | 3/31/2017          | 1                         | Deferred       | 2/9/2021                      | 1/15/2021                        | 1/27/2021                                 | 3/15/2027                                 |
| Eptifibatide            | Injection                 | 0.75 mg/mL, 100 mL vial          | Integrilin 21437             | 6/5/2009           | 1                         | Eligible       | 4/7/2020                      | 6/5/2015                         | 12/14/2015                                | 9/15/2015                                 |
| Eptifibatide            | Injection                 | 2 mg/mL, 10 mL vial              | Integrilin 20718             | 9/30/2008          | 1                         | Extinguished   | 4/7/2020                      | 6/12/2015                        |   | 9/15/2015                                 |
| Eptifibatide            | Injection                 | 2 mg/mL, 100 mL vial             | Integrilin 20718             | 12/18/2008         | 1                         | Extinguished   | 4/7/2020                      | 6/12/2015                        |   | 9/15/2015                                 |
| Eprosartan Mesylate     | Tablets                   | 400 mg and 600 mg                | Teveten 20738                | 5/10/2010          | 1                         | Eligible       | 4/7/2020                      | 11/16/2011                       | 12/20/2011                                | 8/12/2014                                 |
| Erdafitinib             | Tablets                   | 3 mg, 4 mg and 5 mg              | Balversa 212018              | 4/12/2023          | 1                         |                |                               |                                  |   | 2/2/2038                                  |
| Eribulin Mesylate       | Injection                 | 1 mg/2 mL                        | Halaven 201532               | 12/20/2019         | 1                         |                |                               |                                  |   | 1/8/2027                                  |
| Erlotinib Hydrochloride | Tablets                   | 100 mg and 150 mg                | Tarceva 21743                | 11/18/2008         | 2                         | Eligible       | 6/18/2019                     | 6/11/2014                        | 5/9/2019                                  | 11/9/2020                                 |
| Erlotinib Hydrochloride | Tablets                   | 25 mg                            | Tarceva 21743                | 11/18/2008         | 1                         | Eligible       | 6/18/2019                     | 6/11/2014                        | 5/9/2019                                  | 11/9/2020                                 |
| Ertapenem               | Injection                 | 1 g/vial                         | Invanz 21337                 | 12/21/2012         | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 5/15/2017                                 |
| Ertugliflozin           | Tablets                   | 5 mg and 15 mg                   | Steglatro 209803             | 12/20/2021         | 3                         | Eligible       | 8/7/2023                      | 7/13/2023                        |   | 7/13/2030                                 |
| Escitalopram Oxalate    | Capsules                  | 5 mg                             | Lexapro 21323                | 8/17/2005          | 1                         | Eligible       | 4/7/2020                      | 8/3/2007                         |   | 7/25/2022                                 |
| Escitalopram Oxalate    | Capsules                  | 10 mg and 20 mg                  | Lexapro 21323                | 3/30/2005          | 1                         | Eligible       | 4/7/2020                      | 8/3/2007                         |   | 7/25/2022                                 |
| Escitalopram Oxalate    | Tablets                   | 5 mg, 10 mg and 20 mg            | Lexapro 21323                | Pre-MMA            |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                | DOSAGE FORM                            | STRENGTH  | RLD/NDA                        | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--------------------------|--|---|--------------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Esketamine Hydrochloride | Nasal Spray                            | 28 mg   | Spravato<br>211243             | 3/6/2023           | 3                         |                |                               |                                  |   | 9/10/2035                                 |
| Eslicarbazepine Acetate  | Tablets                                | 200 mg, 400 mg,<br>600 mg and 800 mg  | Aptiom<br>22416                | 11/8/2017          | 7                         | Deferred       | 7/13/2021                     | 6/29/2021                        |   | 8/24/2032                                 |
| Esmolol Hydrochloride    | Injection                              | 10 mg/mL,<br>10 mL vial   | Brevibloc<br>19386             | Pre-MMA            |                           |                |                               |                                  |   |   |
| Esmolol Hydrochloride    | Injection                              | 10 mg/mL,<br>250 mL infusion bags<br>and 20 mg/mL,<br>100 mL infusion bags  | Brevibloc<br>19386             | 1/31/2014          | 1                         | Extinguished   | 4/7/2020                      | 6/8/2016                         |   | 1/12/2021                                 |
| Esomeprazole Magnesium   | Delayed-release<br>Capsules            | 20 mg and 40 mg   | Nexium<br>21153                | 8/5/2005           | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 3/1/2008                                  |
| Esomeprazole Magnesium   | Delayed-release<br>Capsules            | 20 mg   | Nexium (OTC)<br>204655         | 4/24/2014          |                           |                |                               |                                  |   |   |
| Esomeprazole Magnesium   | Delayed-release for<br>Oral Suspension | 20 mg and 40 mg   | Nexium<br>21957                | 8/1/2013           | 1                         | Extinguished   | 10/4/2022                     |                                  |   | 11/3/2019                                 |
| Esomeprazole Magnesium   | Delayed-release for<br>Oral Suspension | 10 mg   | Nexium<br>22101                | 7/6/2018           | 1                         | Extinguished   | 1/27/2020                     | 3/23/2020                        |   | 11/3/2019                                 |
| Esomeprazole Magnesium   | Delayed-release for<br>Oral Suspension | 2.5 mg and 5 mg   | Nexium<br>21957                | 9/24/2018          | 1                         | Extinguished   | 1/27/2020                     |                                  |   | 11/3/2019                                 |
| Esomeprazole             | Delayed-release<br>Tablets             | 20 mg   | Nexium 24HR<br>(OTC)<br>207920 | 9/9/2016           | 1                         | Eligible       | 7/2/2019                      | 3/5/2019                         |   | 11/3/2019                                 |
| Esomeprazole Sodium      | For Injection                          | 20 mg/vial and<br>40 mg/vial  | Nexium IV<br>21689             | 11/23/2009         | 1                         | Deferred       | 4/7/2020                      | 3/18/2013                        | 1/15/2014                                 | 5/27/2014                                 |
| Estradiol                | Transdermal System                     | 0.025 mg/day<br>0.0375 mg/day<br>0.05 mg/days<br>0.075 mg/day<br>0.1 mg/day | Vivelle Dot<br>20538           | 4/27/2010          | 1                         | Extinguished   | 4/7/2020                      | 12/19/2014                       |   | 8/12/2014                                 |
| Estradiol                | Transdermal System                     | 0.0375 mg/day and<br>0.06 mg/day  | Climara<br>20375               | Pre-MMA            |                           |                |                               |                                  |   |   |
| Estradiol                | Transdermal System                     | 0.05 mg/day and<br>0.1 mg/day   | Climara<br>20375               | 9/12/2005          |                           |                |                               |                                  |   |   |
| Estradiol                | Vaginal Tablets                        | 10 mcg  | Vagifem<br>20908               | 1/2/2013           | 1                         | Eligible       | 4/7/2020                      | 5/29/2015                        | 10/17/2016                                | 9/17/2022                                 |
| Estradiol                | Vaginal Inserts                        | 4 mcg and 10 mcg  | Imvexxy<br>208564              | 12/30/2019         | 1                         |                |                               |                                  |   | 12/20/2033                                |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                             | DOSAGE FORM                 | STRENGTH   | RLD/NDA                    | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------------------|-----------------------------|--|----------------------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Estradiol                             | Transdermal System          | 0.0375 mg/day<br>0.05 mg/day<br>0.075 mg/day<br>0.1 mg/day | Minivelle<br>203752        | 8/18/2014          | 1                         | Deferred                 | 10/8/2019                     | 8/15/2018                        | 11/1/2018                                 | 7/4/2030                                  |
| Estradiol                             | Transdermal System          | 0.025 mg/day   | Minivelle<br>203752        | 5/8/2015           | 1                         | Deferred                 | 10/8/2019                     | 8/15/2018                        | 11/1/2018                                 | 7/4/2030                                  |
| Estradiol; Estradiol and Norgestimate | Tablets                     | 1 mg; 1 mg and 0.09 mg                                     | Prefest<br>21040           | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Estradiol and Progesterone            | Capsules                    | 1 mg/100 mg  | Bijuva<br>NDA 210132       | 1/6/2020           | 1                         | Eligible                 | 5/31/2022                     | 5/16/2022                        |   | 11/21/2032                                |
| Estradiol Valerate and Dienogest      | Tablets                     | 3 mg;2 mg/2 mg;<br>2 mg/3 mg and 1 mg                      | Natazia<br>22252           | 10/22/2010         | 1                         | Extinguished             | 4/7/2020                      |                                  |   | 10/25/2016                                |
| Eszopiclone                           | Tablets                     | 1 mg, 2 mg and 3 mg  | Lunesta<br>21476           | 12/15/2008         | 10                        | Eligible                 | 4/7/2020                      | 5/23/2011                        | 4/15/2014                                 | 8/30/2012                                 |
| Etelcalcetide                         | Injection                   | 2.5 mg/0.5 mL<br>5 mg/mL<br>10 mg/2 mL                     | Parsabiv<br>208325         | 2/8/2021           | 2                         |                          |                               |                                  |   | 6/27/2034                                 |
| Ethinyl Estradiol and Etonogestrel    | Vaginal Ring                | 0.015 mg/24 hour<br>0.12 mg/24 hour                        | Nuvaring<br>21187          | 6/17/2013          | 1                         | Extinguished             | 3/10/2020                     |                                  |   | 4/8/2018                                  |
| Etodolac                              | Extended-release Tablets    | 400 mg, 500 mg and 600 mg                                  | Lodine XL<br>20584         | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Everolimus                            | Tablets                     | 0.25 mg, 0.5 mg, and 0.75 mg                               | Zortress<br>21560          | 9/30/2013          | 3                         | Extinguished<br>Deferred | 4/7/2020<br>4/7/2020          | 4/12/2018                        |   | 3/9/2020                                  |
| Everolimus                            | Tablets                     | 10 mg  | Afinitor<br>22334          | 6/18/2014          | 1                         | Extinguished             | 2/25/2020                     |                                  |   | 12/6/2019                                 |
| Everolimus                            | Tablets                     | 2.5 mg, 5 mg, and 7.5 mg                                   | Afinitor<br>22334          | 12/10/2014         | 1                         | Extinguished             | 2/25/2020                     | 12/9/2019                        |   | 12/6/2019                                 |
| Everolimus                            | Tablets for Oral Suspension | 2 mg, 3 mg and 5 mg  | Afinitor Disperz<br>203985 | 12/30/2016         | 1                         | Eligible                 | 1/27/2020                     | 4/19/2019                        | 10/1/2021                                 | 9/27/2022                                 |
| Exenatide                             | Injection                   | 250 mg/mL, 1.2 mL and 2.4 mL prefilled syringe             | Byetta<br>21773            | 6/11/2014          | 1                         | Extinguished             | 2/11/2020                     |                                  |   | 1/14/2020                                 |
| Ezetimibe                             | Tablets                     | 10 mg  | Zetia<br>21445             | 10/25/2006         | 1                         | Eligible                 | 6/18/2019                     | 6/26/2015                        | 12/12/2016                                | 1/25/2022                                 |
| Ezetimibe and Simvastatin             | Tablets                     | 10 mg/10 mg<br>10 mg/20 mg<br>10 mg/40 mg<br>10 mg/80 mg   | Vytorin<br>21687           | 7/27/2009          | 1                         | Extinguished             | 3/10/2020                     |                                  |   | 10/25/2016                                |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                           | DOSAGE FORM              | STRENGTH   | RLD/NDA                    | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-------------------------------------|--------------------------|--|----------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Famciclovir                         | Tablets                  | 125 mg, 250 mg and 500 mg                                | Famvir 20363               | 12/28/2004         | 1                         | Eligible       | 5/19/2020                     | 8/24/2007                        |   | 9/1/2015                                  |
| Famotidine                          | Injection                | 10 mg/mL, 2 mL vials; unpreserved                        | Pepcid                     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Famotidine                          | Injection                | 10 mg/mL, 4 mL and 20 mL vials; preserved                | Pepcid                     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Famotidine                          | Injection                | 10 mg/mL, 50 mL vial, pharmacy bulk package; unpreserved | Pepcid                     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Famotidine                          | Tablets                  | 10 mg (OTC)  | Pepcid AC                  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Famotidine                          | Tablets                  | 20 mg and 40 mg  | Pepcid 19462               | Pre-MMA            |                           |                |                               |                                  |   |   |
| Famotidine                          | Tablets (Chewable)       | 10 mg (OTC)  | Pepcid AC (chewable) 20801 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Febuxostat                          | Tablets                  | 40 mg and 80 mg  | Uloric 21856               | 2/13/2013          | 10                        | Eligible       | 8/27/2019                     | 7/1/2019                         | 7/1/2019                                  | 3/8/2024                                  |
| Fedratinib Hydrochloride <b>New</b> | Capsules                 | 100 mg   | Inrebic 212327             | 8/16/2023          | 1                         |                |                               |                                  |   | 9/24/2039                                 |
| Felodipine                          | Extended-release Tablets | 2.5 mg, 5 mg and 10 mg                                   | Plendil ER 19834           | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fenfluramine Hydrochloride          | Oral Solution            | 2.2 mg/mL  | Fintepla NDA 212102        | 6/21/2021          | 1                         |                |                               |                                  |   | 6/29/2038                                 |
| Fenofibrate                         | Tablets                  | 40 mg and 120 mg   | Fenoglide 22118            | 3/17/2010          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 12/9/2024                                 |
| Fenofibrate                         | Capsules                 | 43 mg and 130 mg   | Antara 21695               | 9/15/2008          | 1                         | Extinguished   | 5/19/2020                     | 3/1/2012                         |   | 8/20/2020                                 |
| Fenofibrate Choline                 | Delayed-release Capsules | 45 mg  | Trilipix 22224             | 9/2/2009           | 1                         | Extinguished   | 5/19/2020                     | 9/7/2016                         |   | 1/7/2025                                  |
| Fenofibrate Choline                 | Delayed-release Capsules | 135 mg   | Trilipix 22224             | 9/1/2009           | 1                         | Extinguished   | 5/19/2020                     | 9/7/2016                         |   | 1/7/2025                                  |
| Fenofibrate                         | Capsules                 | 67 mg, 134 mg and 200 mg                                 | Tricor 19304               | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fenofibrate                         | Tablets                  | 48 mg  | Tricor 21656               | 7/1/2008           | 1                         | Extinguished   | 4/7/2020                      | 4/5/2012                         |   | 2/21/2023                                 |
| Fenofibrate                         | Tablets                  | 54 mg, 107 mg and 160 mg                                 | Tricor 21203               | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fenofibrate                         | Tablets                  | 145 mg   | Tricor 21656               | 10/19/2007         | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 2/21/2023                                 |



**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                  | DOSAGE FORM                       | STRENGTH  | RLD/NDA              | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|----------------------------|-----------------------------------|---|----------------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Fentanyl                   | Transdermal Extended-release Film | 0.6 mg/24 hr<br>1.2 mg/ 24 hr<br>1.8 mg/ 24 hr<br>2.4 mg/ 24 hr                                   | Duragesic<br>19813   | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Fentanyl Citrate           | Buccal Tablets                    | 0.1 mg, 0.2 mg,<br>0.3 mg, 0.4 mg,<br>0.6 mg and 0.8 mg   | Fentora<br>21947     | 11/13/2007         | 1                         | Extinguished<br>Deferred | 3/10/2020<br>3/10/2020        | 1/7/2011                         |   | 3/26/2019                                 |
| Fentanyl Citrate           | Lozenges                          | 0.2 mg  | Actiq<br>20747       | 10/29/2004         |                           |                          |                               |                                  |   |   |
| Fentanyl Citrate           | Lozenges                          | 0.4 mg  | Actiq<br>20747       | 10/6/2004          |                           |                          |                               |                                  |   |   |
| Fentanyl Citrate           | Lozenges                          | 0.6 mg  | Actiq<br>20747       | 12/20/2004         |                           |                          |                               |                                  |   |   |
| Fentanyl Citrate           | Lozenges                          | 0.8 mg, 1.2 mg and<br>1.6 mg  | Actiq<br>20747       | 11/22/2004         |                           |                          |                               |                                  |   |   |
| Fentanyl                   | Sublingual Spray                  | 0.4 mg/spray  | Subsys<br>202788     | 5/22/2017          | 1                         | Extinguished             | 9/4/2023                      |                                  |   | 4/27/2030                                 |
| Fentanyl                   | Sublingual Spray                  | 0.1 mg/spray,<br>0.2 mg/spray,<br>0.6 mg/spray,<br>0.8 mg/spray,<br>1.2 mg/spray,<br>1.6 mg/spray | Subsys<br>202788     | 12/7/2017          | 1                         | Extinguished             | 9/4/2023                      |                                  |   | 4/27/2030                                 |
| Fentanyl Citrate           | Sublingual Tablets                | 0.1 mg, 0.2 mg,<br>0.3 mg, 0.4 mg,<br>0.6 mg and 0.8 mg   | Abstral<br>22510     | 6/19/2014          | 1                         | Deferred                 | 5/19/2020                     | 11/17/2017                       |   | 9/24/2019                                 |
| Ferric Carboxymaltose      | Injection                         | 100 mg/2 mL   | Injectafer<br>203565 | 9/23/2022          | 1                         |                          |                               |                                  |   | 2/15/2028                                 |
| Ferric Carboxymaltose      | Injection                         | 750 mg/15 mL  | Injectafer<br>203565 | 3/27/2019          | 1                         |                          |                               |                                  |   | 2/15/2028                                 |
| Ferric Carboxymaltose      | Injection                         | 1 g/20 mL   | Injectafer<br>203565 | 2/15/2022          | 1                         |                          |                               |                                  |   | 2/15/2028                                 |
| Ferumoxitol                | Injection                         | 30 mg/mL, 17 mL<br>single-use vials   | Feraheme<br>22180    | 12/4/2015          | 1                         | Deferred                 | 2/9/2021                      | 1/15/2021                        | 7/15/2021                                 | 6/30/2023                                 |
| Fesoterodine Fumarate      | Extended-release<br>Tablets       | 4 mg and 8 mg   | Toviaz<br>22030      | 10/31/2012         | 16                        | Eligible                 | 5/19/2020                     | 12/10/2015                       | 7/3/2022                                  | 6/7/2027                                  |
| Fexofenadine Hydrochloride | Oral Suspension<br>(OTC)          | 30 mg/5 mL  | Allegra<br>201373    | 1/25/2010          | 1                         | Eligible                 | 11/19/2019                    | 11/18/2014                       | 12/22/2014                                | 3/14/2017                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME  | DOSAGE FORM              | STRENGTH                         | RLD/NDA                            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|----------------------------------|------------------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Fexofenadine Hydrochloride                                   | Capsules                 | 60 mg                            | Allegra 20625                      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fexofenadine Hydrochloride                                   | Tablets                  | 30 mg, 60 mg and 180 mg          | Allegra 20872                      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride | Extended-release Tablets | 60 mg/120 mg                     | Allegra-D 20786                    | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride | Extended-release Tablets | 180 mg/240 mg                    | Allegra-D 24 Hour 21704            | 6/6/2007           | 1                         | Eligible       | 5/19/2020                     | 6/22/2011                        | 1/28/2011                                 | 12/25/2020                                |
| Fidaxomicin  | Tablets                  | 200 mg                           | Difcid 201699                      | 5/27/2015          | 1                         |                |                               |                                  |   | 7/31/2027                                 |
| Finasteride  | Tablets                  | 1 mg                             | Propecia 20788                     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Finasteride  | Tablets                  | 5 mg                             | Proscar 20180                      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fingolimod   | Capsules                 | 0.5 mg                           | Gilenya 22527                      | 9/22/2014          | 19                        | Deferred       | 1/2/2020                      | 12/4/2019                        | 9/21/2022                                 | 3/29/2026                                 |
| Fingolimod   | Capsules                 | 0.25 mg                          | Gilenya 22527                      | 7/19/2018          | 1                         | Eligible       | 11/15/2021                    | 11/12/2021                       |   | 3/30/2032                                 |
| Flecainide Acetate   | Tablets                  | 50 mg, 100 mg and 150 mg         | Tambacor 18830                     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fluconazole  | For Oral Suspension      | 50 mg/5 mL and 200 mg/5 mL       | Diflucan for Oral Suspension 20090 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fluconazole  | Tablets                  | 50 mg, 100 mg, 150 mg and 200 mg | Diflucan 19949                     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Flunisolide  | Nasal Solution           | 0.025%                           | Nasalide 18148                     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fluocinonide   | Cream                    | 0.1%                             | Vanos 21758                        | 1/31/2008          | 1                         | Eligible       | 6/1/2020                      | 1/14/2014                        | 1/14/2014                                 | 12/21/2021                                |
| Fluocinonide   | Ointment                 | 0.05%                            | Lidex 16909                        | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fluorouracil   | Cream                    | 0.5%                             | Carac 20985                        | 7/29/2011          | 1                         | Deferred       | 6/1/2020                      | 4/20/2015                        | 11/1/2014                                 | 6/2/2021                                  |
| Fluoxetine Hydrochloride                                     | Tablets                  | 10 mg and 20 mg                  | Prozac 20974                       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fluoxetine Hydrochloride                                     | Capsules                 | 10 mg, 20 mg and 40 mg           | Prozac 18936                       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fluoxetine Hydrochloride                                     | Delayed-release Capsules | 90 mg                            | Prozac Weekly 21235                | Pre-MMA            |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME   | DOSAGE FORM               | STRENGTH                        | RLD/NDA            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---------------------------|---------------------------------|--------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Fluoxetine Hydrochloride  | Oral Solution             | 20 mg (base)/5 mL               | Prozac 20101       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fluoxetine Hydrochloride  | Capsules                  | 10 mg and 20 mg                 | Sarafem 18936      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Flutamide   | Capsules                  | 125 mg                          | Eulexin 18554      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fluticasone Furoate   | Nasal Spray               | 27.5 mcg                        | Veramyst           | 7/15/2011          | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 8/3/2021                                  |
| Fluticasone Propionate  | Lotion                    | 0.05%                           | Cutivate 21152     | 7/28/2008          | 1                         | Eligible       | 6/15/2020                     | 5/2/2011                         | 3/26/2012                                 | 10/20/2019                                |
| Fluticasone Propionate  | Inhalation Aerosol        | 0.11 mcg/inh                    | Flovent HFA 21433  | 12/23/2016         | 1                         |                |                               |                                  |   | 2/26/2026                                 |
| Fluticasone Propionate  | Inhalation Aerosol        | 0.22 mcg/inh                    | Flovent HFA 21433  | 10/29/2021         | 1                         |                |                               |                                  |   | 2/26/2026                                 |
| Fluvastatin   | Capsules                  | 20 mg and 40 mg                 | Lescol 20261       | 6/4/2008           | 1                         | Extinguished   | 6/15/2020                     | 4/11/2012                        |   | 12/12/2011                                |
| Fluvastatin Sodium  | Extended-release Tablets  | 80 mg                           | Lescol XL 21192    | 3/15/2007          | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 4/13/2020                                 |
| Fluvoxamine Maleate   | Extended-release Capsules | 100 mg                          | Luvox CR 22033     | 4/20/2009          | 1                         | Extinguished   | 6/15/2020                     | 3/13/2013                        |   | 5/10/2020                                 |
| Fluvoxamine Maleate   | Extended-release Capsules | 150 mg                          | Luvox CR 22033     | 4/13/2009          | 1                         | Non-Forfeiture | 6/15/2020                     | 3/13/2013                        | 3/13/2013                                 | 5/10/2020                                 |
| Fomepizole  | Injection                 | 1.5 g/1.5 mL                    | Antizol 20696      | 4/14/2014          | 1                         | Extinguished   | 8/7/2023                      |                                  |   | 6/30/2027                                 |
| Formoterol Fumarate   | Inhalation Solution       | 0.02 mg/2 mL                    | Perforomist 22007  | 1/21/2009          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 6/22/2021                                 |
| Fosamprenavir Calcium   | Tablets                   | 700 mg                          | Lexiva 21548       | 1/18/2012          | 1                         | Extinguished   | 6/15/2020                     | 11/20/2019                       |   | 7/15/2019                                 |
| Fosaprepitant Dimeglumine   | Injection                 | 115 mg/vial                     | Emend 22023        | 1/25/2012          | 1                         | Extinguished   | 3/10/2020                     | 9/5/2019                         |   | 2/10/2015                                 |
| Fosaprepitant Dimeglumine   | Injection                 | 150 mg/vial                     | Emend 22023        | 1/25/2012          | 2                         | Extinguished   | 3/10/2020                     |                                  |   | 3/4/2019                                  |
| Fosinopril Sodium   | Tablets                   | 10 mg, 20 mg and 40 mg          | Monopril 19915     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fosinopril Sodium and Hydrochlorothiazide                           | Tablets                   | 10 mg/12.5 mg and 20 mg/12.5 mg | Monopril HCT 20286 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Fosnetupitant Chloride Hydrochloride and Palonosetron Hydrochloride | Solution in SDV           | 235 mg/0.25 mg per 20 mL        | Akynzeo 210493     | 4/19/2022          | 1                         |                |                               |                                  |   | 6/2/2037                                  |
| Fostamatinib Disodium   | Tablets                   | 100 mg and 150 mg               | Tavalisse 209299   | 4/18/2022          | 1                         |                |                               |                                  |   | 7/27/2032                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME  | DOSAGE FORM               | STRENGTH  | RLD/NDA                    | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|---------------------------|---|----------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Frovatriptan Succinate                           | Tablets                   | 2.5 mg  | Frova<br>21006             | 3/9/2011           | 1                         | Eligible       | 6/15/2020                     | 7/8/2014                         | 4/29/2016                                 | 11/7/2015                                 |
| Fulvestrant                                      | Injection                 | 50 mg/mL, 2.5 mL and 5 mL syringe               | Faslodex<br>21344          | 10/1/2009          | 1                         | Extinguished   | 7/16/2019                     |                                  |   | 1/9/2021                                  |
| Gabapentin                                       | Capsules                  | 100 mg, 300 mg and 400 mg                       | Neurontin<br>20235         | Pre-MMA            |                           |                |                               |                                  |   |   |
| Gabapentin                                       | Tablets                   | 100 mg, 300 mg and 400 mg                       | Neurontin<br>20235         | Pre-MMA            |                           |                |                               |                                  |   |   |
| Gabapentin                                       | Oral Solution             | 250 mg/5 mL                                     | Neurontin<br>21129         | Pre-MMA            |                           |                |                               |                                  |   |   |
| Gabapentin                                       | Tablets                   | 600 mg and 800 mg                               | Neurontin<br>20882         | Pre-MMA            |                           |                |                               |                                  |   |   |
| Gabapentin                                       | Tablets                   | 300 mg and 600 mg                               | Gralise<br>22544           | 10/31/2011         | 1                         |                |                               |                                  |   | 2/26/2024                                 |
| Gabapentin Enacarbil                             | Extended-release Tablets  | 300 mg and 600 mg                               | Horizant<br>22399          | 4/29/2019          | 1                         |                |                               |                                  |   | 6/10/2029                                 |
| Galantamine Hydrobromide                         | Extended-release Capsules | 8 mg  | Razadyne ER<br>21615       | 3/2/2006           | 1                         | Eligible       | 6/15/2020                     | 9/15/2008                        | 10/15/2008                                | 12/20/2019                                |
| Galantamine Hydrobromide                         | Extended-release Capsules | 16 mg and 24 mg                                 | Razadyne ER<br>21615       | 3/11/2006          | 1                         | Eligible       | 6/15/2020                     | 9/15/2008                        | 10/15/2008                                | 12/20/2019                                |
| Galantamine Hydrobromide                         | Tablets                   | 4 mg, 8 mg and 12 mg                            | Razadyne<br>21169          | 2/28/2005          | 14                        | Eligible       | 6/15/2020                     | 8/28/2008                        | 8/28/2008                                 | 6/6/2017                                  |
| Ganciclovir Sodium                               | Capsules                  | 250 mg and 500 mg                               | Cytovene<br>20460          | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ganirelix Acetate                                | Injection                 | 250 mcg/0.5 mL, 1 mL PFS                        | Ganirelix Acetate<br>21057 | 3/30/2012          | 1                         | Extinguished   | 1/27/2020                     | 11/30/2018                       |   | 6/16/2015                                 |
| Gatifloxacin                                     | Injection                 | 10 mg/mL, 20 mL and 40 mL vials                 | Tequin                     | 11/24/2004         | 1                         | Extinguished   | 6/15/2020                     |                                  |   |   |
| Gatifloxacin                                     | Ophthalmic Solution       | 0.3 %   | Zymar<br>21493             | 7/19/2007          | 1                         | Eligible       | 6/15/2020                     | 8/19/2011                        |   | 8/20/2019                                 |
| Gatifloxacin                                     | Ophthalmic Solution       | 0.5 %   | Zymaxid<br>22548           | 12/7/2010          | 1                         | Eligible       | 6/15/2020                     | 8/28/2013                        | 10/1/2013                                 | 8/20/2019                                 |
| Gatifloxacin                                     | Tablets                   | 200 mg and 400 mg                               | Tequin                     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Gatifloxacin in Dextrose 5% in Plastic Container | Injection                 | 2 mg/mL, 100 mL and 200 mL containers (plastic) | Tequin                     | 12/13/2004         | 2                         |                |                               |                                  |   |   |
| Gemcitabine                                      | For Injection             | 200 mg/vial                                     | Gemzar<br>20509            | 11/1/2005          | 1                         | Eligible       | 6/15/2020                     | 12/18/2008                       |   | 11/7/2012                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                             | DOSAGE FORM                 | STRENGTH                                      | RLD/NDA                | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------------------|-----------------------------|---|------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Gemcitabine                           | For Injection               | 1g/vial                                       | Gemzar<br>20509        | 11/14/2005         | 1                         | Eligible       | 6/15/2020                     | 1/25/2011                        |   | 11/7/2012                                 |
| Gemcitabine                           | For Injection               | 2 g/vial                                      | Gemzar                 | 8/24/2007          | 1                         | Eligible       | 6/15/2020                     | 11/15/2010                       | 11/15/2010                                | 11/7/2012                                 |
| Gemifloxacin Mesylate                 | Tablets                     | 320 mg  | Factive<br>21158       | 3/4/2008           | 1                         | Eligible       | 6/18/2019                     | 6/15/2015                        |   | 9/21/2019                                 |
| Gilteritinib Fumarate                 | Tablets                     | 40 mg   | Xospata<br>211349      | 11/28/2022         | 1                         |                |                               |                                  |   | 7/1/2036                                  |
| Glatiramer Acetate                    | Injection                   | 20 mg/mL, 1mL pre-filled syringe              | Copaxone<br>20622      | 12/27/2007         | 1                         | Extinguished   | 2/25/2020                     | 4/16/2015                        |   | 5/24/2014                                 |
| Glatiramer Acetate                    | Injection                   | 40 mg/mL, 1 mL pre-filled syringe             | Copaxone<br>20622      | 2/26/2014          | 2                         | Deferred       | 2/25/2020                     | 10/3/2017                        | 10/4/2017                                 | 8/19/2030                                 |
| Glimepiride and Rosiglitazone Maleate | Tablets                     | 1 mg/4 mg<br>2 mg/4 mg<br>4 mg/4 mg           | Avandaryl<br>21700     | 12/22/2006         | 1                         | Extinguished   | 6/15/2020                     | 4/1/2016                         |   | 10/21/2015                                |
| Glimepiride and Rosiglitazone Maleate | Tablets                     | 8 mg/2 mg<br>8 mg/4 mg                        | Avandaryl<br>21700     | 5/30/2008          | 1                         | Eligible       | 6/15/2020                     | 4/1/2016                         |   | 10/19/2020                                |
| Glipizide                             | Extended-release<br>Tablets | 2.5 mg, 5 mg and<br>10 mg                     | Glucotrol XL<br>20329  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Glyburide                             | Tablets                     | 1.5 mg, 3 mg,<br>4.5 mg and 6 mg              | Glynase<br>20051       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Glyburide/<br>Metformin Hydrochloride | Tablets                     | 1.25mg/250 mg<br>2.5 mg/500 mg<br>5 mg/500 mg | Glucovance<br>21178    | Pre-MMA            |                           |                |                               |                                  |   |   |
| Glycerol Phenylbutyrate               | Oral Liquid                 | 1.1 g/mL                                      | Ravicti<br>203284      | 11/19/2013         | 1                         | Eligible       | 1/11/2022                     | 12/2/2021                        |   | 3/9/2032                                  |
| Glycopyrrolate                        | Tablets                     | 1 mg  | Robinul<br>12827       | 8/14/2009          | 1                         | Extinguished   | 3/10/2020                     | 2/3/2014                         |   | 4/24/2024                                 |
| Glycopyrrolate                        | Tablets                     | 1.5 mg  | Robinul Forte          | 5/6/2009           | 1                         | Deferred       | 6/15/2020                     | 3/12/2012                        |   | 4/24/2024                                 |
| Glycopyrrolate                        | Tablets                     | 2 mg  | Robinul Forte<br>12827 | 10/12/2010         | 1                         | Eligible       | 6/15/2020                     | 2/3/2014                         | 12/21/2015                                | 4/24/2024                                 |
| Glycopyrrolate                        | Oral Solution               | 1 mg/5 mL                                     | Cuvposa<br>22571       | 6/20/2012          | 1                         | Eligible       | 8/24/2021                     | 8/9/2021                         | 1/4/2022                                  | 8/20/2023                                 |
| Glycopyrronium Tosylate               | Topical Cloth               | 2.4%  | Qbrexza<br>210361      | 1/13/2020          | 1                         |                |                               |                                  |   | 2/28/2033                                 |
| Granisetron Hydrochloride             | Injection                   | 0.1 mg/mL, 1 mL<br>single dose vial           | Kytril<br>20239        | 3/8/2007           | 1                         |                |                               |                                  |   |   |
| Granisetron Hydrochloride             | Injection                   | 1 mg/mL, 1 mL vials                           | Kytril<br>20239        | 6/1/2004           | 1                         | Eligible       | 6/15/2020                     | 12/31/2007                       | 12/31/2007                                | 5/4/2019                                  |
| Granisetron Hydrochloride             | Injection                   | 1 mg/mL, 4 mL<br>multi-dose vials             | Kytril<br>20239        | 7/19/2004          | 1                         | Eligible       | 6/15/2020                     | 12/31/2007                       | 12/31/2007                                | 5/4/2019                                  |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                     | DOSAGE FORM               | STRENGTH                                     | RLD/NDA                | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---------------------------|--|------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Granisetron Hydrochloride                     | Transdermal System        | 3.1 mg/24 hrs                                | Sancuso 22198          | 10/9/2015          | 1                         |                |                               |                                  |   | 10/22/2024                                |
| Guaifenesin                                   | Extended-release Tablets  | 600 mg and 1.2 gm                            | Mucinex 21282          | 6/9/2006           | 1                         | Extinguished   | 11/19/2019                    |                                  |   | 4/28/2020                                 |
| Guaifenesin and Dextromethorphan              | Extended-release Tablets  | 600 mg/30 mg and 1200 mg/60 mg               | Mucinex DM 21620       | 12/17/2008         | 1                         | Deferred       | 6/15/2020                     | 8/31/2015                        | 4/5/2016                                  | 4/28/2020                                 |
| Guaifenesin and Pseudoephedrine Hydrochloride | Extended-release Tablets  | 600 mg/60 mg and 1200 mg/120 mg              | Mucinex-D 21585        | 12/29/2008         | 1                         | Deferred       | 6/15/2020                     | 5/27/2015                        | 12/16/2015                                | 4/28/2020                                 |
| Guanfacine Hydrochloride                      | Extended-release Tablets  | 1 mg, 2 mg, 3 mg and 4 mg                    | Intuniv 22037          | 12/29/2009         | 1                         | Eligible       | 6/29/2020                     | 10/5/2012                        | 12/1/2014                                 | 7/4/2022                                  |
| Halobetasol Propionate                        | Lotion                    | 0.05%  | Ultavate 208183        | 1/24/2018          | 1                         | Eligible       | 7/13/2020                     | 6/4/2020                         |   | 6/19/2033                                 |
| Halobetasol Propionate                        | Lotion                    | 0.01%  | Bryhali 209355         | 5/15/2019          | 1                         |                |                               |                                  |   | 11/2/2031                                 |
| Halobetasol Propionate                        | Topical Foam              | 0.05%  | Lexette 210566         | 1/28/2021          | 1                         | Eligible       | 9/4/2023                      | 8/11/2023                        |   | 11/30/2036                                |
| Halobetasol Propionate and Tazarotene         | Lotion                    | 0.01%/0.045%                                 | Duobrii 209354         | 6/11/2020          | 1                         |                |                               |                                  |   | 6/6/2036                                  |
| Hydrocodone Bitartrate                        | Extended-release Capsules | 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, and 50 mg | Zohydro ER 202880      | 2/26/2014          | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 11/1/2019                                 |
| Hydrocodone Bitartrate and Ibuprofen          | Tablets                   | 2.5 mg/200 mg                                | Vicoprofen 20716       | 2/24/2006          | 1                         | Eligible       | 7/25/2022                     | 10/19/2007                       |   | 6/10/2017                                 |
| Hydrocodone Bitartrate and Ibuprofen          | Tablets                   | 5 mg/200 mg                                  | Vicoprofen             | 5/27/2005          | 1                         |                |                               | 3/18/2004                        |   | 6/10/2017                                 |
| Hydrocodone Bitartrate and Ibuprofen          | Tablets                   | 7.5 mg/200 mg                                | Vicoprofen 20716       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Hydrocodone Bitartrate and Ibuprofen          | Tablets                   | 10 mg/200 mg                                 | Vicoprofen 20716       | 3/20/2006          | 1                         | Eligible       | 6/15/2020                     | 11/6/2006                        |   | 6/10/2017                                 |
| Hydrocodone Bitartrate                        | Extended-release Tablets  | 20 mg, 60 mg, and 120 mg                     | Hysingla ER 206627     | 4/15/2015          | 1                         | Deferred       | 3/9/2021                      | 3/1/2021                         | 3/1/2021                                  | 12/21/2031                                |
| Hydrocodone Bitartrate                        | Extended-release Tablets  | 30 mg, 40 mg, 80 mg, and 100 mg              | Hysingla ER 206627     | 5/8/2015           | 1                         | Deferred       | 3/9/2021                      | 3/1/2021                         | 3/1/2021                                  | 12/21/2031                                |
| Hydrocortisone Butyrate                       | Cream                     | 0.10%  | Locoid Lipocream 20769 | 6/28/2010          | 1                         | Eligible       | 6/29/2020                     | 9/27/2013                        | 12/5/2013                                 | 6/3/2014                                  |
| Hydrocortisone Butyrate                       | Lotion                    | 0.10%  | Locoid 22076           | 8/31/2016          | 1                         | Eligible       | 6/29/2020                     | 11/21/2017                       | 2/12/2018                                 | 12/19/2026                                |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                    | DOSAGE FORM               | STRENGTH             | RLD/NDA                                | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|------------------------------|---------------------------|----------------------|--|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Hydromorphone Hydrochloride  | Extended-release Tablets  | 8 mg and 12 mg       | Exlago 21217                           | 9/2/2010           | 1                         | Deferred       | 6/29/2020                     | 5/12/2014                        |   | 7/7/2014                                  |
| Hydromorphone Hydrochloride  | Extended-release Tablets  | 16 mg                | Exlago 21217                           | 8/2/2010           | 1                         | Deferred       | 6/29/2020                     | 5/12/2014                        |   | 7/7/2014                                  |
| Hydromorphone Hydrochloride  | Oral Solution             | 5 mg/5mL             | Dilaudid 19891                         | 2/25/2011          | 1                         | Extinguished   | 1/27/2020                     |                                  |   | 11/9/2020                                 |
| Hydromorphone Hydrochloride  | Injection                 | 10 mg/mL             | Dilaudid-HP 19034                      | 11/4/2011          | 1                         | Extinguished   | 6/29/2020                     |                                  |   |   |
| Hydromorphone Hydrochloride  | Injection                 | 2 mg/mL              | Dilaudid 19034                         | 6/22/2011          |                           |                |                               |                                  |   |   |
| Hydromorphone Hydrochloride  | Tablets                   | 2 mg, 4 mg, and 8 mg | Dilaudid 19892                         | 8/5/2013           | 1                         | Deferred       | 6/29/2020                     | 5/13/2016                        |   | 11/9/2020                                 |
| Hydroxyprogesterone Caproate | Injection (Auto-injector) | 275 mg/1.1 mL        | Makena 21945                           | 9/28/2020          | 1                         |                |                               |                                  |   | 5/2/2036                                  |
| Ibandronate Sodium           | Injection                 | 1 mg/mL, 3 mL Vial   | Boniva 21858                           | 8/31/2007          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 9/2/2014                                  |
| Ibandronate Sodium           | Tablets                   | 150 mg               | Boniva 21455                           | 5/16/2007          | 8                         | Deferred       | 6/29/2020                     | 3/19/2012                        | 3/19/2012                                 | 5/6/2023                                  |
| Ibandronate Sodium           | Tablets                   | 2.5 mg               | Boniva 21455                           | 5/16/2007          | 1                         | Extinguished   | 6/29/2020                     |                                  |   | 5/6/2023                                  |
| Ibrutinib                    | Capsules                  | 70 mg                | Imbruvica 205552                       | 12/14/2018         | 1                         | Eligible       | 4/6/2021                      | 3/31/2021                        |   | 10/30/2033                                |
| Ibrutinib                    | Capsules                  | 140 mg               | Imbruvica 205552                       | 11/13/2017         | 8                         | Deferred       | 4/6/2021                      | 3/31/2021                        |   | 10/24/2034                                |
| Ibrutinib                    | Tablets                   | 140 mg and 560 mg    | Imbruvica 210563                       | 11/5/2018          | 1                         |                |                               |                                  |   | 3/3/2036                                  |
| Ibrutinib                    | Tablets                   | 280 mg and 420 mg    | Imbruvica 210563                       | 12/14/2018         | 1                         |                |                               |                                  |   | 3/3/2036                                  |
| Ibuprofen                    | Oral Drops                | 40 mg/mL             | Children's Motrin Drops 20603          | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ibuprofen                    | Oral Suspension           | 50 mg/1.25 mL        | Concentrated Motrin Infant Drops 20812 | 6/29/2007          | 1                         |                |                               |                                  |   | 12/20/2011                                |
| Ibuprofen                    | Oral Suspension           | 100 mg/5 mL (Rx)     | Motrin                                 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ibuprofen                    | Oral Suspension           | 100 mg/5 mL (OTC)    | Children's Motrin                      | Pre-MMA            |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME   | DOSAGE FORM                     | STRENGTH  | RLD/NDA   | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---------------------------------|---|---|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Ibuprofen   | Chewable Tablets                | 50 mg and 100 mg  | Children's Motrin, Junior Strength Motrin 20601 | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Ibuprofen Lysine                                      | Injection                       | 10 mg/mL, 2 mL vials  | Neoprofen 21903                                 | 10/1/2010          | 1                         | Extinguished<br>Deferred | 4/18/2023<br>6/29/2020        | 3/30/2016                        |   | 3/20/2021                                 |
| Ibuprofen and Diphenhydramine Hydrochloride           | Capsules                        | 200 mg/25 mg  | Advil PM 21393                                  | 2/16/2016          |                           |                          |                               |                                  |   |   |
| Ibuprofen and Diphenhydramine Citrate                 | Tablets                         | 200 mg/38 mg  | Advil PM 21394                                  | 12/28/2017         | 1                         | Extinguished             | 4/18/2023                     |                                  |   | 5/30/2022                                 |
| Ibuprofen and Famotidine                              | Tablets                         | 800 mg/26.6 mg  | Duexis 22519                                    | 12/6/2011          | 1                         | Extinguished             | 8/24/2021                     |                                  |   | 7/18/2026                                 |
| Ibuprofen and Pseudoephedrine Hydrochloride           | Oral Suspension                 | 100 mg/ 15 mg per 5 mL  | Children's Motrin Cold                          | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Ibuprofen and Pseudoephedrine Hydrochloride           | Tablets                         | 200 mg/30 mg  | Advil Cold and Sinus                            | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Ibuprofen Potassium and Pseudoephedrine Hydrochloride | Capsules                        | 200 mg/30 mg  | Advil Cold and Sinus                            | 12/27/2004         | 1                         | Extinguished             | 6/29/2020                     |                                  |   |   |
| Icatibant   | Injection                       | 10 mg/mL  | Firazyr 22150                                   | 8/25/2015          | 2                         | Extinguished             | 8/13/2019                     |                                  |   | 7/15/2019                                 |
| Icosapent Ethyl                                       | Capsules                        | 1 g   | Vascepa 202057                                  | 7/26/2016          | 4                         | Deferred                 | 6/15/2020                     | 5/21/2020                        | 11/4/2020                                 | 4/29/2030                                 |
| Icosapent Ethyl                                       | Capsules                        | 500 mg  | Vascepa 202057                                  | 8/29/2017          | 1                         | Non-Forfeiture           | 12/1/2020                     | 9/11/2020                        | 9/9/2022                                  | 4/29/2030                                 |
| Idelalisib  | Tablets                         | 100 mg and 150 mg   | Zydelig 205858                                  | 3/23/2022          | 1                         |                          |                               |                                  |   | 9/2/2033                                  |
| Ifosfamide  | For Injection                   | 1 g/vial and 3 g/vial   | Ifex 19763                                      | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Ifosfamide  | Injection                       | 50 mg/mL, 20 mL vials and 60 mL vials                                 | Ifex  | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Ifosfamide/ Mesna                                     | For Injection/<br>Injection Kit | 1 g/vial; 100 mg/mL, 10 mL vials and 3 g/vial; 100 mg/mL, 10 mL vials | Ifex/ Mesnex Kit 19763                          | Pre-MMA            |                           |                          |                               |                                  |   |   |



**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                          | DOSAGE FORM               | STRENGTH   | RLD/NDA                    | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS        | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|------------------------------------|---------------------------|--|----------------------------|--------------------|---------------------------|-----------------------|-------------------------------|----------------------------------|---|---|
| Ifosfamide/ Mesna                  | Injection/ Injection Kit  | 50 mg/mL, 20 mL and 60 mL vials; 100 mg/mL, 10 mL vial | Ifex/ Mesnex Kit           | Pre-MMA            |                           |                       |                               |                                  |   |   |
| lloperidone                        | Tablets                   | 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg         | Fanapt 22192               | 5/6/2013           | 1                         | Extinguished          | 6/18/2019                     |                                  |   | 11/15/2016                                |
| Imatinib Mesylate                  | Tablets                   | 100 mg and 400 mg                                      | Gleevec 21588              | 3/12/2007          | 1                         | Non-forfeiture        | 6/18/2019                     | 12/3/2015                        | 2/1/2016                                  | 11/23/2019                                |
| Imatinib Mesylate                  | Capsules                  | 400 mg   | Gleevec                    | 1/24/2014          | 1                         | Extinguished          | 3/10/2020                     |                                  |   | 1/16/2019                                 |
| Imiquimod                          | Cream                     | 5%   | Aldara 20723               | 10/17/2006         | 1                         | Eligible              | 6/29/2020                     | 2/25/2010                        | 2/25/2010                                 | 8/24/2010                                 |
| Imiquimod                          | Cream                     | 2.5%   | Zyclara 22483              | 6/17/2014          | 1                         |                       |                               |                                  |   | 12/11/2029                                |
| Imiquimod                          | Cream                     | 3.75%  | Zyclara 22483              | 8/8/2012           | 1                         | Non-Forfeiture        | 7/16/2019                     |                                  | 7/30/2020                                 | 12/11/2029                                |
| Indocyanine Green                  | For Injection             | 25 mg/vial   | Spy Agent Green Kit 211580 | 11/28/2022         | 1                         |                       |                               |                                  |   | 8/4/2035                                  |
| Indomethacin                       | Extended-release Capsules | 75 mg  | Indocin SR 18185           | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Ingenol Mebutate                   | Gel                       | 0.05%  | Picato 202833              | 1/27/2016          | 2                         | Eligible              | 8/13/2019                     | 1/9/2019                         |   | 7/6/2027                                  |
| Ingenol Mebutate                   | Gel                       | 0.015%   | Picato 202833              | 1/27/2016          | 2                         | Eligible              | 8/13/2019                     | 1/7/2019                         |   | 7/6/2027                                  |
| Irbesartan                         | Tablets                   | 75 mg, 150 mg and 300 mg                               | Avapro 20757               | 5/25/2004          | 1                         | Non-Forfeiture        | 6/29/2020                     | 3/30/2012                        | 3/30/2012                                 | 6/7/2015                                  |
| Irbesartan and Hydrochlorothiazide | Tablets                   | 150 mg/12.5 mg and 300 mg/12.5 mg                      | Avalide 20758              | 11/10/2004         | 1                         | Eligible              | 6/29/2020                     | 3/30/2012                        | 3/30/2012                                 | 6/7/2015                                  |
| Irbesartan and Hydrochlorothiazide | Tablets                   | 300 mg/25 mg   | Avalide 20758              | 6/6/2006           | 1                         | Eligible              | 6/29/2020                     | 3/30/2012                        |   | 6/7/2015                                  |
| Irinotecan Hydrochloride           | Injection                 | 20 mg/mL, 2 mL and 5 mL vials                          | Camptosar 20571            | 7/26/2004          | 1                         | Extinguished          | 6/29/2020                     | 2/20/2008                        |   | 5/1/2020                                  |
| Isotretinoin                       | Capsules                  | 30 mg  | Absorica 21951             | 12/31/2012         | 1                         | Eligible Deferred     | 4/20/2021<br>4/6/2021         | 3/31/2021                        | 3/31/2021                                 | 9/21/2021                                 |
| Isotretinoin                       | Capsules                  | 40 mg  | Absorica 21951             | 12/31/2012         | 1                         | Extinguished Deferred | 4/20/2021<br>4/6/2021         | 3/31/2021                        | 3/31/2021                                 | 9/21/2021                                 |
| Isotretinoin                       | Capsules                  | 20 mg  | Absorica 21951             | 1/7/2013           | 1                         | Eligible Deferred     | 4/20/2021<br>4/6/2021         | 3/31/2021                        | 3/31/2021                                 | 9/21/2021                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME              | DOSAGE FORM         | STRENGTH                                    | RLD/NDA           | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS       | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|------------------------|---------------------|---|-------------------|--------------------|---------------------------|----------------------|-------------------------------|----------------------------------|---|---|
| Isotretinoin           | Capsules            | 10 mg                                       | Absorica 21951    | 6/20/2013          | 1                         | Eligible<br>Deferred | 4/20/2021<br>4/6/2021         | 3/31/2021                        | 3/31/2021                                 | 9/21/2021                                 |
| Isotretinoin           | Capsules            | 35 mg                                       | Absorica 21951    | 11/25/2015         | 1                         | Deferred             | 4/6/2021                      | 3/31/2021                        | 3/31/2021                                 | 9/21/2021                                 |
| Isotretinoin           | Capsules            | 25 mg                                       | Absorica 21951    | 5/16/2016          | 1                         | Deferred             | 4/6/2021                      | 3/31/2021                        | 3/31/2021                                 | 9/21/2021                                 |
| Itraconazole           | Capsules            | 100 mg                                      | Sporanox 20083    | Pre-MMA            |                           |                      |                               |                                  |   |   |
| Itraconazole           | Oral Solution       | 10 mg/mL                                    | Sporanox 20657    | 5/3/2013           | 1                         | Eligible             | 6/29/2020                     | 10/30/2015                       | 9/18/2018                                 | 6/18/2019                                 |
| Ivabradine             | Tablets             | 5 mg and 7.5 mg                             | Corlanor 206143   | 10/15/2019         | 6                         | Eligible             | 1/11/2022                     | 12/30/2021                       |   | 2/22/2026                                 |
| Ivacaftor              | Tablets             | 150 mg                                      | Kalydeco 203188   | 6/10/2020          | 1                         |                      |                               |                                  |   | 8/13/2029                                 |
| Ivacaftor              | Oral Granules       | 25 mg, 50 mg and 75 mg                      | Kalydeco 207925   | 4/13/2022          | 1                         |                      |                               |                                  |   | 2/27/2033                                 |
| Ivermectin             | Lotion              | 0.50%                                       | Sklice 202736     | 9/1/2017           | 1                         | Eligible             | 6/15/2020                     | 5/6/2020                         | 11/30/2020                                | 10/12/2027                                |
| Ivermectin             | Cream               | 1%  | Soolantra 206255  | 12/30/2016         | 1                         | Eligible             | 1/2/2020                      | 9/13/2019                        | 10/14/2019                                | 3/13/2034                                 |
| Ivosidenib             | Tablets             | 250 mg                                      | Tibsovo 211192    | 7/20/2022          | 1                         |                      |                               |                                  |   | 6/7/2039                                  |
| Ixabepilon             | Injection           | 15 mg/vial and 45 mg/vial, single-use vials | Ixempra Kit 22065 | 4/16/2012          | 1                         | Extinguished         | 4/18/2023                     |                                  |   | 2/8/2022                                  |
| Ixazomib Citrate       | Capsules            | 2.3 mg, 3 mg and 4 mg                       | Ninlaro 208462    | 11/20/2019         | 1                         |                      |                               |                                  |   | 11/20/2029                                |
| Ketoconazole           | Foam                | 2%  | Extina 21738      | 7/30/2009          | 1                         | Eligible             | 6/29/2020                     | 8/25/2011                        | 8/25/2011                                 | 10/19/2018                                |
| Ketoprofen             | Capsules            | 25 mg, 50 mg and 75 mg                      | Orudis 18754      | Pre-MMA            |                           |                      |                               |                                  |   |   |
| Ketorolac Tromethamine | Injection           | 15 mg/mL and 30 mg/mL                       | Toradol 19698     | Pre-MMA            |                           |                      |                               |                                  |   |   |
| Ketorolac Tromethamine | Ophthalmic Solution | 0.45%                                       | Acuvail 22427     | 8/24/2011          | 1                         | Eligible             | 6/29/2020                     | 2/10/2014                        |   | 8/15/2029                                 |
| Ketorolac Tromethamine | Ophthalmic Solution | 0.4%  | Acular LS 21528   | 1/28/2005          | 1                         | Extinguished         | 6/29/2020                     | 11/5/2009                        |   | 5/5/2011                                  |
| Ketorolac Tromethamine | Tablets             | 10 mg                                       | Toradol 19645     | Pre-MMA            |                           |                      |                               |                                  |   |   |
| Ketorolac Tromethamine | Nasal Spray         | 15.75 mg/spray                              | Sprix 22382       | 3/12/2012          | 1                         | Extinguished         | 3/10/2020                     |                                  |   | 12/25/2018                                |
| Ketotifen Fumarate     | Ophthalmic Solution | 0.025%                                      | Zaditor 21066     | 12/23/2004         | 1                         | Eligible             | 7/27/2020                     | 5/9/2006                         | 7/3/2006                                  | 1/13/2019                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME   | DOSAGE FORM                                   | STRENGTH   | RLD/NDA            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---|--|--------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Lacosamide  | Oral Solution                                 | 10 mg/mL   | Vimpat 22255       | 10/29/2012         | 3                         | Extinguished   | 4/18/2022                     |                                  |   | 3/17/2022                                 |
| Lacosamide  | Tablets                                       | 50 mg, 100 mg, 150 mg, and 200 mg                | Vimpat 22253       | 10/29/2012         | 14                        | Extinguished   | 4/18/2022                     | 3/17/2022                        |   | 3/17/2022                                 |
| Lacosamide  | Injection                                     | 10 mg/mL, 20 mL                                  | Vimpat 22254       | 6/30/2016          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 3/17/2022                                 |
| Lactic Acid, Citric Acid and Potassium Bitartrate | Vaginal Gel                                   | 1.8%/1%/0.4%                                     | Phexxi 208352      | 2/28/2023          | 1                         |                |                               |                                  |   | 3/15/2033                                 |
| Lactulose   | Oral Syrup                                    | 10 g/15 mL                                       | Cephulac 17657     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Lactulose   | Oral Syrup                                    | 10 g/15 mL                                       | Chronulac 17884    | Pre-MMA            |                           |                |                               |                                  |   |   |
| Lamivudine  | Tablets                                       | 100 mg   | Epivir-HBV         | 10/31/2007         | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 5/18/2016                                 |
| Lamivudine  | Tablets                                       | 150 mg and 300 mg                                | Epivir             | 10/16/2007         | 1                         | Extinguished   | 10/5/2021                     |                                  |   | 11/17/2009                                |
| Lamivudine and Zidovudine                         | Tablets                                       | 150 mg/300 mg                                    | Combivir           | 6/26/2007          | 1                         | Eligible       | 10/5/2021                     | 5/25/2011                        | 2/3/2012                                  | 5/18/2016                                 |
| Lamivudine  | Oral Solution                                 | 10 mg/mL   | Epivir             | 11/22/2011         | 1                         | Eligible       | 4/6/2021                      | 10/31/2014                       | 3/5/2015                                  | 3/20/2018                                 |
| Lamotrigine                                       | Tablets                                       | 25 mg, 100 mg, 150 mg and 200 mg                 | Lamictal 20241     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Lamotrigine                                       | Chewable Tablets                              | 2 mg, 5 mg and 25 mg                             | Lamictal CD 20764  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Lamotrigine                                       | Orally Disintegrating Tablets                 | 25 mg, 50 mg, 100 mg, and 200 mg                 | Lamictal ODT 22251 | 12/21/2009         | 1                         | Deferred       | 10/5/2021                     | 7/15/2013                        |   | 1/4/2029                                  |
| Lamotrigine                                       | Extended-release Tablets                      | 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg | Lamictal XR 22115  | 2/12/2014          | 1                         | Extinguished   | 4/7/2020                      |                                  |   | 6/14/2028                                 |
| Lansoprazole                                      | Delayed-release Pellets/Capsules              | 15 mg and 30 mg                                  | Prevacid 20406     | 12/05/2005         |                           |                |                               |                                  |   |   |
| Lansoprazole                                      | Delayed-release Orally Disintegrating Tablets | 15 mg and 30 mg                                  | Prevacid 21428     | 12/27/2006         | 1                         | Extinguished   | 10/5/2021                     | 10/15/2010                       |   | 5/10/2009                                 |
| Lanthanum Carbonate                               | Chewable Tablet                               | 500 mg, 750 mg and 1000 mg                       | Fosrenol 21468     | 10/27/2008         | 3                         | Deferred       | 7/16/2019                     | 8/11/2017                        | 8/30/2017                                 | 8/26/2024                                 |
| Lanthanum Carbonate                               | Oral Powder                                   | 750 mg and 1000 mg                               | Fosrenol 204734    | 11/25/2015         | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 12/1/2030                                 |
| Lapatinib Ditosylate                              | Tablets                                       | 250 mg   | Tykerb 22059       | 3/14/2011          | 1                         | Deferred       | 11/17/2020                    | 9/29/2020                        | 9/29/2020                                 | 11/19/2021                                |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                             | DOSAGE FORM              | STRENGTH                   | RLD/NDA                                | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------------------|--------------------------|----------------------------|--|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Latanoprost                           | Ophthalmic Solution      | 0.005%                     | Xalatan<br>20597                       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Latanoprost and Netarsudil Dimesylate | Ophthalmic Solution      | 0.005%/0.02%               | Rocklatan<br>208259                    | 12/20/2021         | 2                         |                |                               |                                  |   | 3/14/2034                                 |
| Latanoprostene Bunod                  | Ophthalmic Solution      | 0.024%                     | Vyzulta<br>207795                      | 3/31/2022          | 1                         |                |                               |                                  |   | 10/3/2025                                 |
| Lenalidomide                          | Capsules                 | 5 mg, 10 mg and 15 mg      | Revlimid<br>21880                      | 8/30/2010          | 1                         | Non-Forfeiture | 11/17/2020                    | 5/21/2021                        | 3/3/2022                                  | 4/27/2027                                 |
| Lenalidomide                          | Capsules                 | 25 mg                      | Revlimid<br>21880                      | 7/12/2010          | 1                         | Non-Forfeiture | 11/17/2020                    | 5/21/2021                        | 3/3/2022                                  | 4/27/2027                                 |
| Lenalidomide                          | Capsules                 | 2.5 mg and 20 mg           | Revlimid<br>21880                      | 7/12/2016          | 1                         | Non-Forfeiture | 11/17/2020                    | 10/14/2021                       | 9/7/2022                                  | 4/27/2027                                 |
| Lenvatinib                            | Capsules                 | 4 mg and 10 mg             | Lenvima<br>206947                      | 2/13/2019          | 2                         |                |                               |                                  |   | 7/27/2027                                 |
| Letrozole                             | Tablets                  | 2.5 mg                     | Femara<br>20726                        | 3/2/2006           | 1                         | Eligible       | 4/6/2021                      | 12/24/2008                       |   | 6/3/2011                                  |
| Leuprolide Acetate                    | Injection (depot)        | 7.5 mg/vial                | Lupron Depot<br>19732                  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Levalbuterol Hydrochloride            | Inhalation Solution      | 0.0103%, 0.021% and 0.042% | Xopenex<br>20837                       | 6/20/2005          | 1                         | Eligible       | 10/5/2021                     | 4/9/2008                         |   | 3/21/2021                                 |
| Levalbuterol Hydrochloride            | Inhalation Solution      | 0.25%                      | Xopenex<br>20837                       | 5/23/2006          | 1                         | Eligible       | 10/5/2021                     | 3/20/2009                        |   | 3/21/2021                                 |
| Levalbuterol Tartrate                 | Inhalation Aerosol       | 0.045 mg/actuation         | Xopenex HFA<br>21730                   | 2/27/2012          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 10/8/2024                                 |
| Levetiracetam                         | Tablets                  | 250 mg, 500 mg and 750 mg  | Keppra<br>21035                        | Pre-MMA            |                           |                |                               |                                  |   |   |
| Levetiracetam                         | Tablets                  | 1000 mg                    | Keppra<br>21035                        | 1/24/2007          | 1                         |                |                               | 1/15/2009                        |   | 7/14/2008                                 |
| Levetiracetam                         | Extended-release Tablets | 500 mg and 750 mg          | Keppra XR<br>22285                     | 1/7/2011           | 3                         | Eligible       | 6/15/2020                     | 9/12/2011                        | 9/12/2011                                 | 9/17/2028                                 |
| Levetiracetam                         | Extended-release Tablets | 1000 mg                    | Keppra XR<br>22285                     | 1/7/2011           | 2                         | Extinguished   | 3/10/2020                     |                                  |   | 9/17/2028                                 |
| Levocetirizine Dihydrochloride        | Oral Solution            | 0.5 mg/mL                  | Xyzal<br>22157                         | 1/14/2009          | 1                         | Eligible       | 10/5/2021                     | 11/7/2011                        |   | 9/24/2012                                 |
| Levocetirizine Dihydrochloride        | Oral Solution            | 0.5 mg/mL                  | Xyzal Allergy<br>24 HR (OTC)<br>209090 | 1/4/2018           | 1                         | Deferred       | 10/5/2021                     |                                  |   |   |
| Levocetirizine Dihydrochloride        | Tablets                  | 5 mg                       | Xyzal<br>22064                         | 12/17/2007         | 1                         | Eligible       | 10/5/2021                     | 11/26/2010                       |   | 9/24/2012                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME  | DOSAGE FORM               | STRENGTH   | RLD/NDA  | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|---------------------------|--|--|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Levofloxacin   | Injection                 | 5 mg/mL; 50 mL, 100 mL and 150 mL vials  | Levaquin in Dextrose 5% in Plastic Container 20635 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Levofloxacin   | Injection                 | 25 mg/mL   | Levaquin 20635                                     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Levofloxacin   | Ophthalmic Solution       | 0.5%   | Quixin 21199                                       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Levofloxacin   | Oral Solution             | 25 mg/mL   | Levaquin 21721                                     | 7/30/2009          | 1                         | Eligible       | 10/5/2021                     | 6/20/2011                        |   | 2/26/2022                                 |
| Levofloxacin   | Tablets                   | 250 mg, 500 mg and 750 mg  | Levaquin 20634                                     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Levoleucovorin Calcium                               | Injection                 | 10 mg/mL, 17.5 mL vial and 25 mL vial  | Fusilev 20140                                      | 10/26/2011         | 1                         | Eligible       | 10/5/2021                     | 3/9/2015                         | 4/23/2015                                 | 12/31/2019                                |
| Levoleucovorin Calcium                               | Injection                 | 50 mg/vial   | Fusilev 20140                                      | 12/19/2013         | 1                         |                |                               |                                  |   |   |
| Levomilnacipran                                      | Extended-release Capsules | 20 mg, 40 mg, 80 mg and 120 mg   | Fetzima 204168                                     | 7/25/2017          | 6                         | Eligible       | 5/19/2020                     | 2/4/2019                         |   | 3/2/2031                                  |
| Levonorgestrel and Ethinyl Estradiol                 | Tablets                   | 0.09 mg/0.02 mg  | Lybrel 21864                                       | 10/5/2007          | 1                         | Non-Forfeiture | 10/5/2021                     | 6/6/2011                         |   |   |
| Levonorgestrel and Ethinyl Estradiol                 | Tablets                   | 0.15 mg/0.03 mg  | Seasonale 21544                                    | 3/29/2004          |                           |                |                               |                                  |   |   |
| Levonorgestrel and Ethinyl Estradiol                 | Tablets                   | 0.1 mg/0.02 mg   | Balcoltra 208612                                   | 7/14/2020          | 1                         | Extinguished   | 5/1/2023                      |                                  |   | 8/16/2021                                 |
| Levonorgestrel; Ethinyl Estradiol; Ethinyl Estradiol | Tablets                   | 0.1 mg/0.02 mg and 0.01 mg   | LoSeasonique 22262                                 | 11/16/2009         | 1                         | Eligible       | 10/5/2021                     | 10/26/2011                       |   | 6/15/2023                                 |
| Levonorgestrel; Ethinyl Estradiol; Ethinyl Estradiol | Tablets                   | 0.15 mg/0.03 mg/0.01 mg  | Seasonique 21840                                   | 1/22/2008          |                           |                |                               |                                  |   |   |
| Levonorgestrel; Ethinyl Estradiol;Ethinyl Estradiol  | Tablets                   | 0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg   | Quartette 204061                                   | 7/10/2013          | 1                         | Extinguished   | 10/5/2021                     |                                  |   |   |
| Levothyroxine Sodium                                 | Tablets                   | 0.025 mg, 0.05 mg, 0.075 mg, 0.088 mg, 0.1 mg, 0.112 mg, 0.125 mg, 0.150 mg, 0.175 mg, 0.2 mg and 0.3 mg | Levoxyl 21301                                      | Pre-MMA            |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME            | DOSAGE FORM         | STRENGTH  | RLD/NDA                     | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|----------------------|---------------------|---|-----------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Levothyroxine Sodium | for Injection       | 100 mcg/vial and 500 mcg/vial   | Levothyroxine Sodium 202231 | 4/14/2015          | 2                         | Eligible       | 6/18/2019                     | 6/29/2016                        | 4/2/2018                                  | 10/3/2032                                 |
| Levothyroxine Sodium | for Injection       | 200 mcg/vial  | Levothyroxine Sodium 202231 | 5/1/2015           | 1                         | Deferred       | 6/18/2019                     | 12/7/2015                        | 7/5/2016                                  | 10/3/2032                                 |
| Levothyroxine Sodium | Capsules            | 75 mcg and 150 mcg  | Tirosint 21924              | 12/29/2017         | 1                         | Deferred       | 1/12/2021                     | 10/28/2020                       |   | 3/14/2024                                 |
| Levothyroxine Sodium | Capsules            | 88 mcg, 100 mcg and 125 mcg   | Tirosint 21924              | 8/1/2019           | 1                         | Eligible       | 1/12/2021                     | 1/6/2021                         |   | 3/14/2024                                 |
| Levothyroxine Sodium | Capsules            | 112 mcg   | Tirosint 21924              | 12/18/2020         | 1                         | Eligible       | 7/25/2022                     | 4/16/2021                        |   | 3/14/2024                                 |
| Levothyroxine Sodium | Capsules            | 200 mcg   | Tirosint 21924              | 12/30/2021         | 1                         | Eligible       | 11/15/2022                    | 11/9/2022                        |   | 3/14/2024                                 |
| Levothyroxine Sodium | Capsules            | 137 mcg and 175 mcg   | Tirosint 21924              | 11/4/2022          | 1                         | Eligible       | 5/1/2023                      | 5/2/2023                         |   | 3/14/2024                                 |
| Levothyroxine Sodium | Oral Solution       | 13 mcg/mL<br>25 mcg/mL<br>50 mcg/mL<br>75 mcg/mL<br>88 mcg/mL<br>100 mcg/mL<br>112 mcg/mL<br>125 mcg/mL<br>137 mcg/mL<br>150 mcg/mL<br>175 mcg/mL<br>200 mcg/mL | Tirosint-Sol 206977         | 9/30/2022          | 1                         |                |                               |                                  |   | 2/28/2037                                 |
| Levothyroxine Sodium | Oral Solution       | 100 mcg/5 mL  | Thyquidity 214047           | 12/28/2022         | 1                         |                |                               |                                  |   | 8/6/2031                                  |
| Lidocaine            | Topical Patch       | 5%  | Lidoderm 20612              | 11/13/2009         | 1                         | Deferred       | 10/5/2021                     | 8/23/2012                        |   | 10/27/2015                                |
| Lidocaine            | Topical Patch       | 1.80%   | Ztlido 207962               | 3/17/2022          | 1                         |                |                               |                                  |   | 5/10/2031                                 |
| Lifitegrast          | Ophthalmic Solution | 5%  | Xiidra 208073               | 7/13/2020          | 4                         | Eligible       | 8/7/2023                      | 8/4/2023                         |   | 7/25/2033                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                | DOSAGE FORM              | STRENGTH   | RLD/NDA                            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|--|------------------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Linaclotide                              | Capsules                 | 145 mcg and 290 mcg                              | Linzess 202811                     | 8/30/2016          | 4                         | Deferred       | 2/22/2021                     | 2/9/2021                         |   | 10/30/2031                                |
| Linaclotide                              | Capsules                 | 72 mcg   | Linzess 202811                     | 11/7/2017          | 1                         |                |                               |                                  |   | 8/16/2033                                 |
| Linagliptin                              | Tablets                  | 5 mg   | Tradjenta 201280                   | 5/4/2015           | 11                        | Deferred       | 12/14/2021                    | 8/31/2021                        |   | 6/4/2030                                  |
| Linagliptin and Metformin Hydrochloride  | Tablets                  | 2.5 mg/500 mg<br>2.5 mg/850 mg<br>2.5 mg/1000 mg | Jentaduetto 201281                 | 5/4/2015           | 8                         | Deferred       | 9/7/2021                      | 8/30/2021                        |   | 6/4/2030                                  |
| Linagliptin and Metformin Hydrochloride  | Extended-release Tablets | 2.5 mg/1000 mg<br>5 mg/1000 mg                   | Jentaduetto XR 208026              | 3/28/2018          | 1                         |                |                               |                                  |   | 5/21/2030                                 |
| Linezolid                                | Injection                | 2 mg/mL, 100 mL bag                              | Zyvox 21131                        | 12/29/2009         | 1                         | Extinguished   | 10/5/2021                     | 7/16/2015                        |   | 11/18/2014                                |
| Linezolid                                | Injection                | 2 mg/mL, 300 mL bag                              | Zyvox 21131                        | 9/1/2009           | 1                         | Deferred       | 10/5/2021                     | 6/27/2012                        |   | 11/18/2014                                |
| Linezolid                                | Oral Suspension          | 100 mg/5 mL                                      | Zyvox 21132                        | 8/3/2009           | 1                         | Deferred       | 11/15/2022                    | 6/3/2015                         | 11/18/2015                                | 1/29/2021                                 |
| Linezolid                                | Tablets                  | 600 mg   | Zyvox 21130                        | 12/21/2005         | 1                         | Eligible       | 10/5/2021                     | 5/18/2015                        |   | 11/18/2014                                |
| Liraglutide                              | Injection                | 18 mg/3 mL prefilled syringe                     | Victoza 22341                      | 12/12/2016         | 1                         |                |                               |                                  |   | 1/9/2037                                  |
| Liraglutide                              | Injection                | 18 mg/3 mL prefilled syringe                     | Saxenda 206321                     | 8/16/2021          | 1                         |                |                               |                                  |   | 1/9/2037                                  |
| Lisdexamfetamine Dimesylate              | Capsules                 | 10 mg  | Vyvanse 21977                      | 4/9/2020           | 1                         | Extinguished   | 4/18/2023                     |                                  |   | 2/24/2023                                 |
| Lisdexamfetamine Dimesylate              | Capsules                 | 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg      | Vyvanse 21977                      | 2/23/2011          | 6                         | Extinguished   | 4/18/2023                     |                                  |   | 2/24/2023                                 |
| Lisinopril                               | Oral Solution            | 1 mg/mL  | Qbrelis 208401                     | 10/24/2019         | 1                         | Extinguished   | 6/15/2021                     |                                  |   | 11/6/2035                                 |
| Loperamide Hydrochloride and Simethicone | Chewable Tablets         | 2 mg/125 mg                                      | Imodium Multi-Symptom Relief 20606 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Loperamide Hydrochloride and Simethicone | Tablets                  | 2 mg/125 mg                                      | Imodium Multi-Symptom Relief 21140 | 12/29/2004         |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                  | DOSAGE FORM                   | STRENGTH                       | RLD/NDA                  | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|-------------------------------|--------------------------------|--------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Lopinavir and Ritonavir                    | Tablets                       | 100 mg/25 mg and 200 mg/50 mg  | Kaletra 21906            | 12/23/2008         | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 11/10/2020                                |
| Lopinavir and Ritonavir                    | Oral Solution                 | 80 mg/20 mg per mL             | Kaletra 21251            | 6/19/2014          | 1                         | Deferred       | 2/11/2020                     | 12/27/2016                       | 1/23/2017                                 | 11/28/2021                                |
| Loratadine                                 | Syrup                         | 1 mg/mL                        | Claritin 20641           | Pre-MMA            |                           |                |                               |                                  |   |   |
| Loratadine                                 | Tablets                       | 10 mg                          | Claritin 19658           | Pre-MMA            |                           |                |                               |                                  |   |   |
| Loratadine                                 | Orally Disintegrating Tablets | 10 mg                          | Claritin RediTabs 20704  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Loratadine/ Pseudoephedrine                | Extended-release Tablets      | 5 mg/120 mg                    | Claritin D-12 hour 19670 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Loratadine/ Pseudoephedrine                | Extended-release Tablets      | 10 mg/240 mg                   | Claritin D-24 hour 20470 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Lorcaserin Hydrochloride                   | Extended-release Tablets      | 20 mg                          | Belviq XR 208524         | 12/13/2016         | 1                         | Extinguished   | 5/19/2020                     |                                  |   | 2/7/2033                                  |
| Lorcaserin Hydrochloride                   | Tablets                       | 10 mg                          | Belviq 22529             | 6/27/2016          | 4                         | Extinguished   | 5/19/2020                     |                                  |   | 2/7/2033                                  |
| Losartan Potassium                         | Tablets                       | 25 mg, 50 mg, and 100 mg       | Cozaar 20386             | Pre-MMA            |                           |                |                               |                                  |   |   |
| Losartan Potassium and Hydrochlorothiazide | Tablets                       | 50 mg/12.5 mg and 100 mg/25 mg | Hyzaar 20387             | 5/24/2004          | 1                         | Eligible       | 10/5/2021                     | 4/6/2010                         |   | 9/4/2009                                  |
| Losartan Potassium and Hydrochlorothiazide | Tablets                       | 100 mg/12.5 mg                 | Hyzaar 20387             | 4/4/2006           | 1                         |                |                               |                                  |   |   |
| Loteprednol Etabonate                      | Ophthalmic Gel                | 0.38%                          | Lotemax SM 208219        | 11/14/2022         | 1                         |                |                               |                                  |   | 12/23/2036                                |
| Lovastatin and Niacin                      | Extended-release Tablets      | 20 mg/500 mg                   | Advicor                  | 9/22/2008          |                           |                |                               |                                  |   |   |
| Lovastatin and Niacin                      | Extended-release Tablets      | 20 mg/750 mg                   | Advicor                  | 12/17/2008         |                           |                |                               |                                  |   |   |
| Lovastatin and Niacin                      | Extended-release Tablets      | 20 mg/1000 mg                  | Advicor                  | 5/22/2008          |                           |                |                               |                                  |   |   |
| Lovastatin and Niacin                      | Extended-release Tablets      | 40 mg/1000 mg                  | Advicor                  | 11/19/2009         |                           |                |                               |                                  |   |   |
| Lubiprostone                               | Capsules                      | 8 mcg and 24 mcg               | Amitiza 21908            | 8/20/2012          | 1                         | Extinguished   | 11/30/2021                    | 6/27/2022                        | 1/4/2021                                  | 8/30/2022                                 |



**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME  | DOSAGE FORM               | STRENGTH                               | RLD/NDA          | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS        | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|---------------------------|--|------------------|--------------------|---------------------------|-----------------------|-------------------------------|----------------------------------|---|---|
| Lurasidone Hydrochloride   | Tablets                   | 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg | Latuda 200603    | 10/28/2014         | 14                        | Extinguished Eligible | 1/12/2021<br>8/27/2019        | 1/3/2019                         |   | 5/26/2026                                 |
| Macitentan   | Tablets                   | 10 mg                                  | Opsumit 204410   | 10/18/2017         | 11                        | Eligible              | 5/4/2021                      | 4/6/2021                         |   | 4/18/2029                                 |
| Malathion  | Topical Lotion            | 0.50%                                  | Ovide 18613      | 3/16/2011          | 1                         | Deferred              | 2/8/2022                      | 5/23/2012                        |   | 2/1/2027                                  |
| Maraviroc  | Tablets                   | 150 mg and 300 mg                      | Selzentry 22128  | 8/8/2011           | 2                         | Eligible              | 2/22/2022                     | 2/7/2022                         | 2/7/2022                                  | 11/25/2022                                |
| Mefloquine Hydrochloride   | Tablets                   | 250 mg                                 | Lariam 19591     | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Megestrol Acetate  | Oral Suspension           | 40 mg/mL                               | Megace 20264     | Pre-MMA            |                           |                       |                               |                                  |   |   |
| Megestrol Acetate  | Oral Suspension           | 125 mg/mL                              | Megace ES 21778  | 4/27/2011          | 1                         | Eligible              | 10/5/2021                     | 8/27/2014                        | 7/1/2015                                  | 4/22/2024                                 |
| Meloxicam  | Oral Suspension           | 7.5 mg/5 mL                            | Mobic 21530      | 12/17/2009         | 1                         | Extinguished          | 3/10/2020                     |                                  |   | 9/25/2019                                 |
| Meloxicam  | Capsules                  | 5 mg and 10 mg                         | Vivlodex 207233  | 1/9/2017           | 1                         | Extinguished Deferred | 3/9/2021<br>6/29/2020         | 6/1/2020                         | 12/22/2020                                | 3/31/2033                                 |
| Melphalan Hydrochloride  | Injection                 | 50 mg/vial                             | Evomela 207155   | 9/8/2017           | 1                         | Eligible              | 5/19/2020                     | 3/6/2020                         |   | 2/27/2033                                 |
| Memantine Hydrochloride  | Tablets                   | 5 mg and 10 mg                         | Namenda 21487    | 10/16/2007         | 14                        | Eligible              | 2/8/2022                      | 1/30/2015                        |   | 4/11/2015                                 |
| Memantine Hydrochloride  | Extended-release Capsules | 7 mg, 14 mg, 21 mg, and 28 mg          | Namenda XR 22525 | 6/10/2013          | 1                         | Extinguished          | 2/8/2022                      | 10/12/2016                       |   |   |
| Memantine Hydrochloride Extended-release and Donepezil Hydrochloride | Capsules                  | 14 mg/10 mg and 28 mg/10 mg            | Namzaric 206439  | 5/18/2015          | 1                         | Eligible              | 2/9/2021                      | 1/27/2017                        |   | 12/5/2029                                 |
| Memantine Hydrochloride Extended-release and Donepezil Hydrochloride | Capsules                  | 21 mg/10 mg                            | Namzaric 206439  | 9/23/2016          | 1                         |                       |                               |                                  |   | 12/5/2029                                 |
| Memantine Hydrochloride Extended-release and Donepezil Hydrochloride | Capsules                  | 7 mg/10 mg                             | Namzaric 206439  | 9/26/2016          | 1                         | Extinguished          | 2/9/2021                      |                                  |   | 12/5/2029                                 |
| Mesalamine   | Delayed-release Tablets   | 400 mg                                 | Asacol 19651     | 6/22/2007          | 1                         | Extinguished          | 2/11/2020                     |                                  |   | 7/30/2013                                 |
| Mesalamine   | Delayed-release Tablets   | 800 mg                                 | Asacol HD 21830  | 7/13/2011          | 1                         | Deferred              | 2/11/2020                     | 7/21/2017                        | 8/1/2016                                  | 11/15/2021                                |
| Mesalamine   | Delayed-release Tablets   | 1.2 g                                  | Lialda 22000     | 12/16/2009         | 1                         | Deferred              | 2/11/2020                     | 6/5/2017                         | 7/18/2017                                 | 6/8/2020                                  |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                     | DOSAGE FORM                       | STRENGTH               | RLD/NDA              | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS              | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-------------------------------|-----------------------------------|------------------------|----------------------|--------------------|---------------------------|-----------------------------|-------------------------------|----------------------------------|---|---|
| Mesalamine                    | Extended-release Capsules         | 0.375 g                | Apriso 22301         | 4/3/2012           | 1                         | Extinguished                | 2/11/2020                     |                                  |   | 4/20/2018                                 |
| Mesalamine                    | Suppository                       | 1000 mg                | Canasa 21252         | 5/24/2013          | 1                         | Eligible                    | 8/27/2019                     | 11/24/2015                       | 11/24/2015                                | 6/6/2028                                  |
| Mesalamine                    | Delayed-release Capsules          | 400 mg                 | Delzicol 204412      | 6/17/2014          | 1                         | Extinguished Non-Forfeiture | 6/18/2019<br>6/18/2019        |                                  |   | 4/13/2020                                 |
| Metaxalone                    | Tablets                           | 400 mg                 | Skelaxin 13217       | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Metaxalone                    | Tablets                           | 800 mg                 | Skelaxin 13217       | 11/4/2004          | 1                         | Non-Forfeiture              | 9/8/2020                      | 3/31/2010                        | 3/31/2010                                 | 12/3/2021                                 |
| Metformin Hydrochloride       | Extended-release Tablets          | 500 mg                 | Glucophage XR 21202  | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Metformin Hydrochloride       | Extended-release Tablets          | 750 mg                 | Glucophage XR 21202  | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Metformin Hydrochloride       | Extended-release Tablets          | 500 mg and 1000 mg     | Fortamet 21574       | 10/14/2008         | 1                         | Extinguished Eligible       | 4/17/2023<br>2/8/2022         | 6/29/2011                        |   | 3/17/2021                                 |
| Metformin Hydrochloride       | Extended-release Tablets          | 500 mg and 1000 mg     | Glumetza 21748       | 7/27/2009          | 1                         | Eligible                    | 7/16/2019                     | 7/19/2013                        | 2/1/2016                                  | 500mg:10/25/2021<br>1 g: 6/20/2020        |
| Metformin Hydrochloride       | Oral Solution                     | 500 mg/5 mL            | Riomet 21591         | 2/2/2018           | 1                         | Eligible                    | 11/15/2022                    | 3/3/2020                         | 4/20/2020                                 | 8/7/2021                                  |
| Methylnaltrexone Bromide      | Injection                         | 12 mg/0.6 mL           | Relistor 21964       | 7/22/2015          | 1                         |                             |                               |                                  |   | 12/31/2030                                |
| Methylnaltrexone Bromide      | Injection                         | 8 mg/0.4 mL            | Relistor 21964       | 9/8/2015           | 1                         |                             |                               |                                  |   | 12/31/2030                                |
| Methylnaltrexone Bromide      | Tablets                           | 150 mg                 | Relistor 208271      | 9/6/2016           | 1                         |                             |                               |                                  |   | 3/10/2031                                 |
| Methylphenidate Hydrochloride | Extended-release Capsules         | 10 mg                  | Ritalin LA 21284     | 5/21/2007          | 1                         | Extinguished                | 3/10/2020                     |                                  |   | 11/1/2019                                 |
| Methylphenidate Hydrochloride | Extended-release Capsules         | 20 mg, 30 mg and 40 mg | Ritalin LA 21284     | 8/21/2006          |                           |                             |                               |                                  |   |   |
| Methylphenidate Hydrochloride | Extended-release Capsules         | 10 mg, 20 mg and 30 mg | Metadate CD 21259    | 5/13/2005          | 1                         | Non-Forfeiture              | 9/8/2020                      | 7/19/2012                        | 9/27/2012                                 | 10/27/2020                                |
| Methylphenidate Hydrochloride | Extended-release Capsules         | 40 mg                  | Metadate CD 21259    | 3/15/2007          | 1                         | Non-Forfeiture              | 9/8/2020                      | 7/19/2012                        | 9/27/2012                                 | 10/27/2020                                |
| Methylphenidate Hydrochloride | Extended-release Chewable Tablets | 20 mg, 30 mg and 40 mg | Quillichew ER 207960 | 4/25/2016          | 1                         |                             |                               |                                  |   | 8/14/2033                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                     | DOSAGE FORM                                    | STRENGTH   | RLD/NDA                | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-------------------------------|--|--|------------------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Methylphenidate Hydrochloride | Extended-release Tablets                       | 18 mg*, 27 mg, 36 mg and 54 mg                           | Concerta 21121         | 7/19/2005          |                           |                          |                               |                                  |   |   |
| Methylphenidate Hydrochloride | Oral Solution                                  | 5 mg/5 mL<br>10 mg/5 mL                                  | Methylin 21419         | 4/13/2010          | 1                         | Eligible                 | 1/27/2020                     | 7/23/2010                        | 7/26/2010                                 | 10/7/2024                                 |
| Methylphenidate               | Transdermal System                             | 10 mg/9 hrs<br>15 mg/9 hrs<br>20 mg/9 hrs<br>30 mg/9 hrs | Daytrana 21514         | 4/13/2011          | 1                         | Extinguished             | 3/9/2021                      |                                  |   | 9/30/2018                                 |
| Methylphenidate Hydrochloride | Extended-release Oral Suspension               | 5 mg/mL  | Quillivant XR 202100   | 8/2/2013           |                           |                          |                               |                                  |   |   |
| Methylphenidate Hydrochloride | Extended-release Capsules                      | 60 mg  | Aptensio XR 205831     | 12/23/2015         | 1                         | Eligible                 | 7/30/2019                     | 12/13/2018                       | 9/25/2020                                 | 12/16/2019                                |
| Methylphenidate Hydrochloride | Extended-release Capsules                      | 10 mg  | Aptensio XR 205831     | 12/24/2015         | 1                         | Eligible                 | 7/30/2019                     | 12/13/2018                       | 9/25/2020                                 | 12/16/2019                                |
| Methylphenidate Hydrochloride | Extended-release Capsules                      | 15 mg, 20 mg, 40 mg and 50 mg                            | Aptensio XR 205831     | 12/28/2015         | 1                         | Eligible                 | 7/30/2019                     | 12/13/2018                       | 9/25/2020                                 | 12/16/2019                                |
| Methylphenidate Hydrochloride | Extended-release Capsules                      | 30 mg  | Aptensio XR 205831     | 3/28/2016          | 1                         | Eligible                 | 7/30/2019                     | 12/13/2018                       | 9/25/2020                                 | 12/16/2019                                |
| Methylphenidate               | Extended-release Orally Disintegrating Tablets | 8.6 mg, 17.3 mg and 25.9 mg                              | Cotempla XR-ODT 205489 | 9/1/2017           | 1                         | Eligible                 | 7/13/2020                     | 6/19/2020                        |   | 6/28/2032                                 |
| Metoclopramide Hydrochloride  | Injection                                      | 5 mg/mL, 2 mL, 10 mL, 20 mL and 30 mL vials              | Reglan 17862           | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Metoclopramide Hydrochloride  | Orally Disintegrating Tablets                  | 5 mg and 10 mg   | Metozolv ODT 22246     | 8/24/2010          | 1                         | Extinguished<br>Deferred | 4/18/2023<br>2/8/2022         | 8/15/2014                        |   | 7/11/2017                                 |
| Metoclopramide Hydrochloride  | Metered Nasal Spray                            | 15 mg/spray  | Gimoti 209388          | 12/30/2021         | 1                         |                          |                               |                                  |   | 5/16/2030                                 |
| Metoprolol Succinate          | Extended-release Tablets                       | 25 mg, 50 mg, 100 mg and 200 mg                          | Toprol XL 19962        | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Metronidazole                 | Vaginal Gel                                    | 0.75%  | MetroGel-Vaginal 20208 | 9/2/2004           | 1                         | Extinguished             | 2/8/2022                      |                                  |   | 6/6/2006                                  |
| Metronidazole                 | Topical Gel                                    | 1%   | Metrogel 21789         | 10/21/2008         | 1                         | Eligible                 | 5/4/2021                      | 7/22/2011                        | 7/1/2013                                  | 2/21/2022                                 |
| Metronidazole                 | Vaginal Gel                                    | 1.30%  | Nuessa 205223          | 3/30/2022          | 1                         |                          |                               |                                  |   | 6/28/2032                                 |
| Micafungin Sodium             | For Injection                                  | 50 mg/vial<br>100 mg/vial                                | Mycamine 21506         | 6/16/2014          | 1                         | Eligible                 | 6/1/2020                      | 5/17/2019                        | 5/8/2020                                  | 1/8/2021                                  |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                 | DOSAGE FORM                   | STRENGTH                          | RLD/NDA                                  | DATE OF SUBMISSION             | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS        | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------|-------------------------------|-----------------------------------|--|--------------------------------|---------------------------|-----------------------|-------------------------------|----------------------------------|---|---|
| Miconazole Nitrate        | Vaginal Cream and Suppository | 2% and 1.2 g                      | Monistat 1 Combination Pack 21308        | 12/5/2007                      | 1                         | Extinguished Deferred | 4/18/2023<br>2/8/2022         | 6/2/2010                         |   | 11/28/2020                                |
| Midazolam                 | Nasal Spray                   | 5 mg/spray                        | Nayzilam 211321                          | 6/1/2021                       | 1                         |                       |                               |                                  |   | 1/18/2028                                 |
| Midazolam                 | Intravenous                   | 50 mg/50 mL and 100 mg/100 mL     | Midazolam in 0.9% Sodium Chloride 211844 | 9/29/2021                      | 1                         | Eligible              | 4/18/2023                     | 4/17/2023                        | 7/6/2023                                  | 6/20/2038                                 |
| Midostaurin               | Capsules                      | 25 mg                             | Rydapt 207997                            | 4/28/2021                      | 4                         |                       |                               |                                  |   | 12/2/2030                                 |
| Mifepristone              | Tablets                       | 300 mg                            | Korlym 202107                            | 12/15/2017                     | 1                         | Eligible              | 2/8/2022                      | 8/3/2020                         |   | 8/15/2036                                 |
| Migalastat Hydrochloride  | Capsules                      | 123 mg                            | Galafold 208623                          | 8/10/2022                      | 3                         |                       |                               |                                  |   | 2/6/2039                                  |
| Milnacipran Hydrochloride | Tablets                       | 12.5 mg, 25 mg, 50 mg, and 100 mg | Savella 22256                            | 1/14/2013                      | 8                         | Deferred              | 2/8/2022                      | 1/27/2016                        |   | 9/19/2029                                 |
| Minocycline Hydrochloride | Extended-release Tablet       | 45 mg, 90 mg and 135 mg           | Solodyn 50808                            | PIV received prior to 2/5/2009 |                           |                       |                               |                                  |   |   |
| Minocycline Hydrochloride | Extended-release Tablet       | 55 mg                             | Solodyn 50808                            | 12/2/2010                      | 1                         | Eligible              | 12/13/2022                    | 11/30/2011                       | 2/22/2019                                 | 11/20/2025                                |
| Minocycline Hydrochloride | Extended-release Tablet       | 65 mg and 115 mg                  | Solodyn 50808                            | 11/19/2009                     | 1                         | Extinguished Eligible | 6/18/2019<br>6/18/2019        | 5/18/2012                        | 2/20/2018                                 | 2/19/2018                                 |
| Minocycline Hydrochloride | Extended-release Tablet       | 80 mg                             | Solodyn 50808                            | 10/27/2010                     | 1                         | Non-Forfeiture        | 2/8/2022                      | 9/25/2014                        |   | 2/19/2018                                 |
| Minocycline Hydrochloride | Extended-release Tablet       | 105 mg                            | Solodyn 50808                            | 12/13/2010                     | 1                         | Non-Forfeiture        | 2/8/2022                      |                                  |   | 2/19/2018                                 |
| Minocycline Hydrochloride | Injection                     | 100 mg/vial                       | Minocin NDA 50444                        | 10/16/2020                     | 1                         | Eligible              | 11/15/2022                    | 7/22/2022                        |   | 5/12/2031                                 |
| Minocycline Hydrochloride | Topical Aerosol Foam          | 4%                                | Amzeeq NDA 212379                        | 5/11/2021                      | 1                         |                       |                               |                                  |   | 9/8/2037                                  |
| Minocycline Hydrochloride | Topical Aerosol Foam          | 1.50%                             | Zilxi 213690                             | 2/28/2022                      | 1                         |                       |                               |                                  |   | 10/1/2030                                 |
| Minoxidil                 | Topical Aerosol Foam          | 5%                                | Men's Rogaine 21812                      | 4/6/2009                       | 1                         | Eligible              | 2/8/2022                      | 4/28/2011                        |   | 4/20/2019                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                       | DOSAGE FORM                   | STRENGTH                                    | RLD/NDA                 | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|-------------------------------|---|-------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Minoxidil                                       | Topical Aerosol Foam          | 5%  | Women's Rogaine 21812   | 2/4/2015           | 1                         | Eligible       | 4/18/2022                     | 7/27/2017                        |   | 4/20/2019                                 |
| Mirabegron                                      | Extended-release Tablets      | 25 mg                                       | Myrbetriq 202611        | 6/28/2016          | 6                         | Eligible       | 10/4/2022                     | 12/27/2019                       |   | 11/4/2023                                 |
| Mirabegron                                      | Extended-release Tablets      | 50 mg                                       | Myrbetriq 202611        | 6/28/2016          | 6                         | Deferred       | 10/4/2022                     | 9/28/2022                        |   | 11/4/2023                                 |
| Mirtazapine                                     | Tablets                       | 7.5 mg, 15 mg, 30 mg, and 45 mg             | Remeron 20415           | Pre-MMA            |                           |                |                               |                                  |   |   |
| Mirtazapine                                     | Orally Disintegrating Tablets | 15 mg, 30 mg and 45 mg                      | Remeron SolTab 21208    | Pre-MMA            |                           |                |                               |                                  |   |   |
| Modafinil                                       | Tablets                       | 100 mg and 200 mg                           | Provigil 20717          | Pre-MMA            |                           |                |                               |                                  |   |   |
| Moexipril Hydrochloride                         | Tablets                       | 7.5 mg and 15 mg                            | Univasc 20312           | Pre-MMA            |                           |                |                               |                                  |   |   |
| Moexipril Hydrochloride and Hydrochlorothiazide | Tablets                       | 7.5mg/12.5mg, 15 mg/25 mg and 15 mg/12.5 mg | Uniretic 20729          | 1/15/2004          | 1                         | Extinguished   | 2/8/2022                      | 3/7/2007                         |   | 2/24/2007                                 |
| Mometasone Furoate                              | Nasal Spray                   | 50 mcg/ Spray                               | Nasonex 20762           | 8/7/2009           | 1                         | Deferred       | 2/8/2022                      | 3/22/2016                        | 3/22/2016                                 | 10/3/2017                                 |
| Mometasone Furoate                              | Topical Solution (Cream)      | 0.1%  | Elocon 19625            | Pre-MMA            |                           |                |                               |                                  |   |   |
| Mometasone Furoate                              | Topical Solution (Lotion)     | 0.1%  | Elocon 19796            | 6/10/2004          | 1                         |                |                               | 4/6/2005                         |   | 11/21/2007                                |
| Montelukast                                     | Tablets                       | 10 mg                                       | Singulair 20829         | 2/20/2007          | 2                         | Extinguished   | 2/8/2022                      | 8/3/2012                         |   | 2/3/2012                                  |
| Montelukast Sodium                              | Chewable Tablets              | 4 mg and 5 mg                               | Singulair 20830         | 12/26/2006         | 1                         | Extinguished   | 2/8/2022                      | 8/3/2012                         |   | 8/3/2012                                  |
| Montelukast Sodium                              | Oral Granules                 | 4 mg  | Singular Granules 21409 | 10/17/2008         | 1                         | Extinguished   | 2/25/2020                     | 8/3/2012                         |   | 8/3/2012                                  |
| Morphine Sulfate                                | Extended-release Capsules     | 30 mg, 60 mg, 90 mg and 120 mg              | Avinza 21260            | 6/4/2007           | 1                         | Deferred       | 3/10/2020                     | 1/16/2013                        |   | 11/25/2017                                |
| Morphine Sulfate                                | Extended-release Capsules     | 45 mg and 75 mg                             | Avinza 21260            | 8/11/2009          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 11/25/2017                                |
| Morphine Sulfate                                | Extended-release Tablets      | 15 mg, 30 mg and 60 mg                      | Arymo ER 208603         | 12/29/2017         | 1                         | Extinguished   | 2/8/2022                      |                                  |   | 11/25/2017                                |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                     | DOSAGE FORM               | STRENGTH                                   | RLD/NDA   | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---------------------------|--|---|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Morphine Sulfate                              | Extended-release Tablets  | 15 mg, 30 mg, 60 mg and 100 mg             | Morphabond ER 206544                                      | 1/28/2019          | 1                         |                |                               |                                  |   | 8/21/2028                                 |
| Morphine Sulfate and Naltrexone Hydrochloride | Extended-release Capsules | 20 mg/0.8 mg                               | Embeda 22321  | 8/16/2018          | 1                         | Extinguished   | 2/8/2022                      |                                  |   | 11/7/2029                                 |
| Morphine Sulfate and Naltrexone Hydrochloride | Extended-release Capsules | 100 mg/4 mg                                | Embeda 22321  | 5/3/2010           | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 6/19/2027                                 |
| Morphine Sulfate and Naltrexone Hydrochloride | Extended-release Capsules | 60 mg/2.4 mg                               | Embeda 22321  | 5/25/2010          | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 6/19/2027                                 |
| Morphine Sulfate and Naltrexone Hydrochloride | Extended-release Capsules | 30 mg/1.2 mg<br>50 mg/2 mg<br>80 mg/3.2 mg | Embeda 22321  | 5/28/2010          | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 6/19/2027                                 |
| Moxifloxacin Hydrochloride                    | Ophthalmic Solution/Drops | 0.5%                                       | Vigamox 21598   | 12/22/2005         | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 9/20/2019                                 |
| Moxifloxacin Hydrochloride                    | Ophthalmic Solution       | 0.5%                                       | Moxeza 22428  | 2/29/2012          | 1                         | Eligible       | 2/8/2022                      | 5/28/2015                        | 5/28/2015                                 | 9/20/2019                                 |
| Moxifloxacin Hydrochloride                    | Tablets                   | 400 mg                                     | Avelox 21085  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Moxifloxacin Hydrochloride                    | Injection                 | 1.6 mg/mL                                  | Avelox in Sodium Chloride 0.8% in plastic container 21277 | 2/7/2014           | 1                         | Deferred       | 10/8/2019                     | 5/5/2017                         | 10/3/2017                                 | 7/25/2020                                 |
| Mycophenolic Acid                             | Delayed-release Tablets   | 180 mg                                     | Myfortic 50791  | 6/3/2009           | 1                         | Extinguished   | 2/8/2022                      | 1/8/2014                         |   | 4/10/2017                                 |
| Mycophenolic Acid                             | Delayed-release Tablets   | 360 mg                                     | Myfortic 50791  | 2/2/2009           | 1                         | Non-Forfeiture | 2/8/2022                      | 1/8/2014                         | 1/8/2014                                  | 4/10/2017                                 |
| Mycophenolic Mofetil                          | For Oral Suspension       | 200 mg/mL                                  | Cellcept 50759  | 3/25/2011          | 1                         | Deferred       | 2/8/2022                      | 11/14/2014                       | 11/17/2014                                | 11/18/2014                                |
| Nabumetone                                    | Tablets                   | 500 mg and 750 mg                          | Relafen 19583   | Pre-MMA            |                           |                |                               |                                  |   |   |
| Naftifine Hydrochloride                       | Gel                       | 2%   | Naftin Gel 204286   | 2/4/2015           | 1                         | Deferred       | 8/13/2019                     | 4/10/2019                        | 4/12/2023                                 | 1/31/2033                                 |
| Naloxegol                                     | Tablets                   | 12.5 mg and 25 mg                          | Movantik 204760   | 9/17/2018          | 2                         |                |                               |                                  |   | 4/2/2032                                  |
| Naloxone Hydrochloride                        | Nasal Spray               | 2 mg/spray                                 | Narcan 208411   | 12/28/2017         | 1                         |                |                               |                                  |   | 3/16/2035                                 |
| Naloxone Hydrochloride                        | Nasal Spray               | 4 mg/spray                                 | Narcan 208411   | 7/15/2016          | 1                         | Eligible       | 6/18/2019                     | 4/19/2019                        | 12/22/2021                                | 3/16/2035                                 |
| Naloxone Hydrochloride                        | Nasal Spray               | 8 mg/spray                                 | Kloxxado 212045   | 3/30/2023          | 1                         |                |                               |                                  |   | 8/26/2034                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME  | DOSAGE FORM                            | STRENGTH                                 | RLD/NDA               | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--|--|-----------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Naltrexone   | Extended-release Injectable Suspension | 380 mg/vial                              | Vivitrol 21897        | 6/18/2020          | 1                         | Deferred       | 8/7/2023                      | 7/6/2023                         |   | 10/15/2029                                |
| Naltrexone Hydrochloride and Bupropion Hydrochloride | Extended-release Tablets               | 8 mg/90 mg                               | Contrave 200063       | 3/12/2015          | 1                         |                |                               |                                  |   | 2/2/2030                                  |
| Naproxen Sodium                                      | Extended-release Tablets               | 375 mg (base) and 500 mg (base)          | Naprelan 20353        | Pre-MMA            |                           |                |                               |                                  |   |   |
| Naproxen Sodium                                      | Capsules                               | 200 mg                                   | Naproxen Sodium 21920 | 11/15/2017         | 1                         | Extinguished   | 6/15/2020                     |                                  |   | 3/3/2026                                  |
| Naproxen and Esomeprazole Magnesium                  | Delayed-release Tablets                | 375 mg/20 mg and 500 mg/20 mg            | Vimovo 22511          | 11/5/2010          | 1                         | Extinguished   | 2/25/2020                     |                                  |   | 2/28/2023                                 |
| Naproxen Sodium and Sumatriptan Succinate            | Tablets                                | 500 mg/85 mg                             | Treximet 21926        | 7/23/2008          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 10/2/2025                                 |
| Nateglinide  | Tablets                                | 60 mg and 120 mg                         | Starlix 21204         | 12/22/2004         |                           |                |                               |                                  |   |   |
| Nebivolol Hydrochloride                              | Tablets                                | 2.5 mg, 5 mg, 10 mg, and 20 mg           | Bystolic 21742        | 12/19/2011         | 7                         | Eligible       | 6/18/2019                     | 4/16/2015                        | 9/17/2021                                 | 12/17/2021                                |
| Nebivolol Hydrochloride and Valsartan                | Tablets                                | 5 mg/80 mg                               | Byvalson 206302       | 6/9/2017           | 1                         | Deferred       | 10/4/2022                     | 9/19/2022                        |   | 10/4/2027                                 |
| Nefazodone Hydrochloride                             | Tablets                                | 50 mg, 100 mg, 150 mg, 200 mg and 250 mg | Serzone 20152         | Pre-MMA            |                           |                |                               |                                  |   |   |
| Nepafenac  | Ophthalmic Suspension                  | 0.3%                                     | Ilevro 203491         | 12/21/2015         | 1                         |                |                               |                                  |   | 3/31/2032                                 |
| Neratinib Maleate                                    | Tablets                                | 40 mg                                    | Nerlynx 208051        | 7/19/2021          | 1                         |                |                               |                                  |   | 12/29/2025                                |
| Netarsudil Mesylate                                  | Ophthalmic Solution                    | 0.02%                                    | Rhopressa 208254      | 12/20/2021         | 2                         |                |                               |                                  |   | 3/14/2034                                 |
| Nevirapine   | Extended-release Tablets               | 400 mg                                   | Viramune XR 201152    | 6/21/2013          | 3                         | Eligible       | 12/13/2022                    | 4/3/2014                         | 4/15/2014                                 | 3/12/2029                                 |
| Niacin   | Extended-release Tablets               | 500 mg, 750 mg and 1000 mg               | Niaspan 20381         | Pre-MMA            |                           |                |                               |                                  |   |   |
| Niacin and Simvastatin                               | Extended-release Tablets               | 500 mg/20 mg                             | Simcor                | 2/12/2010          |                           |                |                               |                                  |   |   |
| Niacin and Simvastatin                               | Extended-release Tablets               | 750 mg/20 mg                             | Simcor                | 2/17/2010          |                           |                |                               |                                  |   |   |
| Niacin and Simvastatin                               | Extended-release Tablets               | 1000 mg/20 mg                            | Simcor                | 9/17/2009          |                           |                |                               |                                  |   |   |
| Niacin and Simvastatin                               | Extended-release Tablets               | 1000 mg/40 mg                            | Simcor                | 2/4/2011           |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                 | DOSAGE FORM              | STRENGTH                                    | RLD/NDA  | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------|--------------------------|---|--|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Niacin and Simvastatin    | Extended-release Tablets | 500 mg/40 mg                                | Simcor   | 2/9/2011           |                           |                |                               |                                  |   |   |
| Nicardipine Hydrochloride | Injection                | 2.5 mg/mL, 10 mL Ampoules                   | Cardene 19734  | 12/27/2006         | 1                         |                |                               |                                  |   |   |
| Nicardipine Hydrochloride | Injection                | 0.1 mg/mL, 200 mL<br>0.2mg/mL, 200 mL       | Cardene in 0.86% Sodium Chloride in plastic container and Cardene 0.83% Sodium Chloride in plastic container 19734 | 1/9/2013           | 1                         |                |                               |                                  |   | 12/26/2027                                |
| Nicotine                  | Transdermal System       | 7 mg/day,<br>14 mg/day<br>21 mg/day         | Habitrol 20076   | Pre-MMA            |                           |                |                               |                                  |   |   |
| Nicotine                  | Transdermal System       | 7 mg/24 hrs<br>14 mg/24 hrs<br>21 mg/24 hrs | Nicoderm CQ 20165  | 5/30/2014          | 1                         | Extinguished   | 2/8/2022                      |                                  |   | 5/22/2021                                 |
| Nicotine Polacrilex       | Troche/Lozenge           | 2 mg and 4 mg                               | Commit   | Pre-MMA            |                           |                |                               |                                  |   |   |
| Nicotine Polacrilex       | Troche/Lozenge (Mini)    | 2 mg and 4 mg                               | Nicorette 22360  | 12/2/2015          | 1                         | Eligible       | 10/8/2019                     | 2/7/2019                         | 4/4/2019                                  | 6/14/2029                                 |
| Nicotine Polacrilex       | Gum                      | 2 mg  | Nicorette  | 1/22/2013          |                           |                |                               |                                  |   |   |
| Nicotine Polacrilex       | Gum                      | 4 mg  | Nicorette  | 1/22/2013          |                           |                |                               |                                  |   |   |
| Nifedipine                | Capsules                 | 10 mg and 20 mg                             | Procardia 18482  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Nifedipine                | Extended-release Tablets | 30 mg, 60 mg and 90 mg                      | Adalat CC 20198  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Nifedipine                | Extended-release Tablets | 30 mg, 60 mg and 90 mg                      | Procardia XL 19684   | Pre-MMA            |                           |                |                               |                                  |   |   |
| Nilotinib                 | Capsules                 | 50 mg                                       | Tasigna 22068  | 10/17/2019         | 1                         |                |                               |                                  |   | 4/7/2032                                  |
| Nilotinib                 | Capsules                 | 150 mg and 200 mg                           | Tasigna 22068  | 11/8/2013          | 1                         |                |                               |                                  |   | 8/23/2028                                 |
| Nimodipine                | Oral Solution            | 6 mg/mL                                     | Nymalize 203340  | 11/29/2021         | 1                         |                |                               |                                  |   | 4/16/2038                                 |



**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                    | DOSAGE FORM                 | STRENGTH   | RLD/NDA                            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|-----------------------------|--|------------------------------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Nintedanib                                   | Capsules                    | 100 mg and 150 mg  | Ofev<br>205832                     | 10/15/2018         | 4                         |                          |                               |                                  |   | 6/7/2029                                  |
| Nitric Oxide                                 | for Inhalation              | 100 ppm and<br>800 ppm   | INOmax<br>20845                    | 5/20/2014          | 1                         | Deferred                 | 11/19/2019                    | 10/2/2018                        | 4/1/2019                                  | 1/6/2031                                  |
| Nisoldipine                                  | Extended-release<br>Tablets | 8.5 mg and 17 mg   | Sular<br>20356                     | 3/2/2009           | 1                         | Eligible                 | 2/8/2022                      | 1/26/2011                        | 1/28/2011                                 | 6/6/2012                                  |
| Nisoldipine                                  | Extended-release<br>Tablets | 20 mg and 30 mg  | Sular<br>20356                     | 11/7/2007          | 1                         | Extinguished             | 2/8/2022                      | 7/25/2008                        |   | 6/8/2008                                  |
| Nisoldipine                                  | Extended-release<br>Tablets | 25.5 mg and 34 mg  | Sular<br>20356                     | 11/28/2008         | 1                         | Eligible                 | 2/8/2022                      | 1/26/2011                        | 1/28/2011                                 | 11/30/2014                                |
| Nisoldipine                                  | Extended-release<br>Tablets | 40 mg  | Sular<br>20356                     | 6/11/2007          | 1                         | Extinguished             | 2/8/2022                      | 7/25/2008                        |   | 6/8/2008                                  |
| Nitrofurantoin Monohydrate/<br>Macrocrystals | Capsules                    | 75 mg/25 mg  | Macrobid<br>20064                  | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Nitroglycerin                                | Sublingual Tablets          | 0.3 mg, 0.4 mg, and<br>0.6 mg  | Nitrostat<br>21134                 | 10/19/2005         | 1                         | Extinguished             | 3/10/2020                     |                                  |   | 9/16/2018                                 |
| Nitroglycerin                                | Transdermal System          | 0.1 mg/hr  | Transderm-Nitro<br>20144           | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Nitroglycerin                                | Transdermal System          | 0.1 mg/hr<br>0.2 mg/hr<br>0.3 mg/hr<br>0.4 mg/hr<br>0.6 mg/hr<br>0.8 mg/hr | Nitro-dur<br>20145                 | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Nitroglycerin                                | Sublingual Spray            | 400 mcg/spray,<br>4.9 g and<br>12 g bottles                                | Nitrolingual<br>Pumpspray<br>18705 | 4/17/2012          | 1                         | Eligible                 | 2/8/2022                      | 9/20/2013                        | 9/23/2013                                 | 3/14/2028                                 |
| Nizatidine                                   | Capsules                    | 150 mg and 300 mg  | Axid<br>19508                      | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Nizatidine                                   | Oral Solution               | 15 mg/mL   | Axid<br>21494                      | 5/14/2008          | 1                         | Extinguished<br>Eligible | 4/18/2023<br>2/22/2022        | 11/18/2009                       |   | 7/17/2022                                 |
| Norelgestromin and Ethinyl<br>Estradiol      | Transdermal System          | 0.15 mg/0.02 mg per<br>24 hours  | Ortho Evra<br>21180                | 3/22/2007          | 1                         | Extinguished             | 3/10/2020                     |                                  |   | 11/20/2015                                |
| Norethindrone Acetate/ Ethinyl<br>Estradiol  | Tablets                     | 1 mg/0.005 mg  | Femhrt<br>21065                    | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Norethindrone Acetate/ Ethinyl<br>Estradiol  | Tablets                     | 1 mg/ 0.02 mg<br>1 mg/0.03 mg<br>1 mg /0.035 mg                            | Estrostep Fe<br>20130              | Pre-MMA            |                           |                          |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME  | DOSAGE FORM      | STRENGTH   | RLD/NDA   | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|------------------|--|---|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Norethindrone Acetate/ Ethinyl Estradiol   | Tablets          | 1 mg/0.02 mg<br>1 mg/ 0.03 mg and<br>1 mg /0.035 mg                  | Estrostep 21<br>20130                           | Pre-MMA            |                           |                |                               |                                  |   |   |
| Norethindrone Acetate/ Ethinyl Estradiol and Ferrous Fumarate                        | Tablets          | 1 mg/0.02 mg and 75<br>mg  | Loestrin 24 Fe<br>21871                         | 4/17/2006          | 1                         | Extinguished   | 2/8/2022                      | 9/1/2009                         |   | 7/22/2014                                 |
| Norethindrone Acetate and Ethinyl Estradiol / Ethinyl Estradiol and Ferrous Fumarate | Tablets          | 1 mg/0.01 mg,<br>0.01 mg and 75 mg                                   | Lo Loestrin Fe<br>22501                         | 4/29/2011          | 1                         | Extinguished   | 2/8/2022                      |                                  |   | 2/2/2029                                  |
| Norethindrone and Ethinyl Estradiol and Ferrous Fumarate                             | Chewable Tablets | 0.4 mg/0.035 mg  | Ovcon-35 Fe<br>Femcon Fe<br>NDA 21-490          | 4/27/2007          | 1                         | Non-Forfeiture | 2/8/2022                      | 8/5/2010                         | 3/25/2011                                 | 4/6/2019                                  |
| Norethindrone and Ethinyl Estradiol and Ferrous Fumarate                             | Chewable Tablets | 0.8 mg/0.025 mg and<br>75 mg   | Generess Fe                                     | 8/5/2011           | 1                         | Eligible       | 2/8/2022                      | 4/23/2014                        | 4/1/2015                                  | 4/16/2019                                 |
| Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate                     | Chewable Tablets | 1 mg/0.02 mg and 75<br>mg  | Minastrin 24 Fe<br>203667                       | 4/23/2014          | 1                         | Eligible       | 10/8/2019                     | 5/24/2016                        | 3/15/2017                                 | 4/6/2019                                  |
| Norethindrone/ Ethinyl Estradiol   | Tablets          | 0.5 mg/ 0.035 mg,<br>0.75 mg/ 0.035 mg<br>and 1 mg /0.035 mg         | Ortho-Novum<br>7/7/7, 21 and 28<br>day<br>18985 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Norgestimate/ Ethinyl Estradiol  | Tablets          | 0.18 mg /0.025 mg,<br>0.215 mg /0.025 mg<br>and 0.25 mg /0.025<br>mg | Ortho Tri-Cyclen<br>Lo,<br>28 day<br>21241      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Norgestimate/ Ethinyl Estradiol  | Tablets          | 0.18 mg /0.035 mg,<br>0.215 mg /0.035 mg<br>and<br>0.25 mg /0.035 mg | Ortho Tri-Cyclen,<br>21 and 28 day<br>19697     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Nortriptyline Hydrochloride  | Capsules         | 10 mg, 25 mg,<br>50 mg and 75 mg                                     | Pamelor<br>18013                                | Pre-MMA            |                           |                |                               |                                  |   |   |
| Obeticholic Acid   | Tablets          | 5 mg and 10 mg   | Ocaliva<br>207999                               | 5/27/2020          | 5                         | Eligible       | 6/12/2023                     | 5/30/2023                        |   | 4/26/2036                                 |
| Octreotide Acetate   | Injection        | 0.05 mg /mL,<br>0.1 mg /mL and<br>0.5 mg/mL,<br>1 mL vials           | Sandostatin<br>(Preservative-<br>free)<br>19667 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Octreotide Acetate   | Injection        | 0.2 mg/mL and<br>1 mg /mL, 5 mL vials                                | Sandostatin<br>19667                            | Pre-MMA            |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                       | DOSAGE FORM                      | STRENGTH   | RLD/NDA                                    | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|----------------------------------|--|--|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Octreotide Acetate                              | Injection                        | 0.05 mg/mL (base),<br>0.1 mg/mL (base)<br>and 0.5 mg/mL<br>(base) packaged in 1<br>mL pre-filled syringes<br>(preservative-free) | Octreotide<br>Acetate Injection<br>19667   | 1/17/2008          | 1                         | Extinguished<br>Eligible | 4/18/2023<br>2/8/2022         | 2/10/2011                        |   | 5/19/2015                                 |
| Ofloxacin                                       | Otic Solution                    | 0.3%   | Floxin<br>20799                            | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Olanzapine                                      | Tablets                          | 2.5 mg, 5 mg,<br>7.5 mg, 10 mg and<br>15 mg  | Zyprexa<br>20592                           | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Olanzapine                                      | Tablets                          | 20 mg  | Zyprexa<br>20592                           | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Olanzapine                                      | Orally Disintegrating<br>Tablets | 5 mg, 10 mg, 15 mg<br>and 20 mg  | Zyprexa Zydis<br>21086                     | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Olanzapine and Fluoxetine<br>Hydrochloride      | Capsules                         | 6 mg/25 mg<br>12 mg/25 mg<br>6 mg/50 mg<br>12 mg/50 mg   | Symbyax<br>21520                           | 1/10/2005          | 1                         | Extinguished             | 2/8/2022                      | 6/20/2012                        |   | 11/1/2017                                 |
| Olaparib  | Tablets                          | 100 mg and 150 mg  | Lynparza<br>208558                         | 11/1/2022          | 1                         |                          |                               |                                  |   | 8/4/2031                                  |
| Olmesartan Medoxomil                            | Tablets                          | 5 mg, 20 mg and<br>40 mg   | Benicar<br>21286                           | 4/25/2006          | 1                         | Eligible                 | 2/8/2022                      | 10/26/2016                       | 10/26/2016                                | 11/19/2021                                |
| Olmesartan Medoxomil and<br>Hydrochlorothiazide | Tablets                          | 20 mg/12.5 mg  | Benicar HCT<br>21532                       | 5/11/2007          | 1                         | Eligible                 | 2/8/2022                      | 10/26/2016                       | 10/26/2016                                | 11/19/2021                                |
| Olmesartan Medoxomil and<br>Hydrochlorothiazide | Tablets                          | 40 mg/12.5 mg and<br>40 mg/25 mg   | Benicar HCT<br>21532                       | 2/15/2007          | 1                         | Eligible                 | 2/8/2022                      | 10/26/2016                       | 10/26/2016                                | 11/19/2021                                |
| Olopatadine Hydrochloride                       | Nasal Spray                      | 0.665 mg/ Spray  | Patanase<br>21861                          | 6/29/2009          | 1                         | Extinguished             | 2/8/2022                      | 10/8/2014                        |   | 12/18/2010                                |
| Olopatadine Hydrochloride                       | Ophthalmic Solution              | 0.1%   | Pataday Twice<br>Daily Relief OTC<br>20688 | 7/17/2006          | 1                         | Extinguished             | 4/7/2020                      | 12/7/2015                        |   | 6/6/2015                                  |
| Olopatadine Hydrochloride                       | Ophthalmic Solution              | 0.2%   | Pataday Once<br>Daily Relief OTC<br>21545  | 9/8/2008           | 1                         | Eligible                 | 6/18/2019                     | 7/13/2015                        | 6/8/2017                                  | 11/12/2023                                |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                         | DOSAGE FORM                   | STRENGTH                                | RLD/NDA                              | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS              | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-----------------------------------|-------------------------------|---|--------------------------------------|--------------------|---------------------------|-----------------------------|-------------------------------|----------------------------------|---|---|
| Olopatadine Hydrochloride         | Ophthalmic Solution           | 0.7%                                    | Pataday Once Daily Relief OTC 206276 | 9/10/2015          | 1                         | Non-forfeiture              | 6/18/2019                     | 2/19/2020                        |   | 5/19/2032                                 |
| Omacetaxine Mepesuccinate         | for Injection                 | 3.5 mg/vial                             | Synribo 203585                       | 10/26/2016         | 1                         | Extinguished                | 2/8/2022                      |                                  |   | 6/28/2023                                 |
| Omega-3-Acid Ethyl Esters         | Capsules                      | 1 g                                     | Lovaza 21654                         | 11/10/2008         | 3                         | Deferred                    | 2/22/2022                     | 4/7/2014                         |   | 4/10/2017                                 |
| Omeprazole                        | Delayed-release Capsules      | 10 mg, 20 mg and 40 mg                  | PriLOSEC 19810                       | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Omeprazole and Sodium Bicarbonate | Capsules                      | 20 mg/1100 mg and 40 mg/1100 mg         | Zegerid 21849                        | 4/30/2007          | 1                         | Eligible                    | 2/8/2022                      | 5/25/2010                        | 7/1/2010                                  | 7/16/2016                                 |
| Omeprazole and Sodium Bicarbonate | Capsules                      | 20 mg/1100 mg                           | Zegerid OTC 22281                    | 4/20/2010          | 1                         | Extinguished                | 2/8/2022                      | 7/15/2016                        |   | 7/16/2016                                 |
| Omeprazole and Sodium Bicarbonate | Powder for Oral Suspension    | 20mg/1680mg per packet                  | Zegerid 21636                        | 11/13/2007         | 1                         | Deferred                    | 2/8/2022                      | 4/19/2013                        |   | 7/16/2016                                 |
| Omeprazole and Sodium Bicarbonate | Powder for Oral Suspension    | 40 mg/1680 mg per packet                | Zegerid 21636                        | 8/24/2007          | 1                         | Deferred                    | 2/8/2022                      | 4/19/2013                        |   | 7/16/2016                                 |
| Omeprazole Magnesium              | Delayed-release Capsules      | 20 mg                                   | PriLOSEC OTC 21229                   | 3/19/2007          | 1                         | Eligible                    | 2/8/2022                      | 6/5/2009                         |   | 11/15/2019                                |
| Omeprazole Magnesium              | Delayed-release Tablets       | 20 mg                                   | PriLOSEC OTC 21229                   | 3/30/2012          | 1                         | Eligible                    | 2/8/2022                      | 7/30/2015                        | 12/1/2017                                 | 11/15/2019                                |
| Omeprazole                        | Delayed-release Tablets       | 20 mg                                   | Omeprazole 22032 (OTC)               | 6/3/2015           | 1                         | Extinguished Non-Forfeiture | 2/11/2020<br>2/11/2020        | 10/12/2018                       |   | 8/16/2025                                 |
| Ondansetron Hydrochloride         | Injection                     | 2 mg/mL, 2 mL vials (Preservative-free) | Zofran 20007                         | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Ondansetron Hydrochloride         | Injection                     | 2 mg/mL, 20 mL vials                    | Zofran 20007                         | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Ondansetron Hydrochloride         | Injection                     | 0.64 mg/mL, 50 mL container (plastic)   | Zofran in Plastic Container 20403    | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Ondansetron Hydrochloride         | Oral Solution                 | 4 mg/5 mL                               | Zofran 20605                         | 12/20/2004         | 1                         | Eligible                    | 2/22/2022                     | 12/26/2006                       |   | 5/20/2016                                 |
| Ondansetron Hydrochloride         | Orally Disintegrating Tablets | 4 mg and 8 mg                           | Zofran ODT 20781                     | Pre-MMA            |                           |                             |                               |                                  |   |   |
| Ondansetron Hydrochloride         | Tablets                       | 4 mg, 8 mg, 16 mg and 24 mg             | Zofran 20103                         | Pre-MMA            |                           |                             |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME               | DOSAGE FORM                            | STRENGTH                                    | RLD/NDA                   | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-------------------------|--|---|---------------------------|--------------------|---------------------------|--------------------------|-------------------------------|----------------------------------|---|---|
| Orlistat                | Capsules                               | 60 mg                                       | Alli<br>21887             | 9/8/2010           | 1                         | Extinguished             | 2/8/2022                      |                                  |   | 1/6/2018                                  |
| Oseltamivir Phosphate   | Capsules                               | 30 mg and 45 mg                             | Tamiflu<br>21087          | 8/2/2011           | 1                         | Eligible                 | 2/8/2022                      | 8/3/2016                         | 12/12/2016                                | 12/27/2016                                |
| Oseltamivir Phosphate   | Capsules                               | 75 mg                                       | Tamiflu<br>21087          | 11/15/2010         | 1                         | Eligible                 | 2/8/2022                      | 8/3/2016                         | 12/12/2016                                | 12/27/2016                                |
| Oseltamivir Phosphate   | for Oral Suspension                    | 6 mg/mL                                     | Tamiflu<br>21246          | 6/18/2015          | 1                         | Extinguished             | 10/8/2019                     | 2/20/2018                        |   | 12/27/2016                                |
| Osimertinib Mesylate    | Tablets                                | 40 mg and 80 mg                             | Tagrisso<br>208065        | 11/13/2019         | 3                         |                          |                               |                                  |   | 1/2/2035                                  |
| Ospemifene              | Tablets                                | 60 mg                                       | Osphena<br>203505         | 12/29/2020         | 1                         |                          |                               |                                  |   | 7/9/2028                                  |
| Oxaliplatin             | Injection                              | 5 mg/mL, 10 mL and<br>20 mL vials           | Eloxatin<br>21759         | 2/9/2007           | 11                        | Eligible                 | 3/10/2020                     | 8/7/2009                         |   | 2/9/2017                                  |
| Oxaliplatin             | Injection                              | 5 mg/mL, 40 mL vials                        | Eloxatin<br>21759         | 7/16/2007          | 1                         | Extinguished             | 3/10/2020                     |                                  |   | 8/7/2015                                  |
| Oxandrolone             | Tablets                                | 2.5 mg and 10 mg                            | Oxandrin<br>13718         | 6/19/2006          | 1                         | Extinguished             | 2/8/2022                      |                                  |   | 12/5/2017                                 |
| Oxazepam                | Capsules                               | 10 mg, 15 mg and 30<br>mg                   | Serax<br>15539            | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Oxcarbazepine           | Tablets                                | 150 mg, 300 mg and<br>600 mg                | Trileptal<br>21014        | 5/5/2006           | 1                         | Eligible                 | 2/8/2022                      | 10/9/2007                        |   | 2/12/2018                                 |
| Oxcarbazepine           | Oral Suspension                        | 300 mg/5 mL                                 | Trileptal<br>21285        | 12/26/2006         | 1                         | Eligible                 | 6/15/2021                     | 6/26/2009                        | 12/14/2009                                | 2/12/2018                                 |
| Oxcarbazepine           | Extended-release<br>Tablets            | 600 mg                                      | Oxtellar XR<br>202810     | 3/20/2013          | 1                         | Extinguished             | 3/10/2020                     |                                  |   | 4/13/2027                                 |
| Oxcarbazepine           | Extended-release<br>Tablets            | 150 mg and 300 mg                           | Oxtellar XR<br>202810     | 4/12/2013          | 1                         | Extinguished             | 3/10/2020                     |                                  |   | 4/13/2027                                 |
| Oxybutynin              | Transdermal System<br>Extended-release | 3.9 mg/24 hrs                               | Oxytrol<br>21351          | 8/19/2008          | 1                         | Deferred                 | 2/8/2022                      | 3/4/2014                         |   | 4/26/2020                                 |
| Oxybutynin Chloride     | Extended-release<br>Tablets            | 5 mg, 10 mg and<br>15 mg                    | Ditropan XL<br>20897      | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Oxybutynin Chloride     | Gel                                    | 10%   | Gelnique<br>22204         | 6/19/2014          | 1                         | Extinguished<br>Deferred | 6/15/2020<br>6/18/2019        | 5/31/2018                        |   | 4/26/2020                                 |
| Oxycodone               | Extended-release<br>Tablets            | 10 mg, 20 mg,<br>40 mg, 80 mg and<br>160 mg | Oxycontin (NDA<br>020553) | Pre-MMA            |                           |                          |                               |                                  |   |   |
| Oxycodone Hydrochloride | Extended-release<br>Tablets            | 15 mg                                       | Oxycontin (NDA<br>020553) | 2/15/2007          | 2                         | Extinguished             | 2/8/2022                      |                                  |   | 4/16/2013                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                 | DOSAGE FORM               | STRENGTH                              | RLD/NDA                | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF          | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---------------------------|---------------------------------------|------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|--|---|
| Oxycodone Hydrochloride                   | Extended-release Tablets  | 30 mg and 60 mg                       | Oxycontin (NDA 020553) | 1/3/2007           | 1                         | Extinguished   | 2/8/2022                      |                                  |  | 4/16/2013                                 |
| Oxycodone Hydrochloride                   | Extended-release Tablets  | 10 mg                                 | Oxycontin (NDA 022272) | 10/25/2010         | 1                         | Extinguished   | 10/8/2019                     |                                  |  | 4/19/2025                                 |
| Oxycodone Hydrochloride                   | Extended-release Tablets  | 15 mg                                 | Oxycontin (NDA 022272) | 10/28/2010         | 1                         | Extinguished   | 10/8/2019                     |                                  |  | 4/19/2025                                 |
| Oxycodone Hydrochloride                   | Extended-release Tablets  | 20 mg                                 | Oxycontin (NDA 022272) | 10/29/2010         | 2                         | Extinguished   | 11/19/2019                    |                                  |  | 4/19/2025                                 |
| Oxycodone Hydrochloride                   | Extended-release Tablets  | 30 mg, 60 mg and 80 mg                | Oxycontin (NDA 022272) | 10/18/2010         | 1                         | Extinguished   | 6/18/2019                     |                                  |  | 4/19/2025                                 |
| Oxycodone Hydrochloride                   | Extended-release Tablets  | 40 mg                                 | Oxycontin (NDA 022272) | 10/4/2010          | 1                         | Extinguished   | 10/8/2019                     |                                  |  | 4/19/2025                                 |
| Oxycodone Hydrochloride                   | Tablets                   | 5 mg and 7.5 mg                       | Oxaydo 202080          | 2/7/2012           | 1                         | Extinguished   | 11/17/2020                    |                                  |  | 3/16/2025                                 |
| Oxycodone                                 | Extended-release Capsules | 9 mg, 13.5 mg, 18 mg, 27 mg and 36 mg | Xtampza ER 208090      | 11/15/2017         | 1                         |                |                               |                                  |  | 9/2/2036                                  |
| Oxycodone Hydrochloride and Acetaminophen | Extended-release Tablets  | 7.5 mg/325 mg                         | Xartemis XR            | 4/3/2014           | 1                         | Extinguished   | 2/9/2021                      |                                  |  | 12/21/2030                                |
| Oxymetazoline Hydrochloride               | Topical Cream             | 1%                                    | Rhofade 208552         | 6/20/2019          | 1                         | Eligible       | 11/2/2021                     | 10/4/2021                        |  | 6/11/2035                                 |
| Oxymorphone Hydrochloride                 | Extended-release Tablets  | 5 mg, 10 mg, 20 mg and 40 mg          | Opana ER               | 11/23/2007         | 1                         | Eligible       | 2/8/2022                      | 6/14/2010                        | 20 mg- 1/3/2013<br>5 mg, 10 mg and 40 mg -1/8/2013 | 7/3/2022                                  |
| Oxymorphone Hydrochloride                 | Extended-release Tablets  | 7.5 mg and 15 mg                      | Opana ER               | 5/29/2008          | 1                         | Extinguished   | 2/8/2022                      | 12/13/2010                       |  | 7/3/2022                                  |
| Oxymorphone Hydrochloride                 | Extended-release Tablets  | 30 mg                                 | Opana ER               | 6/12/2008          | 1                         | Eligible       | 2/8/2022                      | 7/22/2010                        | 1/8/2013   | 2/4/2023                                  |
| Oxymorphone Hydrochloride                 | Extended-release Tablets  | 7.5 mg, 10 mg, and 15 mg              | Opana ER (NDA 201655)  | 3/23/2012          | 1                         | Extinguished   | 3/10/2020                     |                                  |  | 7/10/2029                                 |
| Oxymorphone Hydrochloride                 | Extended-release Tablets  | 5 mg                                  | Opana ER (NDA 201655)  | 3/26/2012          | 1                         | Extinguished   | 2/8/2022                      |                                  |  | 7/10/2029                                 |
| Oxymorphone Hydrochloride                 | Extended-release Tablets  | 20 mg, 30 mg and 40 mg                | Opana ER (NDA 201655)  | 4/3/2012           | 1                         | Extinguished   | 2/8/2022                      |                                  |  | 7/10/2029                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                          | DOSAGE FORM                            | STRENGTH   | RLD/NDA               | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|------------------------------------|--|--|-----------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Paclitaxel                         | Injection                              | 6 mg/mL, 5 mL, 16.7 mL, 25 mL, 33.3 mL and 50 mL vials                   | Taxol 20262           | Pre-MMA            |                           |                |                               |                                  |   |   |
| Paclitaxel Protein-Bound Particles | For Injection Suspension               | 100 mg/vial  | Abraxane 21660        | 12/11/2015         | 1                         | Extinguished   | 9/4/2023                      |                                  |   | 10/27/2024                                |
| Palbociclib                        | Capsules                               | 75 mg, 100 mg and 125 mg   | Ibrance 207103        | 2/4/2019           | 12                        | Extinguished   | 4/18/2023                     |                                  |   | 1/22/2023                                 |
| Palbociclib                        | Tablets                                | 75 mg, 100 mg and 125 mg   | Ibrance 212436        | 11/24/2020         | 1                         | Deferred       | 8/28/2023                     | 9/4/2023                         |   | 2/28/2034                                 |
| Paliperidone Palmitate             | Extended-release Injectable Suspension | 39 mg/0.25 mL, 78 mg/0.5 mL, 117 mg/0.75 mL, 156 mg/mL and 234 mg/1.5 mL | Invega Sustenna 22264 | 11/21/2017         | 1                         | Deferred       | 8/24/2021                     | 7/6/2021                         |   | 1/26/2031                                 |
| Paliperidone Palmitate             | Extended-release Injectable Suspension | 546 mg/1.75 mL   | Invega Trinza 207946  | 6/24/2020          | 1                         |                |                               |                                  |   | 4/5/2036                                  |
| Paliperidone Palmitate             | Extended-release Injectable Suspension | 819 mg/2.625 mL  | Invega Trinza 207946  | 4/30/2021          | 1                         |                |                               |                                  |   | 4/5/2036                                  |
| Paliperidone Palmitate             | Extended-release Injectable Suspension | 273 mg/0.875 mL and 410 mg/1.315 mL                                      | Invega Trinza 207946  | 7/14/2021          | 1                         |                |                               |                                  |   | 4/5/2036                                  |
| Palonosetron Hydrochloride         | Injection                              | 0.05 mg/mL, 1.5 mL and 5 mL vials  | Aloxi 21372           | 5/27/2011          | 3                         | Extinguished   | 2/22/2022                     | 10/13/2015                       |   | 4/13/2015                                 |
| Pamidronate Disodium               | For Injection                          | 30 mg/vial<br>60 mg/vial<br>90 mg/vial                                   | Aredia 20036          | Pre-MMA            |                           |                |                               |                                  |   |   |
| Pamidronate Disodium               | Injection                              | 30 mg/vial<br>60 mg/vial<br>90 mg/vial                                   | Aredia 20036          | Pre-MMA            |                           |                |                               |                                  |   |   |
| Pantoprazole Sodium                | For Injection                          | 40 mg/vial   | Prontonix IV 20988    | 4/7/2005           | 1                         | Extinguished   | 8/27/2019                     |                                  |   | 11/17/2021                                |
| Pantoprazole Sodium                | Delayed-release Tablets                | 20 mg and 40 mg  | Protonix 20987        | 2/2/2004           |                           |                |                               |                                  |   |   |
| Pantoprazole Sodium                | for Delayed-release Oral Suspension    | 40 mg  | Protonix 22020        | 9/13/2019          | 1                         | Eligible       | 7/13/2020                     | 6/30/2020                        | 8/13/2020                                 | 6/7/2026                                  |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                           | DOSAGE FORM              | STRENGTH  | RLD/NDA          | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-------------------------------------|--------------------------|---|------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Paricalcitol                        | Injection                | 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials | Zemplar 20819    | 11/28/2008         | 1                         | Eligible       | 3/10/2020                     | 7/27/2011                        |   | 10/8/2018                                 |
| Paricalcitol                        | Capsules                 | 1 mcg and 2 mcg   | Zemplar 21606    | 10/14/2008         | 1                         | Eligible       | 2/22/2022                     | 9/27/2013                        | 9/30/2013                                 | 6/24/2014                                 |
| Paricalcitol                        | Capsules                 | 4 mcg   | Zemplar 21606    | 8/25/2008          | 1                         | Eligible       | 2/22/2022                     | 9/27/2013                        | 9/30/2013                                 | 6/24/2014                                 |
| Paroxetine Hydrochloride            | Capsules                 | 10 mg and 20 mg   | Paxil 20885      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Paroxetine Hydrochloride            | Oral Suspension          | 10 mg/5 mL  | Paxil 20710      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Paroxetine Hydrochloride            | Tablets                  | 10 mg, 20 mg, 30 mg and 40 mg   | Paxil 20031      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Paroxetine Hydrochloride            | Extended-release Tablets | 25 mg   | Paxil CR 20936   | 9/9/2005           | 1                         | Eligible       | 2/22/2022                     | 6/29/2007                        | 5/14/2008                                 | 9/17/2017                                 |
| Paroxetine Hydrochloride            | Extended-release Tablets | 37.5 mg   | Paxil CR 20936   | 5/19/2009          | 1                         | Eligible       | 2/22/2022                     | 4/14/2011                        | 5/5/2011                                  | 3/17/2017                                 |
| Paroxetine                          | Capsules                 | 7.5 mg  | Brisdelle 204516 | 4/7/2014           | 1                         | Extinguished   | 8/13/2019                     | 3/13/2019                        |   | 4/6/2029                                  |
| Patiromer Sorbitex Calcium          | for Oral Suspension      | 8.4 g, 16.8 g and 25.2 g  | Veltassa 205739  | 10/21/2019         | 2                         |                |                               |                                  |   | 10/8/2033                                 |
| Pemetrexed Disodium                 | For Injection            | 100 mg/vial   | Alimta 21462     | 7/1/2008           | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 1/24/2017                                 |
| Pemetrexed Disodium                 | For Injection            | 500 mg/vial   | Alimta 21462     | 2/4/2008           | 2                         | Extinguished   | 3/10/2020                     |                                  |   | 1/24/2017                                 |
| Pemetrexed Disodium                 | For Injection            | 1000 mg/vial  | Alimta 21462     | 6/27/2012          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 11/24/2021                                |
| Pemetrexed Disodium                 | For Injection            | 750 mg/vial   | Alimta 21462     | 10/6/2016          | 1                         | Extinguished   | 2/22/2022                     |                                  |   | 11/24/2021                                |
| Perampanel                          | Tablets                  | 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg                                 | Fycompa 202834   | 10/24/2016         | 2                         |                |                               |                                  |   | 7/1/2026                                  |
| Perampanel                          | Oral Suspension          | 0.5 mg/mL   | Fycompa 208277   | 12/20/2022         | 1                         |                |                               |                                  |   | 7/1/2026                                  |
| Pergolide Mesylate                  | Tablets                  | 0.05 mg, 0.25 mg and 1 mg   | Permax 19385     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Perindopril Arginine and Amlodipine | Tablets                  | 3.5 mg/2.5 mg, 7 mg/5 mg and 14 mg/10 mg                                | Prestalia 205003 | 11/4/2016          | 1                         | Extinguished   | 7/25/2022                     |                                  |   | 10/5/2029                                 |



**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME  | DOSAGE FORM                   | STRENGTH   | RLD/NDA               | DATE OF SUBMISSION             | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS              | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|-------------------------------|--|-----------------------|--------------------------------|---------------------------|-----------------------------|-------------------------------|----------------------------------|---|---|
| Perindopril Erbumine                                   | Tablets                       | 2 mg, 4 mg and 8 mg  | Aceon 20184           | 6/6/2006                       | 1                         | Extinguished                | 2/22/2022                     |                                  |   | 11/10/2009                                |
| Phentermine Hydrochloride                              | Orally Disintegrating Tablets | 15 mg and 30 mg  | Suprenza 202088       | 10/19/2012                     | 1                         | Deferred                    | 2/22/2022                     | 6/28/2017                        |   | 7/23/2018                                 |
| Phentermine Hydrochloride                              | Orally Disintegrating Tablets | 37.5 mg  | Suprenza 202088       | 3/22/2013                      | 1                         | Deferred                    | 2/22/2022                     | 6/28/2017                        |   | 7/23/2018                                 |
| Phentermine Hydrochloride and Topiramate               | Extended-release Capsules     | 3.75 mg/23 mg<br>7.5 mg/46 mg<br>11.25 mg/69 mg<br>15 mg/92 mg | Qsymia 22580          | 7/18/2013                      | 1                         | Extinguished                | 2/22/2022                     |                                  |   | 6/14/2020                                 |
| Phenylephrine and Ketorolac                            | Injection                     | 1%/0.3%  | Omidria 205388        | 5/29/2015                      | 1                         | Extinguished                | 8/13/2019                     |                                  |   | 7/30/2023                                 |
| Pilocarpine Hydrochloride                              | Ophthalmic Solution           | 1.25%  | Vuity 214028          | 12/30/2022                     | 1                         |                             |                               |                                  |   | 4/24/2039                                 |
| Pimavanserin   | Capsules                      | 34 mg  | Nuplazid 210793       | 4/29/2020                      | 5                         |                             |                               |                                  |   | 8/27/2038                                 |
| Pimavanserin   | Tablets                       | 10 mg  | Nuplazid 207318       | 4/29/2020                      | 1                         |                             |                               |                                  |   | 6/3/2028                                  |
| Pioglitazone Hydrochloride                             | Tablets                       | 15 mg, 30 mg and 45 mg   | Actos 21073           | Pre-MMA                        |                           |                             |                               |                                  |   |   |
| Pioglitazone Hydrochloride and Glimepiride             | Tablets                       | 30 mg/2 mg and 30 mg/4 mg                                      | Duetact 21925         | 12/22/2009                     | 1                         | Deferred                    | 2/22/2022                     | 1/4/2013                         | 1/8/2013                                  | 6/8/2028                                  |
| Pioglitazone Hydrochloride and Metformin Hydrochloride | Extended-release Tablets      | 15 mg/1000 mg and 30 mg/1000 mg                                | Actoplus Met XR 22024 | 9/23/2011                      | 1                         | Extinguished                | 1/12/2021                     |                                  |   | 7/31/2026                                 |
| Pioglitazone Hydrochloride and Metformin Hydrochloride | Tablets                       | 15 mg/500 mg and 15 mg/850 mg                                  | Actoplus Met 21824    | 3/6/2008                       | 1                         | Non-Forfeiture Extinguished | 2/22/2022                     | 2/25/2011                        | 8/17/2012                                 | 6/19/2016                                 |
| Piperacillin Sodium and Tazobactam Sodium              | For Injection                 | 2.25 g/vial<br>3.375 g/vial<br>4.5 g/vial                      | Zosyn 50684           | PIV received prior to 2/5/2009 |                           |                             |                               |                                  |   |   |
| Piperacillin Sodium and Tazobactam Sodium              | For Injection                 | 12 g/1.5 g per vial (pharmacy bulk)                            | Zosyn 50684           | 12/6/2011                      | 1                         | Eligible                    | 2/22/2022                     | 10/29/2014                       | 1/24/2017                                 | 4/14/2023                                 |
| Piperacillin Sodium and Tazobactam Sodium              | For Injection                 | 36 mg/4.5 g per vial (pharmacy bulk)                           | Zosyn 50684           | PIV received prior to 2/5/2009 | 1                         | Eligible                    | 12/1/2020                     | 9/15/2009                        | 10/29/2009                                | 4/14/2023                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME   | DOSAGE FORM   | STRENGTH   | RLD/NDA                     | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS             | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|---|--|-----------------------------|--------------------|---------------------------|----------------------------|-------------------------------|----------------------------------|---|---|
| Pirfenidone   | Capsules  | 267 mg   | Esbriet<br>22535            | 10/15/2018         | 9                         | Eligible                   | 1/25/2022                     | 1/3/2022                         | 6/13/2022                                 | 8/30/2033                                 |
| Pirfenidone   | Tablets   | 267 mg and 801 mg  | Esbriet<br>208780           | 10/15/2018         | 17                        | Eligible                   | 2/8/2022                      | 1/25/2022                        | 5/2/2022                                  | 8/30/2033                                 |
| Pirfenidone   | Tablets   | 534 mg   | Esbriet<br>208780           | 10/15/2018         | 2                         | Eligible                   | 7/25/2022                     | 7/19/2022                        |   | 8/30/2033                                 |
| Pitavastatin Calcium  | Tablets   | 1 mg, 2 mg, and<br>4 mg  | Livalo<br>22363             | 8/5/2013           | 7                         | Eligible                   | 7/25/2022                     | 12/20/2016                       |   | 2/19/2024                                 |
| Plecanatide   | Tablets   | 3 mg   | Trulance<br>208745          | 1/19/2021          | 2                         |                            |                               |                                  |   | 6/5/2034                                  |
| Plerixafor  | Injection   | 24 mg/1.2 mL vials<br>(20 mg/mL)                                   | Mozobil<br>22311            | 12/17/2012         | 3                         | Extinguished               | 87/2023                       |                                  |   | 7/23/2023                                 |
| Polyethylene Glycol 3350  | Powder for Oral<br>Solution                         | 17g/Scoopful   | Miralax<br>22015            | Pre-MMA            |                           |                            |                               |                                  |   |   |
| Polyethylene Glycol 3350,<br>Sodium Chloride, Sodium<br>Bicarbonate, Potassium<br>Chloride and Bisacodyl                                      | For Oral Solution and<br>Delayed-release<br>Tablet  | 210 g, 5.6 g, 0.74 g,<br>2.86 g and 5 mg (1<br>Tablet Regimen)     | Halflytely and<br>Bisacodyl | 7/30/2010          | 1                         | Eligible                   | 2/22/2022                     | 8/20/2014                        | 4/21/2015                                 | 10/22/2022                                |
| Polyethylene Glycol 3350,<br>Sodium Chloride, Sodium<br>Bicarbonate, Potassium<br>Chloride and Bisacodyl                                      | For Oral Solution and<br>Delayed-release<br>Tablets | 210 g, 5.6 g, 0.74 g,<br>2.86 g and 5 mg (2<br>Tablet Regimen)     | Halflytely and<br>Bisacodyl | 1/28/2008          | 1                         | Extinguished               | 2/22/2022                     |                                  |   | 10/22/2022                                |
| Polyethylene Glycol 3350,<br>Sodium Sulfate, Sodium<br>Chloride, Potassium Chloride,<br>Sodium Ascorbate and<br>Ascorbic Acid                 | For Oral Solution                                   | 100 g, 7.5 g,<br>2.691 g, 1.015 g,<br>5.9 g and 4.7 g per<br>pouch | Moviprep<br>21881           | 11/27/2007         | 1                         | Eligible                   | 9/8/2020                      | 1/25/2012                        | 8/31/2020                                 | 9/1/2024                                  |
| Polyethylene Glycol 3350,<br>Sodium Sulfate, Sodium<br>Chloride, Potassium Chloride,<br>Sodium Ascorbate, Sodium<br>Sulfate and Ascorbic Acid | For Oral Solution                                   | 140 g, 5.2 g, 2.2g,<br>48.11 g, 9 g and 7.54<br>g per pouch        | Plenvu<br>209381            | 12/6/2018          | 1                         |                            |                               |                                  |   | 9/10/2033                                 |
| Pomalidomide  | Capsules  | 1 mg, 2 mg, 3 mg<br>and 4 mg                                       | Pomalyst<br>204026          | 2/8/2017           | 6                         | Non-Forfeiture<br>Deferred | 12/14/2021<br>1/12/2021       | 10/3/2020                        |   | 6/21/2031                                 |
| Ponatinib Hydrochloride   | Tablets   | 15 mg and 45 mg  | Iclusig<br>203469           | 3/31/2021          | 1                         | Eligible                   | 8/7/2023                      | 7/14/2023                        |   | 12/12/2033                                |
| Ponatinib Hydrochloride   | Tablets   | 10 mg and 30 mg  | Iclusig<br>203469           | 12/12/2022         | 1                         |                            |                               |                                  |   | 12/12/2033                                |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                     | DOSAGE FORM                   | STRENGTH                                   | RLD/NDA          | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS        | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF        | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-------------------------------|-------------------------------|--|------------------|--------------------|---------------------------|-----------------------|-------------------------------|----------------------------------|--|---|
| Posaconazole                  | Oral Suspension               | 40 mg/mL                                   | Noxafil 22003    | 2/28/2011          | 1                         | Extinguished          | 7/30/2019                     |                                  |  | 7/19/2019                                 |
| Posaconazole                  | Delayed-release Tablets       | 100 mg                                     | Noxafil 205053   | 6/16/2014          | 1                         | Extinguished          | 7/30/2019                     |                                  |  | 7/19/2019                                 |
| Posaconazole                  | Injection                     | 18 mg/mL, 16.7 mL vials                    | Noxafil 205596   | 11/24/2015         | 1                         | Eligible              | 7/25/2022                     | 5/25/2022                        | 6/28/2023  | 7/4/2031                                  |
| Potassium Chloride            | Extended-release Capsules     | 8 mEq and 10 mEq                           | Micro K          | Pre-MMA            |                           |                       |                               |                                  |  |   |
| Potassium Chloride            | Extended-release Tablets      | 10 mEq and 20 mEq                          | K-Dur            | Pre-MMA            |                           |                       |                               |                                  |  |   |
| Pralatrexate                  | Injection                     | 20 mg/mL and 40 mg/2 mL                    | Folotyn 22468    | 9/24/2013          | 4                         |                       |                               |                                  |  | 5/31/2025                                 |
| Pramipexole Dihydrochloride   | Tablets                       | 0.125 mg, 0.5 mg, 1 mg and 1.5 mg          | Mirapex 20667    | 6/24/2005          | 1                         | Eligible              | 2/22/2022                     | 2/19/2008                        | 1/4/2010   | 3/25/2011                                 |
| Pramipexole Dihydrochloride   | Tablets                       | 0.25 mg                                    | Mirapex 20667    | 5/27/2005          | 1                         | Eligible              | 2/22/2022                     | 2/19/2008                        | 1/4/2010   | 3/25/2011                                 |
| Pramipexole Dihydrochloride   | Tablets                       | 0.75 mg                                    | Mirapex 20667    | 7/31/2008          | 1                         | Extinguished Eligible | 4/18/2023<br>2/22/2022        | 4/9/2010                         |  | 10/8/2010                                 |
| Pramipexole Dihydrochloride   | Extended-release Tablets      | 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg | Mirapex ER 22421 | 6/1/2010           | 1                         | Extinguished          | 2/8/2022                      |                                  |  | 4/26/2028                                 |
| Pramipexole Dihydrochloride   | Extended-release Tablets      | 2.25 mg and 3.75 mg                        | Mirapex ER 22421 | 7/26/2011          | 1                         | Eligible              | 2/8/2022                      | 2/6/2014                         | 11/20/2015 -<br>2.25 mg<br>3.75 mg -<br>7/5/2016 | 4/26/2028                                 |
| Prasugrel Hydrochloride       | Tablets                       | 5 mg and 10 mg                             | Effient 22307    | 7/10/2013          | 17                        | Eligible              | 6/29/2020                     | 7/12/2017                        | 8/15/2017  | 3/2/2022                                  |
| Pravastatin Sodium            | Tablets                       | 10 mg, 20 mg, 40 mg and 80 mg              | Pravachol 19898  | Pre-MMA            |                           |                       |                               |                                  |  |   |
| Pravastatin Sodium            | Tablets                       | 30 mg                                      | Pravachol 19898  | 6/1/2005           | 1                         | Eligible              | 2/22/2022                     | 11/28/2006                       |  | 4/22/2014                                 |
| Prazosin Hydrochloride        | Capsules                      | 1 mg, 2 mg and 5 mg                        | Minipress 17442  | Pre-MMA            |                           |                       |                               |                                  |  |   |
| Prednisolone Sodium Phosphate | Oral Solution                 | 5 mg(base)/ 5 mL and 15 mg (base)/ 5 mL    | Pediapred 19157  | Pre-MMA            |                           |                       |                               |                                  |  |   |
| Prednisolone Sodium Phosphate | Orally Disintegrating Tablets | 10 mg, 15 mg and 30 mg                     | Orapred 21959    | 7/22/2010          | 1                         | Eligible              | 8/27/2019                     | 4/10/2013                        | 12/8/2014  | 11/24/2019                                |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                 | DOSAGE FORM               | STRENGTH   | RLD/NDA           | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------|---------------------------|--|-------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Prednisone                | Delayed-release Tablets   | 1 mg, 2 mg, and 5 mg   | Rayos 202020      | 11/26/2012         | 1                         | Deferred       | 2/22/2022                     | 4/25/2017                        |   | 4/23/2024<br>1/7/2028 - 5 mg              |
| Pregabalin                | Capsules                  | 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg | Lyrica 21446      | 12/30/2008         | 8                         | Extinguished   | 12/13/2022                    |                                  |   | 12/30/2018                                |
| Pregablin                 | Oral Solution             | 20 mg/mL   | Lyrica 22488      | 5/19/2010          | 1                         | Extinguished   | 7/25/2022                     |                                  |   | 12/30/2018                                |
| Pregabalin                | Extended-release Tablets  | 330 mg   | Lyrica CR 209501  | 1/29/2018          | 1                         | Extinguished   | 4/20/2021                     | 4/12/2021                        |   | 11/2/2026                                 |
| Pregabalin                | Extended-release Tablets  | 82.5 mg and 165 mg   | Lyrica CR 209501  | 2/2/2018           | 1                         | Extinguished   | 4/20/2021                     | 4/12/2021                        |   | 11/2/2026                                 |
| Propafenone               | Extended-release Capsules | 325 mg   | Rythmol SR 21416  | 11/07/2006         | 1                         | Deferred       | 7/25/2022                     | 10/18/2010                       | 1/3/2011                                  | 10/28/2014                                |
| Propafenone Hydrochloride | Extended-release Capsules | 225 mg and 425 mg  | Rythmol SR 21416  | 10/11/2006         | 1                         | Deferred       | 7/25/2022                     | 10/18/2010                       | 1/3/2011                                  | 10/28/2014                                |
| Propofol                  | Injection                 | 10 mg/mL ; 20 mL, 50 mL and 100 mL vials and 20 mL syringe     | Diprivan 19627    | Pre-MMA            |                           |                |                               |                                  |   |   |
| Propranolol Hydrochloride | Extended-release Capsules | 60 mg, 80 mg, 120 mg and 160 mg                                | Inderal LA 18553  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Propranolol Hydrochloride | Oral Solution             | 4.28 mg/mL   | Hemangeol 205410  | 7/21/2022          | 1                         |                |                               |                                  |   | 10/16/2028                                |
| Quetiapine Fumarate       | Extended-release Tablets  | 400 mg   | Seroquel XR 22047 | 6/18/2008          | 1                         | Eligible       | 8/24/2020                     | 11/1/2016                        | 11/1/2016                                 | 5/28/2017                                 |
| Quetiapine Fumarate       | Extended-release Tablets  | 150 mg   | Seroquel XR 22047 | 11/17/2008         | 1                         | Eligible       | 8/24/2020                     | 5/9/2017                         | 11/1/2016                                 | 5/28/2017                                 |
| Quetiapine Fumarate       | Extended-release Tablets  | 200 mg and 300 mg  | Seroquel XR 22047 | 6/12/2008          | 1                         | Eligible       | 8/24/2020                     | 5/9/2017                         | 11/1/2016                                 | 5/28/2017                                 |
| Quetiapine Fumarate       | Extended-release Tablets  | 50 mg  | Seroquel XR 22047 | 10/17/2008         | 1                         | Eligible       | 8/24/2020                     | 5/9/2017                         | 11/1/2016                                 | 5/28/2017                                 |
| Quetiapine Fumarate       | Tablets                   | 25 mg  | Seroquel 20639    | 8/12/2005          | 1                         | Extinguished   | 8/24/2020                     | 3/27/2012                        |   | 9/26/2011                                 |
| Quetiapine Fumarate       | Tablets                   | 50 mg, 150 mg and 400 mg                                       | Seroquel 20639    | 2/12/2007          | 1                         | Extinguished   | 8/24/2020                     | 3/27/2012                        |   | 9/26/2011                                 |
| Quetiapine Fumarate       | Tablets                   | 100 mg, 200 mg and 300 mg                                      | Seroquel 20639    | 2/21/2006          | 1                         | Extinguished   | 8/24/2020                     | 3/27/2012                        |   | 9/26/2011                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                       | DOSAGE FORM                | STRENGTH                                     | RLD/NDA                                     | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|----------------------------|--|---|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Quinapril Hydrochloride                         | Tablets                    | 5 mg, 10 mg, 20 mg and 40 mg                 | Accupril<br>19885                           | Pre-MMA            |                           |                |                               |                                  |   |   |
| Quinapril Hydrochloride/<br>Hydrochlorothiazide | Tablets                    | 10 mg/12.5 mg<br>20 mg/12.5 mg<br>20mg/25 mg | Accuretic<br>20125                          | Pre-MMA            |                           |                |                               |                                  |   |   |
| Rabeprazole Sodium                              | Delayed-release<br>Tablets | 20 mg  | Aciphex<br>20973                            | Pre-MMA            |                           |                |                               |                                  |   |   |
| Raltegravir Potassium                           | Tablets                    | 400 mg                                       | Isentress<br>22145                          | 10/12/2011         | 1                         |                |                               |                                  |   | 3/11/2029                                 |
| Raltegravir Potassium                           | Tablets                    | 600 mg                                       | Isentress HD<br>22145                       | 10/21/2022         | 1                         |                |                               |                                  |   | 3/30/2032                                 |
| Raloxifene Hydrochloride                        | Tablets                    | 60 mg  | Evista<br>20815                             | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ramelteon                                       | Tablets                    | 8 mg   | Rozerem<br>21782                            | 7/22/2009          | 2                         | Deferred       | 6/18/2019                     | 7/26/2013                        | 7/22/2019                                 | 7/22/2019                                 |
| Ramipril  | Capsules                   | 1.25 mg, 2.5 mg,<br>5 mg and 10 mg           | Altace<br>19901                             | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ranitidine                                      | Capsules                   | 150 mg and 300 mg                            | Zantac                                      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ranitidine                                      | Injection                  | 25 mg/mL, 2 mL and<br>6 mL and 40 mL vials   | Zantac                                      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ranitidine                                      | Oral Solution              | 15 mg/mL                                     | Zantac                                      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ranitidine                                      | Tablets                    | 75 mg, 150 mg and<br>300 mg                  | Zantac                                      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ranitidine Hydrochloride                        | Tablets                    | 150 mg                                       | Zantac 150<br>(NDA<br>21698/Product<br>002) | 10/30/2007         | 1                         | Extinguished   | 3/23/2021                     |                                  |   | 12/20/2010                                |
| Ranolazine                                      | Extended-release           | 500 mg and<br>1000 mg                        | Renexa<br>21526                             | 5/17/2010          | 1                         | Eligible       | 3/23/2021                     | 7/29/2013                        | 1/27/2019                                 | 5/27/2019                                 |
| Rasagiline Mesylate                             | Tablets                    | 0.5 mg and 1 mg                              | Azilect<br>21461                            | 5/17/2010          | 5                         | Eligible       | 3/23/2021                     | 9/12/2013                        | 1/2/2017                                  | 12/5/2026                                 |
| Regadenoson                                     | Injection                  | 0.08 mg/mL, 5 mL<br>vial                     | Lexiscan<br>22161                           | 4/10/2012          | 1                         | Extinguished   | 1/12/2021                     |                                  |   | 2/2/2027                                  |
| Regorafenib                                     | Tablets                    | 40 mg  | Stivarga<br>203085                          | 9/27/2016          | 2                         |                |                               |                                  |   | 2/16/2031                                 |
| Remifentanyl Hydrochloride                      | for Injection              | 1 mg/vial, 2 mg/vial<br>and 5 mg/vial        | Ultiva<br>20630                             | 12/27/2013         | 1                         | Extinguished   | 7/2/2019                      | 1/16/2018                        | 1/26/2018                                 | 9/10/2017                                 |
| Repaglinide                                     | Tablets                    | 0.5 mg*, 1 mg and<br>2 mg                    | Prandin<br>20741                            | 2/10/2005          | 1                         | Eligible       | 3/23/2021                     | 7/11/2013                        | 7/24/2013                                 | 6/12/2018                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                       | DOSAGE FORM                   | STRENGTH                              | RLD/NDA                       | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT       |
|---|-------------------------------|---------------------------------------|-------------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Repaglinide and Metformin Hydrochloride         | Tablets                       | 1 mg/500 mg and 2 mg/500 mg           | Prandimet 22386               | 4/9/2009           | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 6/12/2018                                       |
| Revefenacin                                     | Inhalation Solution           | 175 mcg/3 mL                          | Yupelri 210598                | 11/9/2022          | 7                         |                |                               |                                  |   | 10/23/2039                                      |
| Ribavirin                                       | Capsules                      | 200 mg                                | Rebetol 20903                 | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ribavirin                                       | for Inhalation Solution       | 6 gm/vial                             | Virazole 18859                | 5/22/2014          | 1                         | Eligible       | 3/23/2021                     | 10/6/2016                        | 12/15/2016                                | 11/21/2017                                      |
| Ribociclib Succinate                            | Tablets                       | 200 mg                                | Kisqali 209092                | 3/15/2021          | 4                         |                |                               |                                  |   | 4/14/2036                                       |
| Ribociclib Succinate and Letrozole (Copackaged) | Tablets                       | 200 mg and 2.5 mg                     | Kisqali Femara Co-Pack 209935 | 3/15/2021          | 4                         |                |                               |                                  |   | 4/14/2036                                       |
| Rifaximin                                       | Tablets                       | 550 mg                                | Xifaxan 21361                 | 12/18/2015         | 1                         | Non-Forfeiture | 8/24/2021                     |                                  |   | 10/2/2029                                       |
| Rifaximin                                       | Tablets                       | 200 mg                                | Xifaxan 21361                 | 1/28/2019          | 1                         |                |                               |                                  |   | 7/24/2029                                       |
| Riluzole  | Oral Suspension               | 50 mg/10 mL                           | Tiglutik Kit 209080           | 3/12/2021          | 1                         |                |                               |                                  |   | 3/12/2029                                       |
| Riociguat                                       | Tablets                       | 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg | Adempas 204819                | 10/10/2017         | 3                         | Deferred       | 10/4/2022                     | 9/1/2022                         |   | 12/4/2026                                       |
| Risedronate Sodium                              | Tablets                       | 5 mg, 30 mg and 35 mg                 | Actonel 20835                 | 4/23/2004          | 1                         | Eligible       | 3/10/2020                     | 10/5/2007                        | 6/1/2015                                  | 6/10/2018 - 5 mg and 30 mg<br>7/17/2018 - 35 mg |
| Risedronate Sodium                              | Tablets                       | 75 mg                                 | Actonel 20835                 | 9/7/2007           | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 6/10/2018                                       |
| Risedronate Sodium                              | Tablets                       | 150 mg                                | Actonel 20835                 | 8/12/2008          | 1                         | Extinguished   | 3/10/2020                     | 6/13/2014                        |   | 5/6/2023  |
| Risedronate Sodium                              | Delayed-release Tablets       | 35 mg                                 | Atelvia 22560                 | 6/9/2011           | 1                         | Deferred       | 3/23/2021                     | 5/18/2015                        | 5/18/2015                                 | 1/9/2028  |
| Risedronate Sodium with Calcium Carbonate       | Tablets                       | 35 mg; 500 mg                         | Actonel with Calcium          | 12/18/2007         | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 7/17/2018                                       |
| Risperidone                                     | Oral Solution                 | 1 mg/mL                               | Risperdal 20588               | Pre-MMA            |                           |                |                               |                                  |   |   |
| Risperidone                                     | Tablets                       | 0.25 mg, 1 mg, 2 mg, 3 mg and 4 mg    | Risperdal 20272               | Pre-MMA            |                           |                |                               |                                  |   |   |
| Risperidone                                     | Orally Disintegrating Tablets | 0.25 mg                               | Risperdal 21444               | 4/11/2005          | 1                         | Eligible       | 3/23/2021                     | 4/30/2009                        | 6/1/2009                                  | 6/10/2017                                       |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                | DOSAGE FORM                         | STRENGTH                       | RLD/NDA          | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--------------------------|-------------------------------------|--------------------------------|------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Risperidone              | Orally Disintegrating Tablets       | 0.5 mg, 1 mg and 2 mg          | Risperdal 21444  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Risperidone              | Orally Disintegrating Tablets       | 3 mg and 4 mg                  | Risperdal 21444  | 3/23/2005          | 1                         | Eligible       | 3/23/2021                     | 4/30/2009                        | 6/1/2009                                  | 6/10/2017                                 |
| Ritonavir                | Tablets                             | 100 mg                         | Norvir 22417     | 12/21/2010         | 1                         | Eligible       | 6/18/2019                     | 1/15/2015                        | 3/20/2018                                 | 5/10/2021                                 |
| Ritonavir                | Capsules                            | 100 mg                         | Norvir           | 10/31/2012         | 1                         | Extinguished   | 2/9/2021                      |                                  |   | 5/22/2020                                 |
| Rivastigmine Tartrate    | Capsules                            | 1.5 mg, 3 mg, 4.5 mg and 6 mg  | Exelon 20823     | 4/21/2004          | 3                         | Eligible       | 3/23/2021                     | 10/22/2007                       |   | 2/11/2014                                 |
| Rivastigmine Tartrate    | Oral Solution                       | 2 mg/mL                        | Exelon 21025     | 11/5/2004          | 1                         | Extinguished   | 8/27/2019                     |                                  |   | 2/11/2014                                 |
| Rivastigmine             | Transdermal System Extended-release | 4.6 mg/24 hr and 9.5 mg/24 hr  | Exelon 22083     | 4/27/2011          | 1                         | Extinguished   | 3/23/2021                     |                                  |   | 1/8/2019                                  |
| Rivastigmine             | Transdermal System Extended-release | 13.3 mg/24 hr                  | Exelon 22083     | 1/22/2013          | 1                         | Eligible       | 3/23/2021                     | 8/31/2015                        | 9/2/2015                                  | 1/8/2019                                  |
| Rivaroxaban              | Tablets                             | 2.5 mg                         | Xarelto 22406    | 11/19/2018         | 4                         |                |                               |                                  |   | 11/13/2024                                |
| Rivaroxaban              | Tablets                             | 10 mg, 15 mg, and 20 mg        | Xarelto 22406    | 7/1/2015           | 8                         |                |                               |                                  |   | 8/28/2024                                 |
| Rivaroxaban              | Capsules                            | 10 mg, 15 mg and 20 mg         | Xarelto 22406    | 6/17/2022          | 1                         |                |                               |                                  |   | 2/17/2034                                 |
| Rizatriptan Benzoate     | Tablets                             | 5 mg and 10 mg                 | Maxalt 20864     | 9/2/2004           | 1                         | Extinguished   | 3/23/2021                     | 12/31/2012                       |   | 2/11/2014                                 |
| Rizatriptan Benzoate     | Orally Disintegrating Tablets       | 5 mg and 10 mg                 | Maxalt-MLT 20865 | 2/17/2006          | 1                         | Eligible       | 3/23/2021                     | 12/31/2012                       | 12/31/2012                                | 2/11/2014                                 |
| Rofecoxib                | Tablets                             | 12.5 mg, 25 mg and 50 mg       | Vioxx 21052      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Roflumilast              | Tablets                             | 500 mcg                        | Daliresp 22522   | 3/2/2015           | 7                         | Eligible       | 6/18/2019                     | 7/13/2018                        | 10/19/2022                                | 3/8/2024                                  |
| Roflumilast              | Tablets                             | 250 mcg                        | Daliresp 22522   | 1/25/2019          | 1                         | Eligible       | 9/20/2022                     | 9/7/2022                         | 10/20/2022                                | 3/8/2024                                  |
| Romidepsin               | Injection                           | 10 mg/vial                     | Istodax 22393    | 11/5/2013          | 1                         | Extinguished   | 11/2/2021                     | 10/12/2021                       |   | 8/22/2021                                 |
| Ropinirole Hydrochloride | Tablets                             | 0.25 mg, 0.5 mg, 1 mg and 2 mg | Requip 20658     | 12/22/2004         | 1                         | Extinguished   | 3/10/2020                     | 5/5/2008                         |   | 5/19/2008                                 |
| Ropinirole Hydrochloride | Tablets                             | 3 mg, 4 mg and 5 mg            | Requip 20658     | 2/4/2005           | 1                         | Extinguished   | 3/10/2020                     | 5/5/2008                         |   | 5/19/2008                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME   | DOSAGE FORM                       | STRENGTH   | RLD/NDA         | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS           | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL   | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|-----------------------------------|--|-----------------|--------------------|---------------------------|--------------------------|-------------------------------|------------------------------------|---|---|
| Ropinirole Hydrochloride                          | Extended-release Tablets          | 2 mg   | Requip XL 22008 | 10/14/2008         | 1                         | Eligible                 | 3/10/2020                     | 5/17/2012                          | 5/17/2012                                 | 6/6/2012                                  |
| Ropinirole Hydrochloride                          | Extended-release Tablets          | 4 mg   | Requip XL 22008 | 10/31/2008         | 1                         | Eligible                 | 3/10/2020                     | 5/17/2012                          | 5/17/2012                                 | 6/6/2012                                  |
| Ropinirole Hydrochloride                          | Extended-release Tablets          | 6 mg   | Requip XL 22008 | 7/14/2009          | 1                         | Eligible                 | 3/10/2020                     | 5/17/2012                          | 5/17/2012                                 | 6/6/2012                                  |
| Ropinirole Hydrochloride                          | Extended-release Tablets          | 8 mg   | Requip XL 22008 | 11/3/2008          | 1                         | Eligible                 | 3/10/2020                     | 5/17/2012                          | 5/17/2012                                 | 6/6/2012                                  |
| Ropinirole Hydrochloride                          | Extended-release Tablets          | 3 mg   | Requip XL 22008 | 1/8/2009           | 1                         | Extinguished             | 3/10/2020                     |                                    |   | 6/6/2012                                  |
| Ropinirole Hydrochloride                          | Extended-release Tablets          | 12 mg  | Requip XL 22008 | 2/5/2009           | 1                         | Eligible                 | 3/10/2020                     | 5/17/2012                          | 5/17/2012                                 | 6/6/2012                                  |
| Ropivacaine Hydrochloride                         | Injection                         | 2 mg/mL, 5 mg/mL and 10 mg/mL, 20 mL, 30 mL and 20 mL vials                      | Naropin 20533   | 11/13/2006         | 1                         | Extinguished             | 3/23/2021                     | 7/17/2014                          |   | 9/23/2014                                 |
| Ropivacaine Hydrochloride                         | Injection                         | 2 mg/mL, 100 mL  | Naropin 20533   | 1/30/2015          | 1                         | Eligible                 | 3/23/2021                     | 7/13/2016                          | 9/15/2016                                 | 11/28/2026                                |
| Ropivacaine Hydrochloride                         | Injection                         | 2 mg/mL, 200 mL  | Naropin 20533   | 9/3/2015           | 1                         | Extinguished             | 6/18/2019                     | 3/16/2018                          |   | 11/28/2026                                |
| Rosiglitazone Maleate                             | Tablets                           | 2 mg, 4 mg and 8 mg  | Avandia 21071   | Pre-MMA            |                           |                          |                               |                                    |   |   |
| Rosiglitazone Maleate and Metformin Hydrochloride | Tablets                           | 1 mg/ 500 mg, 2 mg/ 500mg, 4 mg/ 500 mg, 2 mg/ 1000 mg, 4 mg/ 1000 mg            | Avandamet 21410 | 10/22/2004         | 1                         | Eligible                 | 3/23/2021                     | 5/7/2014<br>5/19/2017<br>1mg/500mg |   | 2/11/2017                                 |
| Rosuvastatin Calcium                              | Tablets                           | 5 mg, 10 mg, 20 mg and 40 mg   | Crestor 21366   | 8/13/2007          | 9                         | Non-Forfeiture           | 8/27/2019                     | 4/29/2016                          | 5/2/2016                                  | 8/4/2020                                  |
| Rotigotine  | Extended-release Transdermal Film | 1 mg/24 hr<br>2 mg/24 hr<br>3 mg/24 hr<br>4 mg/24 hr<br>6 mg/24 hr<br>8 mg/24 hr | Neupro 21829    | 11/26/2013         | 1                         |                          |                               |                                    |   | 9/1/2027                                  |
| Rufinamide  | Tablets                           | 100 mg   | Banzel 21911    | 11/14/2012         | 1                         | Extinguished<br>Deferred | 4/18/2023<br>9/6/2022         | 8/17/2022                          |   | 11/14/2022                                |



**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME   | DOSAGE FORM              | STRENGTH  | RLD/NDA              | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS    | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---|--------------------------|---|----------------------|--------------------|---------------------------|-------------------|-------------------------------|----------------------------------|---|---|
| Rufinamide  | Tablets                  | 200 mg and 400 mg   | Banzel 21911         | 11/14/2012         | 5                         | Eligible          | 3/23/2021                     | 5/16/2016                        | 6/1/2021                                  | 11/14/2022                                |
| Rufinamide  | Oral Suspension          | 40 mg/mL  | Banzel 201367        | 6/16/2014          | 1                         | Extinguished      | 10/8/2019                     |                                  |   | 11/14/2022                                |
| Ruxolitinib Phosphate <b>New</b>                      | Cream                    | 1.5%  | Opzelura 215309      | 7/31/2023          | 1                         |                   |                               |                                  |   | 5/5/2041                                  |
| Ruxolitinib Phosphate                                 | Tablets                  | 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg                            | Jakafi 202192        | 12/17/2015         | 1                         |                   |                               |                                  |   | 6/12/2028                                 |
| Sacubitril and Valsartan                              | Tablets                  | 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg                          | Entresto 207620      | 7/8/2019           | 18                        |                   |                               |                                  |   | 5/27/2027                                 |
| Safinamide Mesylate                                   | Tablets                  | 50 mg and 100 mg  | Xadago 2071454       | 3/22/2021          | 6                         | Eligible          | 6/26/2023                     | 6/14/2023                        |   | 12/10/2028                                |
| Sapropterin Dihydrochloride                           | Tablets                  | 100 mg  | Kuvan 22181          | 6/5/2014           | 1                         | Eligible          | 11/19/2019                    | 5/10/2019                        | 10/1/2020                                 | 11/16/2025                                |
| Sapropterin Dihydrochloride                           | Powder for Oral Solution | 100 mg per packet   | Kuvan 205065         | 11/9/2015          | 1                         | Eligible Deferred | 1/27/2020<br>8/27/2019        | 8/20/2019                        | 10/1/2020                                 | 5/17/2025                                 |
| Sapropterin Dihydrochloride                           | Powder for Oral Solution | 500 mg per packet   | Kuvan 205065         | 2/23/2017          | 1                         | Eligible          | 11/19/2019                    | 8/20/2019                        | 10/1/2020                                 | 11/1/2032                                 |
| Saxagliptin Hydrochloride                             | Tablets                  | 2.5 mg and 5 mg   | Onglyza 22350        | 7/31/2013          | 8                         | Eligible          | 8/7/2023                      | 7/31/2023                        | 7/31/2023                                 | 11/30/2028                                |
| Saxagliptin Hydrochloride and Metformin Hydrochloride | Extended-release Tablets | 5 mg/500 mg, 2.5 mg/1000 mg, 5 mg/1000 mg                       | Kombiglyze XR 200678 | 7/31/2013          | 3                         | Extinguished      | 8/7/2023                      |                                  |   | 7/31/2023                                 |
| Selexipag   | Tablets                  | 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1 mg, 1.2 mg, 1.4 mg and 1.6 mg | Uptravi 207947       | 12/23/2019         | 4                         | Eligible          | 1/10/2023                     | 12/21/2022                       |   | 8/1/2030                                  |
| Selexipag   | For Injection            | 1.8 mg/vial   | Uptravi 214275       | 7/29/2022          | 1                         |                   |                               |                                  |   | 8/1/2030                                  |
| Semaglutide   | Injection                | 2 mg/1.5 mL and 4 mg/3 mL                                       | Ozempic 209637       | 12/6/2021          | 7                         |                   |                               |                                  |   | 6/21/2033                                 |
| Semaglutide   | Injection                | 8 mg/3 mL   | Ozempic 209637       | 12/21/2022         | 1                         |                   |                               |                                  |   | 2/1/2032                                  |



**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME  | DOSAGE FORM              | STRENGTH                                  | RLD/NDA                     | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|---|-----------------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Sitagliptin Phosphate and Metformin Hydrochloride                                  | Tablets                  | 50 mg/500 mg and 50 mg/1000 mg            | Janumet 22044               | 10/18/2010         | 5                         |                |                               |                                  |   | 11/24/2026                                |
| Sitagliptin Phosphate and Metformin Hydrochloride                                  | Extended-release Tablets | 50 mg/500 mg and 50 mg/1000 mg            | Janumet XR 202270           | 3/16/2012          | 1                         |                |                               |                                  |   | 11/24/2026                                |
| Sitagliptin Phosphate and Metformin Hydrochloride                                  | Extended-release Tablets | 100 mg/1000 mg                            | Janumet XR 202270           | 10/22/2012         | 1                         |                |                               |                                  |   | 11/24/2026                                |
| Sitagliptin Phosphate and Simvastatin  | Tablets                  | 100 mg/10 mg and 100 mg/40 mg             | Juvisync 21995              | 6/19/2012          | 1                         | Extinguished   | 8/24/2020                     |                                  |   | 4/11/2026                                 |
| Sitagliptin Phosphate and Simvastatin  | Tablets                  | 100 mg/20 mg                              | Juvisync 21995              | 6/25/2012          | 1                         | Extinguished   | 8/24/2020                     |                                  |   | 4/11/2026                                 |
| Sitagliptin Phosphate and Simvastatin  | Tablets                  | 50 mg/10 mg<br>50 mg/20 mg<br>50 mg/40 mg | Juvisync 21995              | 11/6/2012          | 1                         | Extinguished   | 8/24/2020                     |                                  |   | 4/11/2026                                 |
| Sodium Phosphate Monobasic Monohydrate and Sodium Phosphate Dibasic Anhydrous, USP | Tablets                  | 1.102 g and 0.398 g                       | Osmoprep 21892              | 4/9/2008           | 1                         | Eligible       | 8/24/2020                     | 12/30/2011                       |   | 5/18/2013                                 |
| Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid                      | Oral Solution            | 10 mg, 3.5 g, and 12 g                    | Prepopik 202535             | 5/21/2014          | 1                         | Extinguished   | 8/13/2019                     |                                  |   | 10/10/2028                                |
| Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid                      | Oral Solution            | 10 mg, 3.5 g, and 12 g                    | Clenpiq 209589              | 2/11/2019          | 1                         |                |                               |                                  |   | 6/26/2034                                 |
| Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate                            | Oral Solution            | 17.5 g/3.13 g/1.6 g                       | Suprep Bowel Prep Kit 22372 | 11/8/2010          | 1                         | Eligible       | 11/17/2020                    | 2/23/2017                        | 9/7/2022                                  | 3/7/2023                                  |
| Sodium Sulfate, Magnesium Sulfate and Potassium Chloride                           | Tablets                  | 1.479 g/0.225 g/<br>0.188 g               | Sutab 213135                | 3/3/2023           | 1                         |                |                               |                                  |   | 8/4/2037                                  |
| Sodium Oxybate   | Oral Solution            | 500 mg/mL                                 | Xyrem 21196                 | 7/8/2010           | 1                         | Eligible       | 7/2/2019                      | 1/17/2017                        |   | 6/16/2024                                 |
| Sodium Thiosulfate   | Intravenous Injection    | 12.5 g/50 mL                              | Sodium Thiosulfate 203923   | 4/29/2022          | 1                         |                |                               |                                  |   | 3/29/2031                                 |
| Sodium Thiosulfate   | Intravenous Injection    | 12.5 g/100 mL                             | Pedmark 212937              | 10/7/2022          | 1                         |                |                               |                                  |   | 7/1/2039                                  |
| Sodium Zirconium Cyclosilicate   | for Oral Suspension      | 5 g/packet and 10 g/packet                | Lokelma 207078              | 5/18/2022          | 5                         |                |                               |                                  |   | 10/14/2035                                |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                  | DOSAGE FORM               | STRENGTH                                 | RLD/NDA            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|----------------------------|---------------------------|--|--------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Solifenacin Succinate      | Tablets                   | 5 mg and 10 mg                           | Vesicare 21518     | 4/8/2009           | 1                         | Deferred       | 8/24/2020                     | 4/2/2014                         |   | 11/9/2018                                 |
| Solifenacin Succinate      | Oral Suspension           | 1 mg/mL                                  | Vesicare LS 209529 | 5/27/2021          | 1                         |                |                               |                                  |   | 5/18/2031                                 |
| Solriamfetol Hydrochloride | Tablets                   | 75 mg and 150 mg                         | Sunosi 211230      | 6/20/2023          | 6                         |                |                               |                                  |   | 3/19/2040                                 |
| Sofosbuvir                 | Tablets                   | 400 mg                                   | Sovaldi 204671     | 12/6/2017          | 2                         | Deferred       | 2/8/2022                      | 1/27/2022                        |   | 12/11/2030                                |
| Sorafenib Tosylate         | Tablets                   | 200 mg                                   | Nexavar 21923      | 2/28/2014          | 1                         | Eligible       | 11/17/2020                    | 9/10/2020                        |   | 2/11/2023                                 |
| Spironolactone             | Oral Suspension           | 25 mg/5 mL                               | Carospir 209478    | 12/31/2020         | 1                         | Eligible       | 9/18/2023                     | 9/5/2023                         |   | 10/28/2036                                |
| Sugammadex Sodium          | Injection                 | 200 mg/2 mL and 500 mg/5 mL              | Bridion 22225      | 12/16/2019         | 14                        | Deferred       | 6/12/2023                     | 6/9/2023                         |   | 1/27/2026                                 |
| Sumatriptan Succinate      | Injection                 | 6 mg/0.5 mL, 0.5 mL vials                | Imitrex            | 10/25/2004         | 1                         | Extinguished   | 8/24/2020                     | 10/9/2009                        |   | 8/6/2008                                  |
| Sumatriptan Succinate      | Injection                 | 6 mg/0.5 mL, 0.5 mL (prefilled syringes) | Imitrex            | 5/9/2006           | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 8/6/2008                                  |
| Sumatriptan Succinate      | Tablets                   | 25 mg, 50 mg and 100 mg                  | Imitrex 20132      | Pre-MMA            |                           |                |                               |                                  |   |   |
| Sunitinib Malate           | Capsules                  | 12.5 mg, 25 mg, 37.5 mg and 50 mg        | Sutent 21938       | 1/26/2010          | 1                         | Extinguished   | 9/7/2021                      |                                  |   | 2/15/2021                                 |
| Tacrolimus                 | Ointment                  | 0.03%                                    | Protopic 50777     | 11/22/2010         | 1                         | Extinguished   | 8/24/2020                     | 9/9/2014                         |   | 9/9/2014                                  |
| Tacrolimus                 | Ointment                  | 0.10%                                    | Protopic 50777     | 9/9/2010           | 1                         | Extinguished   | 8/24/2020                     | 9/9/2014                         |   | 9/9/2014                                  |
| Tacrolimus                 | Extended-release Capsules | 0.5 mg, 1 mg, and 5 mg                   | Astagraf XL 204096 | 9/24/2013          | 1                         | Extinguished   | 8/24/2020                     |                                  |   | 3/25/2019                                 |
| Tacrolimus                 | Extended-release Tablets  | 0.75 mg, 1 mg and 4 mg                   | Envarsus XR 206406 | 3/31/2022          | 1                         |                |                               |                                  |   | 5/30/2028                                 |
| Tadalafil                  | Tablets                   | 2.5 mg                                   | Cialis 21368       | 10/14/2008         | 1                         | Eligible       | 6/18/2019                     | 5/22/2018                        | 9/27/2018                                 | 11/19/2020                                |
| Tadalafil                  | Tablets                   | 5 mg, 10 mg and 20 mg                    | Cialis 21368       | 11/21/2007         | 1                         | Eligible       | 6/18/2019                     | 5/22/2018                        | 9/27/2018                                 | 11/19/2020                                |
| Tadalafil                  | Tablets                   | 20 mg                                    | Adcirca 22332      | 10/15/2009         | 1                         | Eligible       | 6/18/2019                     | 8/3/2018                         | 8/8/2018                                  | 4/26/2020                                 |
| Tafamidis Meglumine        | Capsules                  | 20 mg                                    | Vyndaqel 211996    | 5/3/2023           | 1                         |                |                               |                                  |   | 4/27/2024                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                              | DOSAGE FORM                 | STRENGTH  | RLD/NDA               | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS       | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|-----------------------------|---|-----------------------|--------------------|---------------------------|----------------------|-------------------------------|----------------------------------|---|---|
| Tafamidis                              | Capsules                    | 61 mg   | Vyndamax<br>212161    | 5/3/2023           | 3                         |                      |                               |                                  |   | 8/31/2035                                 |
| Taf luprost                            | Ophthalmic Solution         | 0.0015%   | Zioptan<br>202514     | 2/10/2016          | 2                         | Eligible<br>Deferred | 2/20/2023<br>12/14/2021       | 8/19/2019                        | 12/6/2022                                 | 12/18/2022                                |
| Tamoxifen Citrate                      | Tablets                     | 10 mg and 20 mg                                 | Nolvadex<br>17970     | Pre-MMA            |                           |                      |                               |                                  |   |   |
| Tamsulosin Hydrochloride               | Capsules                    | 0.4 mg  | Flomax<br>20579       | 12/20/2004         | 1                         | Extinguished         | 8/24/2020                     |                                  |   |   |
| Tapentadol Hydrochloride               | Tablets                     | 50 mg, 75 mg, and<br>100 mg                     | Nucynta<br>22304      | 11/20/2012         | 4                         |                      |                               |                                  |   | 6/27/2025                                 |
| Tapentadol Hydrochloride               | Extended-release<br>Tablets | 50 mg, 100 mg,<br>150 mg, 200 mg, and<br>250 mg | Nucynta ER<br>200533  | 11/20/2012         | 2                         |                      |                               |                                  |   | 6/27/2025                                 |
| Tapentadol                             | Oral Solution               | 20 mg/mL  | Nucynta<br>203794     | 12/20/2013         | 1                         |                      |                               |                                  |   | 6/27/2025                                 |
| Tasimelteon                            | Capsules                    | 20 mg   | Hetlioz<br>205677     | 1/31/2018          | 3                         | Eligible<br>Deferred | 1/10/2023<br>12/13/2022       | 12/12/2022                       | 12/29/2022                                | 5/17/2034                                 |
| Tavaborole                             | Topical Solution            | 5%  | Kerydin<br>204427     | 7/9/2018           | 13                        | Eligible             | 11/17/2020                    | 10/13/2020                       | 10/19/2020                                | 5/26/2027                                 |
| Tazarotene                             | Topical Lotion              | 0.045%  | Arazlo<br>211882      | 5/12/2022          | 1                         |                      |                               |                                  |   | 5/11/2038                                 |
| Teduglutide                            | Injection                   | 5 mg/vial                                       | Gattex Kit<br>203411  | 12/21/2016         | 1                         |                      |                               |                                  |   | 11/1/2025                                 |
| Telmisartan                            | Tablets                     | 20 mg, 40 mg and 80<br>mg                       | Micardis<br>20850     | 12/26/2006         | 1                         | Eligible             | 8/24/2020                     | 1/8/2014                         | 1/8/2014                                  | 1/10/2020                                 |
| Telmisartan and<br>Hydrochlorothiazide | Tablets                     | 80 mg/12.5 mg and<br>40 mg/12.5 mg              | Micardis HCT<br>21162 | 12/31/2008         | 1                         | Extinguished         | 8/24/2020                     |                                  |   | 1/10/2020                                 |
| Temazepam                              | Capsules                    | 7.5 mg  | Restoril<br>18163     | 11/01/2006         | 1                         | Eligible             | 8/24/2020                     | 9/8/2009                         |   | 5/18/2010                                 |
| Temozolomide                           | Capsules                    | 5 mg, 20 mg,<br>100 mg and 250 mg               | Temodar<br>21029      | 3/20/2007          | 1                         | Eligible             | 8/24/2020                     | 3/1/2010                         | 8/12/2013                                 | 8/11/2013                                 |
| Temozolomide                           | Capsules                    | 140 mg and 180 mg                               | Temodar<br>21029      | 3/24/2008          | 1                         | Eligible             | 8/24/2020                     | 3/1/2010                         | 8/12/2013                                 | 8/11/2013                                 |
| Temsirolimus                           | Injection                   | 25 mg/mL, 1.8 mL<br>vial                        | Torisel<br>22088      | 5/25/2011          | 1                         | Extinguished         | 3/10/2020                     |                                  |   | 4/18/2014                                 |
| Tenofovir Alafenamide<br>Fumarate      | Tablets                     | 25 mg   | Vemlidy<br>208464     | 11/5/2019          | 6                         | Eligible             | 4/18/2023                     | 3/30/2023                        |   | 8/15/2032                                 |
| Tenofovir Disoproxil Fumarate          | Tablets                     | 300 mg  | Viread<br>21356       | 1/26/2010          | 1                         | Eligible             | 6/18/2019                     | 3/18/2015                        | 12/15/2017                                | 1/25/2018                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                     | DOSAGE FORM      | STRENGTH                         | RLD/NDA        | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|-------------------------------|------------------|----------------------------------|----------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Tenofovir Disoproxil Fumarate | Tablets          | 150 mg, 200 mg, and 250 mg       | Viread 21356   | 5/17/2012          | 1                         | Extinguished   | 6/18/2019                     |                                  |   | 1/25/2018                                 |
| Terazosin Hydrochloride       | Capsules         | 1 mg, 2 mg, 5 mg and 10 mg       | Hytrin 20347   | Pre-MMA            |                           |                |                               |                                  |   |   |
| Terazosin Hydrochloride       | Tablets          | 1 mg, 2 mg, 5 mg and 10 mg       | Hytrin 19057   | Pre-MMA            |                           |                |                               |                                  |   |   |
| Terbinafine Hydrochloride     | Tablets          | 250 mg                           | Lamisil 20539  | Pre-MMA            |                           |                |                               |                                  |   |   |
| Terfenadine                   | Tablets          | 60 mg                            | Seldane        | Pre-MMA            |                           |                |                               |                                  |   |   |
| Teriflunomide                 | Tablets          | 7 mg and 14 mg                   | Aubagio 202992 | 9/12/2016          | 21                        | Eligible       | 6/18/2019                     | 7/27/2018                        | 3/12/2023                                 | 2/4/2034                                  |
| Teriparatide                  | Injection        | 250 mcg/mL, 2.4 mL prefilled Pen | Forteo 21318   | 7/27/2015          | 1                         |                |                               |                                  |   | 3/25/2025                                 |
| Testosterone                  | Gel              | 1%                               | Androgel       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Testosterone                  | Gel              | 1%                               | Testim 21454   | 8/21/2008          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 6/11/2008                                 |
| Testosterone                  | Gel              | 1% (pump)                        | Androgel       | 12/19/2008         | 1                         | Extinguished   | 8/24/2020                     |                                  |   | 3/1/2021                                  |
| Testosterone                  | Gel              | 1.62% (pump)                     | Androgel       | 4/6/2012           | 1                         | Eligible       | 10/8/2019                     | 8/4/2015                         | 10/12/2018                                | 8/30/2020                                 |
| Testosterone                  | Gel              | 1.62% (1.25 g and 2.5 g packets) | Androgel       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Testosterone                  | Gel              | 10 mg/actuation                  | Fortesta 21463 | 8/14/2012          | 1                         | Deferred       | 8/24/2020                     | 8/5/2015                         |   | 11/9/2018                                 |
| Testosterone                  | Topical Solution | 30 mg/1.5 mL                     | Axiron 22504   | 1/29/2013          | 1                         | Extinguished   | 8/24/2020                     | 8/7/2017                         |   | 2/19/2017                                 |
| Testosterone Undecanoate      | Injection        | 250 mg/mL                        | Aveed 22219    | 6/11/2014          | 1                         |                |                               |                                  |   | 3/14/2027                                 |
| Thalidomide                   | Capsules         | 50 mg and 100 mg                 | Thalomid 20785 | 12/18/2006         | 1                         | Extinguished   | 8/13/2019                     |                                  |   | 10/23/2020                                |
| Thalidomide                   | Capsules         | 200 mg                           | Thalomid 20785 | 9/25/2006          | 1                         | Extinguished   | 8/13/2019                     |                                  |   | 10/23/2020                                |
| Thalidomide                   | Capsules         | 150 mg                           | Thalomid 20785 | 2/3/2014           | 1                         |                |                               |                                  |   | 12/9/2023                                 |
| Tiagabine Hydrochloride       | Tablets          | 2 mg and 4 mg                    | Gabitril 20646 | 2/1/2005           | 1                         | Eligible       | 8/24/2020                     | 11/4/2011                        |   | 6/10/2017                                 |
| Tiagabine Hydrochloride       | Tablets          | 12 mg and 16 mg                  | Gabitril 20646 | 1/24/2014          | 1                         | Extinguished   | 8/24/2020                     | 10/13/2017                       |   | 6/10/2017                                 |
| Ticagrelor                    | Tablets          | 90 mg                            | Brilinta 22433 | 7/20/2015          | 16                        | Eligible       | 11/19/2019                    | 9/4/2018                         |   | 4/17/2030                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                 | DOSAGE FORM                   | STRENGTH                 | RLD/NDA                   | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS                             | 180-DAY DECISION POSTING DATE    | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------|-------------------------------|--------------------------|---------------------------|--------------------|---------------------------|--|----------------------------------|----------------------------------|---|---|
| Ticagrelor                | Tablets                       | 60 mg                    | Brilinta<br>22433         | 9/30/2015          | 3                         | Eligible                                   | 8/13/2019                        | 9/4/2018                         |   | 4/17/2030                                 |
| Ticlopidine Hydrochloride | Tablets                       | 250 mg                   | Ticlid                    | Pre-MMA            |                           |  |                                  |                                  |   |   |
| Tigecycline               | For Injection                 | 50 mg per vial           | Tygal                     | 6/15/2009          | 1                         | Extinguished                               | 8/24/2020                        | 5/27/2015                        |   | 4/9/2016                                  |
| Timolol Maleate           | Ophthalmic Solution           | 0.25% and 0.5%           | Timoptic                  | Pre-MMA            |                           |  |                                  |                                  |   |   |
| Timolol Maleate           | Ophthalmic Solution           | 0.5%                     | Istalol<br>21516          | 10/19/2012         | 1                         | Eligible                                   | 8/10/2020                        | 4/17/2015                        | 4/17/2015                                 | 11/16/2018                                |
| Tiopronin                 | Delayed-release<br>Tablets    | 100 mg and 300 mg        | Thiola EC<br>211843       | 10/11/2022         | 2                         | Eligible                                   | 3/6/2023                         | 2/24/2023                        |   | 11/14/2038                                |
| Tiotropium Bromide        | Inhalation Powder<br>Capsules | 18 mcg                   | Spiriva<br>21395          | 5/11/2018          | 1                         | Deferred                                   | 6/26/2023                        | 6/20/2023                        | 8/16/2023                                 | 4/19/2030                                 |
| Tiotropium Bromide        | Inhalation Aerosol            | 2.5 mcg per<br>actuation | Spiriva Respimat<br>21936 | 3/7/2023           | 1                         |  |                                  |                                  |   | 4/16/2031                                 |
| Tirofiban Hydrochloride   | Injection                     | 12.5 mg/250 mL           | Aggrastat<br>20913        | 10/3/2018          | 1                         | Extinguished<br>Non-Forfeiture<br>Deferred | 5/2/2023<br>2/6/2023<br>5/4/2021 | 4/8/2021                         |   | 5/1/2023                                  |
| Tirofiban Hydrochloride   | Injection                     | 5 mg/100 mL              | Aggrastat<br>20913        | 8/29/2019          | 1                         | Extinguished<br>Deferred                   | 5/2/2023<br>2/6/2023             | 2/7/2023                         |   | 5/1/2023                                  |
| Tizanidine Hydrochloride  | Capsules                      | 2 mg, 4 mg and<br>6 mg   | Zanaflex<br>21447         | 8/10/2007          | 1                         | Deferred                                   | 8/10/2020                        | 2/3/2012                         | 2/3/2012                                  | 11/28/2021                                |
| Tobramycin                | Inhalation Solution           | 300 mg/5 mL              | Tobi<br>50753             | 6/29/2009          | 1                         | Extinguished                               | 8/10/2020                        | 10/10/2013                       |   | 10/19/2014                                |
| Tobramycin                | Inhalation Solution           | 300 mg/4 mL              | Bethkis<br>201820         | 8/31/2017          | 1                         | Extinguished<br>Eligible                   | 4/18/2023<br>7/2/2019            | 6/26/2019                        |   | 9/22/2022                                 |
| Tofacitinib               | Tablets                       | 5 mg                     | Xeljanz<br>203214         | 11/7/2016          | 3                         | Eligible                                   | 3/20/2023                        | 3/13/2023                        |   | 12/8/2025                                 |
| Tofacitinib               | Tablets                       | 10 mg                    | Xeljanz<br>203214         | 7/24/2019          | 1                         | Eligible                                   | 7/13/2021                        | 6/1/2021                         |   | 12/8/2025                                 |
| Tofacitinib               | Extended-release<br>Tablets   | 11 mg                    | Xeljanz XR<br>208246      | 11/7/2016          | 1                         | Extinguished                               | 8/10/2020                        |                                  |   | 3/25/2023                                 |
| Tofacitinib               | Extended-release<br>Tablets   | 22 mg                    | Xeljanz XR<br>208246      | 12/28/2020         | 1                         | Eligible                                   | 8/24/2021                        | 8/19/2021                        |   | 3/14/2034                                 |
| Tofacitinib               | Oral Solution                 | 1 mg/mL                  | Xeljanz<br>213082         | 11/12/2021         | 1                         |  |                                  |                                  |   | 12/8/2025                                 |
| Tolterodine Tartrate      | Extended-release<br>Capsules  | 2 mg and 4 mg            | Detrol LA<br>21228        | 7/30/2007          | 1                         | Extinguished                               | 8/10/2020                        | 11/22/2016                       |   | 11/11/2019                                |
| Tolterodine Tartrate*     | Tablets                       | 1 mg and 2 mg            | Detrol<br>20771           |                    |                           |  |                                  |                                  |   |   |
| Tolvaptan                 | Tablets                       | 30mg                     | Samsca<br>22275           | 9/23/2013          | 1                         | Extinguished<br>Non-Forfeiture             | 6/15/2020<br>6/15/2020           |                                  |   | 5/19/2020                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME              | DOSAGE FORM               | STRENGTH                                 | RLD/NDA                | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS                       | 180-DAY DECISION POSTING DATE        | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|------------------------|---------------------------|--|------------------------|--------------------|---------------------------|--------------------------------------|--------------------------------------|----------------------------------|---|---|
| Tolvaptan              | Tablets                   | 15 mg                                    | Samsca 22275           | 10/10/2013         | 1                         | Non-Forfeiture                       | 5/19/2020                            | 2/15/2022                        | 3/10/2022                                 | 9/1/2026                                  |
| Tolvaptan              | Tablets                   | 60 mg                                    | Samsca 22275           | 3/26/2018          | 1                         | Eligible                             | 6/15/2020                            | 5/19/2020                        |   | 9/1/2026                                  |
| Tolvaptan              | Tablets                   | 15 mg, 30 mg, 45 mg, 60 mg, 90 mg        | Jynarque 204441        | 4/8/2021           | 1                         |                                      |                                      |                                  |   | 4/7/2030                                  |
| Topiramate             | Capsules                  | 15 mg and 25 mg                          | Topamax Sprinkle 20844 | 9/7/2005           | 1                         | Eligible                             | 8/10/2020                            | 4/15/2009                        | 4/15/2009                                 | 9/1/2019                                  |
| Topiramate             | Tablets                   | 25 mg, 100 mg and 200 mg                 | Topamax 20505          | 12/26/2001         |                           |                                      |                                      |                                  |   |   |
| Topiramate             | Tablets                   | 50 mg                                    | Topamax 20505          | 9/8/2005           | 1                         | Extinguished                         | 8/10/2020                            | 3/27/2009                        |   | 9/26/2008                                 |
| Topiramate             | Extended-release Capsules | 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg | Qudexy XR 205122       | 12/24/2015         | 1                         | Extinguished Non-Forfeiture          | 12/1/2020<br>8/27/2019               |                                  |   | 3/19/2033                                 |
| Topiramate             | Extended-release Capsules | 200 mg                                   | Trokendi XR 201635     | 4/3/2014           | 1                         | Extinguished                         | 3/6/2023                             |                                  |   | 3/18/2029                                 |
| Topiramate             | Extended-release Capsules | 25 mg, 50 mg, and 100 mg                 | Trokendi XR 201635     | 5/12/2014          | 1                         | Extinguished Non-Forfeiture Deferred | 3/20/2023<br>3/20/2023<br>11/19/2019 | 11/24/2017                       | 1/4/2023                                  | 3/18/2029                                 |
| Topiramate             | Oral Solution             | 25 mg/mL                                 | Epronita 214679        | 10/6/2022          | 1                         |                                      |                                      |                                  |   | 8/21/2040                                 |
| Torsemide              | Tablets                   | 5 mg, 10 mg, 20 mg, and 100 mg           | Demadex 20136          | Pre-MMA            |                           |                                      |                                      |                                  |   |   |
| Trabectedin            | Powder for Injection      | 1 mg/vial                                | Yondelis 207953        | 4/23/2020          | 2                         |                                      |                                      |                                  |   | 1/7/2028                                  |
| Tramadol Hydrochloride | Tablets                   | 50 mg                                    | Ultram 20281           | Pre-MMA            |                           |                                      |                                      |                                  |   |   |
| Tramadol Hydrochloride | Extended-release Tablets  | 100 mg                                   | Ultram ER 21692        | 1/8/2007           | 1                         | Eligible                             | 8/10/2020                            | 11/13/2009                       | 11/13/2009                                | 5/10/2014                                 |
| Tramadol Hydrochloride | Extended-release Tablets  | 200 mg                                   | Ultram ER 21692        | 3/28/2007          | 1                         | Eligible                             | 8/10/2020                            | 11/13/2009                       | 11/13/2009                                | 5/10/2014                                 |
| Tramadol Hydrochloride | Extended-release Tablets  | 300 mg                                   | Ultram ER 21692        | 9/25/2007          | 1                         | Extinguished                         | 8/10/2020                            | 9/20/2011                        |   | 5/10/2014                                 |
| Tramadol Hydrochloride | Extended-release Tablets  | 100 mg, 200 mg and 300 mg                | Ryzolt 21745           | 6/18/2009          | 1                         | Eligible                             | 8/10/2020                            | 12/30/2011                       | 12/30/2011                                | 6/29/2020                                 |



**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                                | DOSAGE FORM              | STRENGTH                                    | RLD/NDA          | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--|--------------------------|---|------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Trandolapril                             | Tablets                  | 1 mg, 2 mg and 4 mg                         | Mavik 20528      | 10/4/2004          | 1                         | Extinguished   | 8/10/2020                     | 6/12/2007                        |   | 6/12/2007                                 |
| Trandolapril and Verapamil Hydrochloride | Extended-release Tablets | 2 mg/180 mg and 2 mg/240 mg                 | Tarka 20591      | 11/9/2007          | 1                         | Eligible       | 8/10/2020                     | 5/26/2010                        |   | 2/24/2015                                 |
| Trandolapril and Verapamil Hydrochloride | Extended-release Tablets | 1 mg/240 mg                                 | Tarka 20591      | 2/20/2008          | 1                         | Eligible       | 8/10/2020                     | 8/30/2010                        | 9/20/2010                                 | 2/24/2015                                 |
| Trandolapril and Verapamil Hydrochloride | Extended-release Tablets | 4 mg/ 240 mg                                | Tarka 20591      | 7/24/2007          | 1                         | Eligible       | 8/10/2020                     | 5/5/2010                         |   | 2/24/2015                                 |
| Tranexamic Acid                          | Tablets                  | 650 mg                                      | Lysteda 22430    | 5/24/2011          | 2                         | Eligible       | 8/10/2020                     | 12/27/2012                       | 1/3/2013                                  | 3/4/2025                                  |
| Travoprost                               | Ophthalmic Solution      | 0.003%                                      | Izba 204822      | 12/30/2015         | 1                         | Extinguished   | 8/10/2020                     |                                  |   | 10/10/2029                                |
| Travoprost                               | Ophthalmic Solution      | 0.004%                                      | Travatan 21257   | 11/28/2008         | 1                         | Extinguished   | 8/10/2020                     |                                  |   | 12/22/2014                                |
| Travoprost (Preserved)                   | Ophthalmic Solution      | 0.004%                                      | Travatan Z 21994 | 2/19/2009          | 1                         | Extinguished   | 8/13/2019                     |                                  |   | 12/2/2014                                 |
| Trazodone Hydrochloride                  | Tablets                  | 150 mg                                      | Desyrel 18207    | Pre-MMA            |                           |                |                               |                                  |   |   |
| Trazodone Hydrochloride                  | Extended-release Tablets | 150 mg and 300 mg                           | Oleptro 22411    | 10/18/2010         | 1                         | Extinguished   | 8/10/2020                     |                                  |   | 6/29/2020                                 |
| Treprostinil Sodium                      | Injection                | 10 mg/mL, 20 mL vial                        | Remodulin 21272  | 12/2/2011          | 1                         | Eligible       | 6/18/2019                     | 11/30/2017                       | 3/25/2019                                 | 3/29/2029                                 |
| Treprostinil Sodium                      | Injection                | 1 mg/mL, 2.5 mg/mL, and 5 mg/mL, 20 mL vial | Remodulin 21272  | 12/7/2012          | 1                         | Eligible       | 6/18/2019                     | 11/30/2017                       | 3/25/2019                                 | 3/29/2029                                 |
| Treprostinil Sodium                      | Inhalation Solution      | 0.6 mg/mL, 2.9 mL ampules                   | Tyvaso 22387     | 4/13/2015          | 1                         | Extinguished   | 12/14/2021                    |                                  |   | 12/15/2028                                |
| Treprostinil                             | Extended-release Tablets | 2.5 mg                                      | Orenitram 203496 | 12/24/2015         | 1                         |                |                               |                                  |   | 1/22/2031                                 |
| Treprostinil                             | Extended-release Tablets | 0.25 mg and 1 mg                            | Orenitram 203496 | 5/19/2016          | 1                         |                |                               |                                  |   | 1/22/2031                                 |
| Treprostinil                             | Extended-release Tablets | 0.125 mg and 5 mg                           | Orenitram 203496 | 12/28/2020         | 1                         |                |                               |                                  |   | 8/11/2031                                 |
| Trientine Tetrahydrochloride             | Tablets                  | 300 mg                                      | Cuvrior 215760   | 6/21/2023          | 1                         |                |                               |                                  |   | 5/3/2039                                  |
| Tretinoin                                | Cream                    | 0.025%, 0.05% and 0.1%                      | Retin-A          | Pre-MMA            |                           |                |                               |                                  |   |   |
| Tretinoin                                | Gel                      | 0.025%                                      | Retin-A 17579    | Pre-MMA            |                           |                |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                            | DOSAGE FORM               | STRENGTH  | RLD/NDA             | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|--------------------------------------|---------------------------|---|---------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Tretinoin                            | Gel                       | 0.04%   | Retin-A Micro 20475 | 12/20/2010         | 1                         | Eligible       | 8/10/2020                     | 7/17/2013                        |   | 9/21/2016                                 |
| Tretinoin                            | Gel                       | 0.1%  | Retin-A Micro 20475 | 7/8/2010           | 1                         | Eligible       | 8/10/2020                     | 7/17/2013                        | 7/31/2013                                 | 9/21/2016                                 |
| Triamcinolone Acetonide              | Nasal Spray               | 0.055 mg/Spray                                  | Nasacort AQ         | 12/29/2005         | 1                         | Deferred       | 8/10/2020                     | 7/30/2009                        |   | 7/3/2016                                  |
| Triamterene/<br>Hydrochlorothiazide  | Tablets                   | 37.5 mg/25 mg and<br>75 mg/50 mg                | Maxzide 19129       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Trifluridine and Tipiracil           | Tablets                   | 15 mg/6.14 mg and<br>20 mg/8.19 mg              | Lonsurf 207981      | 9/23/2019          | 4                         | Deferred       | 6/26/2023                     | 6/13/2023                        |   | 6/17/2034                                 |
| Tropium Chloride                     | Extended-release Capsules | 60 mg   | Sanctura XR 22103   | 3/2/2009           | 1                         | Deferred       | 8/10/2020                     | 10/12/2012                       | 10/12/2012                                | 2/1/2025                                  |
| Ulipristal Acetate                   | Tablets                   | 30 mg   | Ella 22474          | 8/13/2014          | 1                         | Eligible       | 8/10/2020                     | 2/13/2017                        |   | 6/12/2030                                 |
| Unoprostone Isopropyl                | Ophthalmic Solution       | 0.15%   | Rescula 21214       | 5/12/2014          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 7/9/2021                                  |
| Valacyclovir Hydrochloride           | Tablets                   | 500 mg and<br>1000 mg                           | Valtrex 20487       | Pre-MMA            |                           |                |                               |                                  |   |   |
| Valbenazine Tosylate                 | Capsules                  | 40 mg and 80 mg                                 | Ingrezza 209241     | 4/12/2021          | 4                         |                |                               |                                  |   | 8/10/2040                                 |
| Valbenazine Tosylate                 | Capsules                  | 60 mg   | Ingrezza 209241     | 2/14/2022          | 1                         |                |                               |                                  |   | 8/10/2040                                 |
| Valganciclovir Hydrochloride         | for Oral Solution         | 50 mg/mL  | Valcyte 22257       | 3/21/2011          | 1                         | Extinguished   | 1/2/2020                      |                                  |   | 3/29/2015                                 |
| Valganciclovir Hydrochloride         | Tablets                   | 450 mg  | Valcyte 21304       | 12/27/2005         | 1                         | Extinguished   | 7/27/2020                     |                                  |   | 7/28/2014                                 |
| Valsartan                            | Tablets                   | 40 mg, 80 mg,<br>160 mg and 320 mg              | Diovan 21283        | 12/28/2004         | 1                         | Non-Forfeiture | 7/27/2020                     | 6/26/2014                        | 7/7/2014                                  | 6/18/2017                                 |
| Valsartan and<br>Hydrochlorothiazide | Tablets                   | 80 mg/12.5 mg<br>160 mg/12.5 mg<br>160 mg/25 mg | Diovan HCT 20818    | 12/2/2005          | 1                         | Eligible       | 7/27/2020                     | 9/21/2012                        | 9/21/2012                                 | 6/18/2017                                 |
| Valsartan and<br>Hydrochlorothiazide | Tablets                   | 320 mg/12.5 mg and<br>320 mg/25 mg              | Diovan HCT 20818    | 2/7/2007           | 1                         | Eligible       | 7/27/2020                     | 9/21/2012                        | 9/21/2012                                 | 6/18/2017                                 |
| Vancomycin Hydrochloride             | For Oral Solution         | 25 mg/mL and<br>50 mg/mL                        | Firvanq Kit 208910  | 5/18/2020          | 1                         | Eligible       | 12/13/2022                    | 11/14/2022                       | 8/29/2023                                 | 3/13/2035                                 |
| Vardenafil Hydrochloride             | Tablets                   | 2.5 mg  | Levitra 21400       | 9/4/2009           | 1                         | Deferred       | 7/27/2020                     | 5/3/2012                         | 10/3/2018                                 | 10/31/2018                                |
| Vardenafil Hydrochloride             | Tablets                   | 5 mg and 10 mg                                  | Levitra 21400       | 7/10/2009          | 1                         | Deferred       | 7/27/2020                     | 5/3/2012                         | 10/3/2018                                 | 10/31/2018                                |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                 | DOSAGE FORM                   | STRENGTH                                | RLD/NDA                            | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS          | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------|-------------------------------|---|------------------------------------|--------------------|---------------------------|-------------------------|-------------------------------|----------------------------------|---|---|
| Vardenafil Hydrochloride  | Tablets                       | 20 mg                                   | Levitra<br>21400                   | 3/5/2009           | 1                         | Deferred                | 7/27/2020                     | 5/3/2012                         | 10/3/2018                                 | 10/31/2018                                |
| Vardenafil Hydrochloride  | Orally Disintegrating Tablets | 10 mg                                   | Staxyn<br>200179                   | 12/22/2011         | 1                         | Extinguished Eligible   | 6/18/2019<br>6/18/2019        | 4/23/2015                        |   | 10/31/2018                                |
| Varenicline Tartrate      | Tablets                       | 0.5 mg and 1 mg                         | Chantix<br>21928                   | 5/10/2010          | 5                         | Deferred                | 9/7/2021                      | 8/11/2021                        | 9/21/2021                                 | 8/3/2022                                  |
| Varenicline Tartrate      | Nasal Spray                   | 0.03 mg/spray                           | Tyvaya<br>213978                   | 4/21/2023          | 1                         |                         |                               |                                  |   | 10/19/2035                                |
| Vasopressin               | Injection                     | 20 units/mL, 1 mL                       | Vasopressin<br>204485              | 3/23/2018          | 1                         | Non-Forfeiture Deferred | 12/28/2021<br>12/28/2021      | 12/15/2021                       | 1/18/2022                                 | 1/30/2035                                 |
| Vasopressin               | Injection                     | 200 units/10 mL                         | Vasopressin<br>204485              | 6/29/2018          | 1                         | Non-Forfeiture          | 2/6/2023                      |                                  |   | 1/30/2035                                 |
| Vasopressin               | Injection                     | 20 units/100 mL                         | Vasopressin<br>204485              | 12/20/2022         | 1                         |                         |                               |                                  |   | 1/30/2035                                 |
| Vasopressin               | Injection                     | 40 units/100 mL and 60 units/100 mL     | Vasopressin<br>204485              | 2/28/2022          | 1                         |                         |                               |                                  |   | 1/30/2035                                 |
| Vecuronium Bromide        | For Injection                 | 10 mg/vial and 20 mg/vial               | Norcuron<br>18776                  | Pre-MMA            |                           |                         |                               |                                  |   |   |
| Venetoclax                | Tablets                       | 10 mg, 50 mg and 100 mg                 | Venclexta<br>208573                | 4/13/2020          | 2                         |                         |                               |                                  |   | 1/29/2032                                 |
| Venlafaxine Hydrochloride | Tablets                       | 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg | Effexor<br>20151                   | 11/03/2005         | 1                         |                         |                               | 8/3/2006                         | 6/15/2006                                 | 6/13/2008                                 |
| Venlafaxine Hydrochloride | Extended-release Tablets      | 37.5 mg, 75 mg and 150 mg               | Effexor XR<br>20699                | 5/3/2007           | 1                         | Extinguished            | 7/27/2020                     |                                  |   | 3/20/2017                                 |
| Venlafaxine Hydrochloride | Extended-release Tablets      | 37.5 mg, 75 mg and 150 mg               | Venlafaxine Hydrochloride<br>22104 | 2/12/2009          | 1                         | Eligible                | 7/27/2020                     | 8/18/2010                        | 6/15/2006                                 | 3/20/2017                                 |
| Venlafaxine Hydrochloride | Extended-release Tablets      | 225 mg                                  | Venlafaxine Hydrochloride<br>22104 | 1/10/2011          | 1                         | Extinguished            | 7/27/2020                     | 1/8/2019                         |   | 3/20/2017                                 |
| Verapamil Hydrochloride   | Extended-release Capsules     | 100 mg and 200 mg                       | Verelan PM<br>20943                | 7/20/2006          | 1                         | Extinguished            | 7/27/2020                     | 8/9/2007                         |   | 6/19/2007                                 |
| Verapamil Hydrochloride   | Extended-release Capsules     | 120 mg, 180 mg and 240 mg               | Verelan SR                         | Pre-MMA            |                           |                         |                               |                                  |   |   |
| Verapamil Hydrochloride   | Extended-release Tablets      | 180 mg                                  | Isopтин SR                         | Pre-MMA            |                           |                         |                               |                                  |   |   |

**Paragraph IV Patent Certifications  
September 18, 2023**

| DRUG NAME                 | DOSAGE FORM               | STRENGTH                           | RLD/NDA           | DATE OF SUBMISSION | NUMBER OF ANDAs SUBMITTED | 180-DAY STATUS | 180-DAY DECISION POSTING DATE | DATE OF FIRST APPLICANT APPROVAL | DATE OF FIRST COMMERCIAL MARKETING BY FTF | EXPIRATION DATE OF LAST QUALIFYING PATENT |
|---------------------------|---------------------------|------------------------------------|-------------------|--------------------|---------------------------|----------------|-------------------------------|----------------------------------|---|---|
| Verapamil Hydrochloride   | Extended-release Tablets  | 240 mg                             | Covera HS 20552   | Pre-MMA            |                           |                |                               |                                  |   |   |
| Verapamil Hydrochloride   | Extended-release Capsules | 300 mg                             | Verelan PM 20943  | 5/19/2006          | 1                         | Extinguished   | 7/27/2020                     | 8/9/2007                         |   | 6/17/2007                                 |
| Vilazodone Hydrochloride  | Tablets                   | 10 mg, 20 mg, and 40 mg            | VIIBRYD 22567     | 1/21/2015          | 5                         | Eligible       | 7/27/2020                     | 9/13/2019                        | 6/4/2022                                  | 6/5/2022                                  |
| Vincristine Sulfate       | Injection                 | 1 mg/mL, 1 mL, 2 mL and 5 mL vials | Oncovin 14103     | Pre-MMA            |                           |                |                               |                                  |   |   |
| Voriconazole              | For Injection             | 200 mg/vial                        | Vfend 21267       | 9/12/2008          | 1                         | Eligible       | 7/27/2020                     | 5/30/2012                        | 5/30/2012                                 | 6/2/2018                                  |
| Voriconazole              | Oral Suspension           | 40 mg/mL                           | Vfend 21630       | 10/8/2010          | 1                         | Eligible       | 7/27/2020                     | 5/28/2013                        | 9/25/2013                                 | 5/24/2016                                 |
| Voriconazole              | Tablets                   | 50 mg and 200 mg                   | Vfend 21266       | 4/14/2008          | 1                         | Eligible       | 7/27/2020                     | 4/22/2010                        | 2/15/2011                                 | 5/24/2016                                 |
| Vortioxetine              | Tablets                   | 5 mg, 10 mg, 15 mg and 20 mg       | Trintellix 204447 | 10/2/2017          | 15                        | Deferred       | 10/5/2021                     | 9/17/2021                        |   | 6/30/2031                                 |
| Zafirlukast               | Tablets                   | 10 mg and 20 mg                    | Accolate 20547    | 2/29/2008          | 1                         | Eligible       | 7/27/2020                     | 11/18/2010                       | 11/18/2010                                | 3/18/2014                                 |
| Zaleplon                  | Capsules                  | 5 mg and 10 mg                     | Sonata 20859      | 6/21/2005          | 1                         | Extinguished   | 7/27/2020                     | 6/6/2008                         |   | 6/6/2008                                  |
| Zidovudine                | Capsules                  | 100 mg                             | Retrovir 19665    | Pre-MMA            |                           |                |                               |                                  |   |   |
| Ziprasidone Hydrochloride | Capsules                  | 20 mg, 40 mg, 60 mg and 80 mg      | Geodon 20825      | 2/7/2005           | 5                         | Eligible       | 7/27/2020                     | 3/2/2012                         | 3/2/2012                                  | 5/27/2019                                 |
| Zoledronic Acid           | Injection                 | 0.05 mg/mL, 100 mL vial            | Reclast 21817     | 8/29/2008          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 9/2/2012                                  |
| Zoledronic Acid           | Injection                 | 0.8 mg (base) /mL                  | Zometa 21223      | 6/11/2008          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 9/2/2012                                  |
| Zoledronic Acid           | Injection                 | 4 mg/100 mL, 100 mL vial           | Zometa 21223      | 1/31/2012          | 1                         | Extinguished   | 3/10/2020                     |                                  |   | 2/5/2028                                  |
| Zolmitriptan              | Nasal Spray               | 2.5 mg/spray                       | Zomig 21450       | 6/9/2016           | 1                         | Extinguished   | 7/27/2020                     |                                  |   | 11/28/2020                                |
| Zolmitriptan              | Nasal Spray               | 5 mg/spray                         | Zomig 21450       | 11/14/2013         | 1                         | Extinguished   | 1/12/2021                     |                                  |   | 11/28/2020                                |
| Zolpidem Tartrate         | Extended-release Tablets  | 6.25 mg                            | Ambien CR 21774   | 2/24/2006          | 1                         | Non-Forfeiture | 7/27/2020                     | 10/13/2010                       | 10/13/2010                                | 6/1/2020                                  |
| Zolpidem Tartrate         | Extended-release Tablets  | 12.5 mg                            | Ambien CR 21774   | 1/19/2006          | 1                         | Non-Forfeiture | 7/27/2020                     | 12/3/2010                        | 12/6/2020                                 | 6/1/2020                                  |
| Zolpidem Tartrate         | Sublingual Tablets        | 5 mg and 10 mg                     | Edluar 21997      | 4/29/2010          | 1                         | Extinguished   | 7/27/2020                     | 8/1/2016                         |   | 9/24/2018                                 |

**Paragraph IV Patent Certifications  
September 18, 2023**

| <b>DRUG NAME</b>                             | <b>DOSAGE FORM</b> | <b>STRENGTH</b>    | <b>RLD/NDA</b>      | <b>DATE OF SUBMISSION</b> | <b>NUMBER OF ANDAs SUBMITTED</b> | <b>180-DAY STATUS</b> | <b>180-DAY DECISION POSTING DATE</b> | <b>DATE OF FIRST APPLICANT APPROVAL</b> | <b>DATE OF FIRST COMMERCIAL MARKETING BY FTF</b> | <b>EXPIRATION DATE OF LAST QUALIFYING PATENT</b> |
|--|--------------------|--------------------|---------------------|---------------------------|----------------------------------|-----------------------|--------------------------------------|---|--|--|
| Zolpidem Tartrate                            | Sublingual Tablets | 1.75 mg and 3.5 mg | Intermezzo<br>22328 | 4/10/2012                 | 1                                | Eligible              | 7/27/2020                            | 6/3/2015                                | 3/23/2016  | 4/15/2027  |
| * ANDA withdrawn or exclusivity relinquished |                    |                    |                     |                           |                                  |                       |                                      |   |  |  |